Knock-in gene correction of induced pluripotent stem cells from pyruvate kinase deficient patient by Garate Mutiloa, Zita
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Knock-In Gene Correction of  
induced Pluripotent Stem Cells from 
Pyruvate Kinase Deficient Patients 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
 
UNIVERSIDAD AUTÓNOMA DE MADRID 
Facultad de Ciencias 
Departamento Biología molecular 
 
 
Zita Garate Mutiloa 
-
 
 
Memoria presentada por ZITA GARATE MUTILOA, licenciada en Biotecnología, para optar al grado 
de doctor por la Universidad Autónoma de Madrid 
 
 
 
Directores de Tesis: 
José Carlos Segovia Sanz 
Oscar Quintana Bustamante 
 
 
 
 
CENTRO DE INVESTIGACIONES ENERGÉTICAS, MEDIOAMBIENTALES Y TECNOLÓGICAS (CIEMAT) y 
CENTRO DE INVESTIGACIONES BIOMÉDICAS EN RED DE ENFERMEDADES RARAS (CIBERER) 
 
División de Terapias Innovadoras del Sistema Hematopoyético 
 
MADRID  
2013 
  
 
 
-
 
 
 
 
 
 
 
 
José Carlos Segovia Sanz, Jefe de la Unidad de Diferenciación y Citometría de la División de 
Terapias Innovadoras del Sistema Hematopoyético del Centro de Investigaciones 
Energéticas, Medioambientales y Tecnológicas, y Oscar Quintana Bustamante, investigador 
post doctoral de la misma unidad, certifican que la memoria adjunta, titulada “ -
” 
ha sido realizada por Zita Garate Mutiloa bajo la dirección conjunta de los que suscriben, y 
cumple las condiciones exigidas para optar al título de Doctor por la Universidad Autónoma 
de Madrid. 
 
 
 
 
 
 
 
José Carlos Segovia Sanz                                             Oscar Quintana Bustamante
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
El presente trabajo de investigación ha sido realizado en la División de Terapias Innovadoras del 
Sistema Hematopoyético del CIEMAT y Centro de Investigaciones Biomédicas en Red de 
Enfermedades Raras (CIBERER), del Instituto de Salud Carlos III, con la colaboración del proyecto 
PERSIST del programa de salud de la Unión Europea, la Red Española de Terapia Celular (TERCEL) y el 
Ministerio de Economía y Competitividad (MINECO), Secretaría de Estado de Investigación, 
Desarrollo e Innovación.  
 
 
 
Zita Garate Mutiloa ha disfrutado de una beca del programa PREDOC del departamento de 
Educación, Política Lingüística y Cultura del Gobierno Vasco. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9 
 
SUMMARY 
 
  
I. Summary 
Pyruvate Kinase Deficiency (PKD) is a rare disease caused by mutations in the PKLR gene that leads 
to Chronic Non-Spherocytic Hemolytic Anemia (CNSHA). The only definitive treatment for severe 
cases of PKD is allogeneic Bone Marrow Transplantation (BMT). The risks associated to BMT, such as 
graft versus host disease, together with the low availability of suitable donors, make autologous cell 
therapy desirable for this disease. Patient specific induced Pluripotent Stem Cells (hiPSC) coupled 
with targeted gene correction via Homologous Recombination (HR), is a promising alternative for the 
treatment of hematopoietic inherited disorders. In order to prove the feasibility of this therapeutic 
alternative for PKD, we have generated integration free iPSCs from Peripheral Blood Mononuclear 
Cells (PB-MNC) of PKD patients (PKDiPSCs) using Sendai based viral vectors, and have corrected 
them through a Knock-In approach in the PKLR locus by using two types of DNA nucleases, 
Meganucleases (MG) and TALE nucleases (TALENTM). Different hiPSC clones were obtained from two 
patients and one healthy donor; these hiPSC clones showed pluripotent characteristics even after 
the disappearance of reprogramming vectors. A strategy to avoid lymphoid cells reprogramming 
within PB-MNC was successfully applied as neither T nor B cell receptor rearrangements were found 
in any of the analyzed hiPSC lines. Interestingly, erythroid differentiation of PKDiPSC was impaired as 
occurs in PKD patients, showing an accumulation of immature CD71/CD235a double positive 
erythroid cells and assessing the use of hiPSC for disease modeling. To restore the genetic defect, 
specific MG and TALENTM were used to facilitate the Knock-In of a codon optimized RPK cDNA in the 
second intron of the PKLR gene. Whereas the MG generated DSB with very low specificity, after 
using the PKLR1 TALENTM, correct integration in PKLR locus was confirmed by PCR and southern blot, 
and the presence of the recombinant therapeutic RPK was assessed at the protein level. Surprisingly, 
allele specific integration due to the presence of a single nucleotide polymorphism was identified in 
one of the patients, pointing out its potential use in specific allele substitution. Genome integrity 
was examined by analyzing the appearance of de novo somatic mutations and Copy Number 
Variations (CNVs), detecting three single nucleotide variants and six CNVs in the corrected PKD2iPSC. 
The majority of them were already present before correction but not in the PB-MNC. These 
modifications did not include genes that were clearly associated either to a selective advantage or to 
the use of the nucleases. More importantly, gene corrected coPKDiPSCs displayed a normal 
erythroid maturation profile, similar to the one observed in wild-type hiPSCs. Overall, we show the 
feasibility of PKLR locus specific gene correction in patient specific iPSCs. 
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I Resumen 
La Deficiencia en Piruvato Quinasa (DPQ) es una enfermedad rara causada por mutaciones en el gen 
PKLR que provoca Anemia Hemolítica no Esferocítica Crónica (AHNEC). El único tratamiento 
definitivo para los casos graves de DPQ es el Trasplante Alogénico de Médula Ósea (TAMO). Debido 
a los riesgos asociados a TAMO, como la enfermedad de injerto contra huésped, y la baja 
disponibilidad de donantes adecuados, hacen que la terapia celular autóloga sea una alternativa 
atractiva para el tratamiento de los casos graves de DPQ. Una alternativa prometedora para el 
tratamiento de trastornos hereditarios hematopoyéticos es la combinación de la generación de 
células madre pluripotentes inducidas (iPSCs) a partir de muestras de pacientes, junto con la 
corrección especifica de sitio mediada por Recombinación Homóloga (RH). Con el fin de evaluar esta 
posibilidad como alternativa terapéutica para DPQ, hemos generado iPSC derivadas de Células 
Mononucleares de sangre periférica (CMN) de pacientes con DPQ (DPQiPSCs) mediante vectores 
virales basados en el virus Sendai y las hemos corregido mediante RH específica de sitio asistida por 
dos tipos de nucleasas de ADN, Meganucleasas (MG) y TALE nucleasas (TALENTM). Para ello, hemos 
seguido una estrategia de Knock-in en el locus PKLR. Se obtuvieron diferentes clones de hiPSC a 
partir de dos pacientes de DPQ y un donante sano, de los cuales se confirmó la pluripotencia y la 
desaparición de los vectores de reprogramación. Con el fin de evitar la reprogramación de células 
linfoides, se llevó a cabo una estrategia basada en el uso de citoquinas, verificándose mediante el 
análisis de reordenamientos somáticos genómicos característicos de linfocitos B y T. Es importante 
señalar que la diferenciación eritroide de DPQiPSCs es deficiente tal como ocurre en los pacientes 
con DPQ, manifestando una acumulación de células eritroides inmaduras positivas para los 
marcadores CD71 y CD235a, lo que confirma el potencial uso de hiPSC para el modelado de 
enfermedades. Con el fin de restaurar el defecto genético, se han utilizado MG y TALENTM para 
facilitar la introducción de parte del ADNc de RPK  terapéutico en el intrón 2 del gen PKLR. La MG 
presentó una muy baja especificidad para el gen PKLR, sin embargo, después del uso de PKLR1 
TALENTM, se consiguió una correcta integración en un alto porcentaje de clones analizados mediante 
PCR y Southern Blot, así como la presencia de la proteína terapéutica RPK recombinante. 
Sorprendentemente, debido a la presencia de un polimorfismo en un único nucleótido en el ADN 
genómico de uno de los pacientes, se detectó exclusivamente integración específica en uno de 
alelos. Se examinó la integridad del genoma mediante el análisis de mutaciones somáticas y de 
Variaciones de Número de Copia (VNC), detectándose tres mutaciones y seis VNC en la muestra de 
DPQiPSC corregida, que no estaban presentes en la muestra de CMN de sangre periférica original. 
Estas modificaciones no afectan a ningún gen que confiera ninguna ventaja selectiva durante el 
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cultivo de hiPSC ni al uso de nucleasas. Por último, cabe destacar que las células DPQiPSC corregidas, 
una vez diferenciadas a al linaje eritroide, muestran un perfil de maduración normal, similar al 
observado en las hiPSCs de CMN de un donante sano. Como conclusión, los resultados presentados 
muestran la posibilidad de generar eritrocitos genéticamente corregidos específicamente en el locus 
PKLR, a partir de hiPSC de pacientes de DPQ. 
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III. Abbreviations 
A1ATD-hiPSC: Alpha 1 Antitrypsin Deficiency induced Pluripotent Stem Cells 
Aa: Amino Acids AAVS1: Adeno-Associated Virus Integration Site 1 
aCGH: array based Comparative Genomic Hybridization  
ADN: Ácido Desoxirribonucleico 
ADNc: ADN copia 
AHEC: Anemia Hemolítica No-Esferocítica Crónica 
AP: Alkaline Phosphatase 
APEL: Albumin Polyvinylalcohol Essential Lipids 
ATP: Adenosine Triphosphate 
bFGF: basic Fibroblast Growth Factor 
bGH: bovine Growth Hormone 
BGM: Blast Growing Media 
BM: Bone Marrow 
BM-MSC: Bone Marrow Mesenchymal Stem Cells 
BMP4: Bone Morphogenetic Protein 4 
BMT: Bone Marrow Transplantation 
bp: base pairs 
BSA: Bovine Serum Albumin 
Cas: CRISPR associated system 
CMN: Células Mononucleadas de Sangre Periférica 
CNSHA: Chronic Non-Spherocytic Hemolytic Anemia 
CNV: Copy Number Variation 
coPKDiPSC: corrected Pyruvate Kinase Deficiency induced Pluripotent Stem Cells 
coRPK: codon optimized RPK 
CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats 
DAPI: 4',6-Diamidino-2-Phenylindole, Dihydrochloride 
DHA: Docosahexaenoic Acid 
DM: Donor Matrix 
DMEM: Dulbecco's modified Eagle's medium 
DMSO: Dimethyl sulfoxide 
DNA: Deoxyribonucleic acid 
DPQ: Deficiencia en Piruvato Quinasa 
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DPQiPSC: Células Madre Pluripotentes inducidas de Deficiencia en Piruvato Quinasa 
DSB: Double Strand Breaks 
EBs: Embryoid Bodies 
EC: Expression Cassette 
ECL: Enhanced Chemiluminescence 
EDTA: Ethylenediaminetetraacetic Acid 
EF1 α: Elongation Factor 1 α  
FACS: Fluorescence Activated Cell Sorting 
FA-hiPSC: Fanconi Anemia Human induced Pluripotent Stem Cells 
FBS: Fetal Bovine Serum 
FLT3L: Fms-Related Tyrosine Kinase 3 Ligand 
FV: Foamy Virus  
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase 
G-CSF: Granulocyte Colony-Stimulating Factor 
gDNA: genomic DNA 
GFP: Green Fluorescent Protein 
GT: Gene Therapy  
GVHD: Graft Versus Host Disease 
HA: Homology Arms  
HE: Homing Endonucleases 
hES: human Embryonic Stem 
hESCs: human Embryonic Stem Cells 
HFF: Human Foreskin Fibroblasts 
hiPSCs: Human induced Pluripotent Stem Cells 
HIV: Human Immunodeficiency Virus 
hPSCs: human Pluripotent Stem Cells 
HR: Homologous Recombination 
HSCs: Hematopoietic Stem Cells 
IgH: Immunoglobulin Heavy Chain 
IL3: Interleukin 3 
IL-6: Interleukin 6 
ISCA: International Standards for Cytogenomics Array 
lncRNA: Long non-coding RNA 
LOH: Loss of Heterozygosity  
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LPK: liver pyruvate kinase 
mCpGs: Methylated CpG dinucleotide 
MEF: Mouse Embryonic Fibroblasts 
MG: Meganucleases 
mRNA: messenger RNA  
NHEJ: Non-Homologous End Joining 
NSG: Non-obese diabetic SCID gamma  
Nts: nucleotides 
OMIM: Online Mendelian Inheritance in Man 
OpPCR: Overlapping PCR 
PB: Peripheral Blood 
PB1: Peripheral Blood from healthy donor number 1 
PB2: Peripheral Blood from healthy donor number 2 
PBA: BSA and Sodium Azide in PBS 
PB-MNC: Peripheral Blood Mononuclear Cells 
PBS: Phosphate Buffer Saline 
PCR: Polymerase Chain Reaction 
PFA: Paraformaldehyde 
PK: Pyruvate Kinase 
PKD: Pyruvate Kinase Deficiency 
PKD1: Pyruvate Kinase Deficient patient number 1 
PKD2: Pyruvate Kinase Deficient patient number 2 
PKD3: Pyruvate Kinase Deficient patient number 3 
PKDiPSCs: Pyruvate Kinase Deficiency induced Pluripotent Stem Cells 
PKLR: Pyruvate Kinase, Liver and Red Blood Cells 
PKM: Pyruvate Kinase, Muscle 
Puro-MEF: Puromycin resistant mouse embryonic fibroblasts 
qRT-PCR: quantitative Real Time PCR 
RBCs: Red Blood Cells 
RH: Recombinación Homóloga 
RNA: Ribonucleic acid 
RPK: R type Pyruvate Kinase 
RT: Room Temperature 
SA: Splicing Acceptor 
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SC: Selection Cassette 
SCF: Stem Cell Factor 
SDS: sodium dodecyl sulfate  
SELEX: Systematic Evolution of Ligands by Exponential Enrichment 
SeV: Sendai Viral Vectors 
SNP: Single Nucleotide Polymorphism 
SNV: Single Nucleotide Variants 
SR-RNA: Self-Replicating RNAs 
SSC: saline-sodium citrate 
TA: TALENTM: Transcription Activator-Like Effector Nucleases 
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TBS: Tris-Buffered Saline 
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IV. Introduction 
1. Pyruvate Kinase Deficiency (PKD) 
PKD (OMIM 266200) is a rare erythroid metabolic disease diagnosed for the first time in the early 
1960s (Valentine, Tanaka et al. 1961), caused by mutations in PKLR gene, which codes the R-type 
Pyruvate Kinase (RPK) in erythrocytes. It shows a worldwide geographical distribution and the most 
common type of genetic inheritance is autosomal recessive. Its incidence is around 51 cases per 
million in the North American white population (Beutler and Gelbart 2000) and together with 
glucose-6-phosphate deficiency (G6PD) are the most common causes of Chronic Non-spherocytic 
Hemolytic Anemia (CNSHA). The majority of the diagnosed patients are compound heterozygotes, as 
homozygotes are rare but very severe (van Wijk, Huizinga et al. 2009).  
The human genome encodes four Pyruvate Kinase (PK) Isotypes: M1, M2, R and L and its expression 
is tissue specific. M1 and M2 are encoded by the PKM gene and are expressed in Muscle and Brain 
(M1) and lung and many types of highly proliferating cells (M2) (Tsutsumi, Tani et al. 1988). RPK and 
LPK are expressed from the PKLR gene, the first one in erythrocytes and the second in liver, kidney 
and intestine. Two different tissue specific promoters drive the transcription of these two isoforms. 
The length of the PKLR gene is 9.5 Kilobases (Kb) and is located in Chromosome 1 (1q21) (Fig. 1). RPK 
and LPK transcripts differ in the first exon, which is different in each transcript, sharing all the 
downstream exons (Kanno, Fujii et al. 1992). RPK cDNA is 2060 base pairs (bp) long and codes for 
574 amino acids (aa), while LPKs cDNA and protein length are 1632 bp and 543 aa respectively.  
 
 
 
    
 
 
 
 
 
PK catalyzes the conversion of phosphoenolpyruvate to pyruvate in Embden-Meyerhof pathway of 
anaerobic glycolysis (Zanella, Bianchi et al. 2007) (Fig. 2), which is highly important in mature 
 
Figure 1: PKLR gene structure. Exons 1 to 11 are represented in blue and untranslated region (UTR) in grey.  There are two 
exons 1 that by alternative splicing are going to generate the R-isoform or the L-isoform respectively. 
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erythrocytes. The disease becomes clinically relevant when, due to PKLR mutations, the protein 
activity decreases below 25% of the normal activity in erythrocytes (Certo, Gwiazda et al. 2012). ATP 
depletion leads to ATP-dependent cation pumps failure disrupting the adequate cell electrolyte 
concentration. This causes damage in erythrocyte cell membrane leading to early erythrocyte 
destruction in liver and spleen (Mentzer, Baehner et al. 1971). 
1.1 Pyruvate Kinase (PK) and erythroid differentiation 
During erythroid differentiation there is a switch in the presence of the different PK isoenzymes (Fig 
2). M2PK is expressed in immature proerythroblasts but at the stage of polychromatic erythroblast it 
decreases while RPK levels rise, being the only PK enzyme expressed in mature erythrocytes. Mature 
erythrocytes are then highly affected by alterations in RPK function. As erythroid cells lose the 
nucleus and mitochondria, they become highly dependent on glycolysis for ATP production. Mature 
erythrocytes do not have residual M2PK and as they do not have nucleus and cannot compensate 
RPK defect by increasing RPK levels. Although the majority of PKLR mutations affect both isoforms, 
no hepatic affectation is observed in PKD patients, mainly because hepatocytes can compensate the 
defect in two ways: 1) when the genetic defect leads to a loss of activity, the level of enzyme 
generated can be increased by increasing gene expression, and 2) residual levels of M2PK could be 
present (Zanella, Bianchi et al. 2007).  
RPK protein structure varies during erythrocyte differentiation. Whereas eritroblastic RPK is a 
homotetramer of 4 L subunits (unmodified), RPK isolated from mature erythrocytes is a 
heterotetramer composed by 2 L and 2 Lc subunits, which are generated by proteolysis of L in its N 
terminal region. L molecular weight is 62 kDa whereas Lc is 58 kDa and the catalytic constant of the 
heterotetramer is lower than the one from the homotetramer (van Dongen, Langerak et al. 2003, Ju, 
Kim et al. 2011). 
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1.2 Mutations, clinical manifestations and treatment 
Up to now, more than 190 PKD-associated mutations have been identified throughout the whole 
PKLR gene (Zanella, Fermo et al. 2007, Kedar, Hamada et al. 2009, van Wijk, Huizinga et al. 2009, 
Machado, Manco et al. 2012). The number of mutations described in exons 8 to 11 is higher than in 
the rest of exons, and mutations in exon 1R and 1L have never been described. The mutations have 
been designated using the RPK cDNA sequence, being the A from the ATG the +1 (Genebank 
Accession number: NM_000298.5). The majority are missense mutations (69%), but splice sites 
(11%) and stop codon (5%) mutations have also been identified. Small deletions, insertions and 
frameshift mutations are rare (12%). Two large deletions have been reported: the “Gypsy” deletion 
of the whole exon 11 and the PK “Viet”, which leads to the loss of exons 4 to 10. A few mutations at 
the promoter region have also been described (-72AG and -83GC) and have been associated to 
defects in gene regulation. The most common ones are 1529A, 1456T and 1468T, being the first one 
the most common in USA and in Northern and central Europe. (Zanella, Fermo et al. 2005).   
  
Alberto Zanella and colleagues established a correlation between mutations and clinical phenotype 
in 54 PKD patients (Zanella, Fermo et al. 2007). They identified three phenotypes: 1) Severe 
phenotype, in which patients presented severe neonatal jaundice and most of them required blood 
 
Figure 2: Energy generation during erythrocyte maturation. Top: Pyruvate Kinase (PK) catalyzes the conversion of 
phosphoenolpyruvate into pyruvate and its consequent generation of ATP. Bottom: The presence of the different PKs varies 
during erythropoiesis. In early progenitors, M2PK isoform catalyzes this reaction whereas in mature erythrocytes RPK is the 
responsible one. 
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transfusions, splenectomy and one case of death in utero. The associated mutations included 
disruptive mutations (stop codons, frame shifts, splicing and large deletions) and missense 
mutations where amino acids from the active site or crucial for protein stability were affected. 2) 
Moderate phenotype, usually diagnosed around the age of 25 and the majority showing 1529A 
mutation. 3) Mild phenotype: showing mild or fully compensated hemolysis and diagnosed in 
adulthood. The predominant mutation in this group is: 1456T. Although not included in this study 
because the known incidence is very low, patients suffering homozygous ¨null mutations¨ would also 
be included in the first category, as they usually result in a total loss of protein activity leading to the 
reported symptoms and in some cases intrauterine growth retardation (Zanella and Bianchi 2000, 
Sedano, Rothlisberger et al. 2004).  
Being its incidence between 5 and 51 cases per million in the North American white population, PKD 
prevalence might be influenced by the facts that its diagnosis is mainly performed in some 
population groups and that it is based on observed mutation frequencies (Beutler and Gelbart 2000). 
Therefore, the frequencies of unreported PKD cases due to hydrops fetalis and early neonatal death 
may increase its incidence (Gilsanz, Vega et al. 1993, Certo, Gwiazda et al. 2012). Based on the fact 
that heterozygous PKD mutants show a decreased RPK activity, its frequency was studied in Spanish 
population (Garcia, Moragon et al. 1979) and it was determined that the frequency of a mutated 
allele in the healthy population is 0.24%.  
Overall, PKD patients show a highly variable phenotype. Depending on the severity of the mutation, 
the symptomatology can range from fully compensated hemolysis with no apparent anemia to fetal 
death in utero (Gilsanz, Vega et al. 1993, Zanella, Fermo et al. 2005). The most common symptoms 
are CNSHA and jaundice in new-borns. Patients suffering from severe anemia may need periodical 
blood transfusions. Splenectomy is also sometimes recommended, as it decreases erythrocyte 
destruction.  Nevertheless, the only definitive cure for PKD is allogeneic bone marrow 
transplantation (BMT), which was successfully carried out in a 5-year-old boy who developed 
neonatal jaundice and severe transfusion-dependent hemolytic anemia (Suvatte, Tanphaichitr et al. 
1998, Tanphaichitr, Suvatte et al. 2000). Three years after the BMT, he showed normal hemoglobin 
levels and normal red blood cell pyruvate kinase activity without evidence of hemolysis. This 
treatment usually requires the use of immunosuppressive drugs or regimes that can induce toxicity 
and increase the risk of infections and cancer. This, together with the low availability of suitable 
donors makes the development of new treatment options a need to treat severe patients. 
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1.3 New treatments development 
1.3.1 Cell and Gene Therapy 
As an alternative to avoid BMT complications, other approaches such as gene therapy of autologous 
hematopoietic stem cells (HSCs) or the transfusion of in vitro generated erythrocytes have also been 
proposed. Cell therapy and related applications should be developed and tested in the very valuable 
PKD animal models before they are used in the clinics. Natural mutations in homologous genes of 
the human PKLR have been described in several animal models including mice (Morimoto, Kanno et 
al. 1995, Min-Oo, Fortin et al. 2004), cats (Kohn and Fumi 2008, Grahn, Grahn et al. 2012) and dogs 
(Whitney and Lothrop 1995, Beard and Kiem 2009).  These models are of enormous importance for 
the study of the physiopathological characteristics of the disease and to explore new treatment 
choices. They have already been used in several reports, especially in the gene and cell therapy field. 
The first attempt of cell therapy was performed in the PKD canine model, in which the feasibility of 
non-myeloablative BMT was tested as PKD treatment. The achieved level of chimerism was not 
enough to accomplish a long-term cure (Zaucha, Yu et al. 2001). Nevertheless, similar levels of 
chimerism in an equivalent approach carried out in a PKD mouse model (CBA-Pk-1slc/Pk-1slc) were 
successful in PKD phenotype correction (Morimoto, Kanno et al. 1995). In order to use autologous 
HSCs for PKD treatment, previous work from our group explored the use of human RPK expressing γ-
retroviral vectors to treat the disease in a mouse model of PKD, by transplanting autologous BM 
hematopoietic progenitors and HSC transduced with the developed retroviral vectors into 
myeloablated PKD mice (Meza, Alonso-Ferrero et al. 2009). In this study, the PKD mouse model used 
showed a phenotype very similar to the one seen in PKD patients (Min-Oo, Fortin et al. 2004). Long-
term expression of RPK was achieved in red blood cells of primary and secondary recipients and PKD 
associated hematological manifestations were reverted without showing any adverse effects. The 
latest reported PKD gene therapy (GT) approach used a foamy virus (FV) engineered vector to 
express the wild type RPK cDNA. For this study, one PKD dog was transplanted with autologous 
CD34+ hematopoietic cells transduced with the RPK FV resulting in a long-term functional cure 
(Trobridge, Beard et al. 2012).  
Periodical blood transfusion is a routine therapeutic procedure for PKD treatment. However, adverse 
effects have been observed in some patients treated with frequent blood transfusions, such as 
alloimmunization against donor blood cells. This and others side effects made them refractory to 
future additional blood transfusions. Consequently, autologous blood transfusions after gene 
correction might overcome this problem, which could be obtained by the in vitro generation of 
terminally differentiated and functional red blood cells (RBC) (Migliaccio, Whitsett et al. 2012, 
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Zeuner, Martelli et al. 2012). Many attempts have been carried out by using different sources of 
stem cells such as hematopoietic progenitors (Giarratana, Rouard et al. 2011) and induced 
pluripotent stem cells (Lu, Feng et al. 2008). By using peripheral blood isolated CD34+ cells, 
Giarratana et al generated and expanded RBC in vitro and in vivo which showed all the biochemical 
and functional characteristics of normal RBCs. More importantly, they were capable of transfusing 
the same donor with the in vitro generated chromium labeled autologous erythrocytes and showed 
that after 26 days, between 41% and 63% of the total infused cells survived.  
Another disease model that could also be used to study PKD and to develop new therapeutic options 
is patient specific induced Pluripotent Stem Cells (iPSCs). Human iPSCs show unlimited self-renewal 
capacity while retaining the ability, in principle, to differentiate into any cell type of the human body 
(Takahashi, Tanabe et al. 2007). This includes the hematopoietic system and which is more 
important for PKD study, the opportunity to study the whole erythropoietic differentiation process 
(Lu, Feng et al. 2007, Lu, Feng et al. 2008, Hatzistavrou, Micallef et al. 2009). Due to this enormous 
potential, many disease-specific iPSC lines have been generated and in some cases genetically 
corrected (Garate, Davis et al. 2013). These aspects will be deeply analyzed in depth through-out this 
thesis manuscript. 
1.3.2 In situ gene correction 
The viral vectors used in conventional GT integrate randomly in the genome and this fact could 
cause insertional mutagenesis and promote the activation of surrounding oncogenes, which may 
result in oncogenic events (Hacein-Bey-Abina, Von Kalle et al. 2003, Hacein-Bey-Abina, Garrigue et 
al. 2008, Fischer, Hacein-Bey-Abina et al. 2010). Newly designed vectors are exploring the possibility 
of using safer strategies but until now no definitive ideal vector has been reported. The identification 
of integrations in safe harbor genomic sites (e.g., far away from genes or coding information) in 
clonal cultures could represent an alternative. However, the selection of cells with safe integrations 
requires long culture periods, incompatible with the maintenance of stem cell properties of HSCs. 
The clonal nature of pluripotent cultures could allow this type of selection and the concomitant 
differentiation of hiPSCs to HSCs could provide the proper cells for safe hematopoietic 
transplantation. In two different approaches performing lentiviral gene correction in thalassemia 
and erythropoietic porphyria patient iPSC (Papapetrou, Lee et al. 2011, Bedel, Taillepierre et al. 
2012), the clonal expansion of corrected patient hiPSC allowed the analysis of the integration of 
these vectors at a clonal level a and the selection of the ones integrated in safe harbors. However, 
the definition of a safe harbor is complex and might be influenced by unknown genomic functions. 
Special attention should be taken to the newly generated information from ENCODE project, which 
is showing unannotated genomic functions (http://www.encodeproject.org/ENCODE/pubs.html or 
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http://www.nature.com/ENCODE/). Future therapeutic applications of hiPSCs for cell therapy would 
benefit from a site-specific gene correction approach. The cooperation between hiPSC technology 
and gene editing, which is the introduction of a piece of genetic information in a specific site of the 
genome on a controlled manner via homologous recombination (HR), has been extensively explored. 
HR is presented as an exciting and novel alternative, to avoid insertional mutagenesis associated 
with integrative vector-mediated correction. Its possibilities will be extensively reviewed later. 
2. Induced Pluripotent Stem Cells (iPSCs) 
Human Pluripotent Stem Cells (human Embryonic Stem Cells (hESCs) and hiPSCs) are a powerful 
source of cells for regenerative medicine, as they have the ability to differentiate into any cell type 
of the human body. Thomson’s group described the isolation of hESCs from the Inner Cell mass of 
human blastocysts in 1998 (Thomson, Itskovitz-Eldor et al. 1998) establishing the pluripotent culture 
conditions that were later used for the derivation of human induced Pluripotent Stem Cells. Human 
iPSC technology combines the potential of hESCs in terms of self-renewal and pluripotency with the 
absence of problems related to hESC lines establishment and clinical application, (i.e. ethical issues 
associated with embryo disruption and immuno-incompatibility with the recipient of the cells).  In 
addition to their potential as a pluripotent autologous cell source, iPSCs clonal nature makes them 
an ideal platform to perform gene editing mediated gene correction. iPSCs generation was reported 
for the first time in 2006 in the mouse system by the transduction of fibroblasts with the following 
transcription factors (TFs): Oct4, Sox2, Klf4 and C-Myc (Takahashi and Yamanaka 2006). One year 
later the groups of Yamanaka (Takahashi, Tanabe et al. 2007) and Thomson (Yu, Vodyanik et al. 
2007) achieved the same result in human cells revolutionizing the stem cells field. Many laboratories 
have been able to reprogram a large variety of somatic cells into pluripotent stem cells, from neural 
stem cells (Kim, Zaehres et al. 2009) to terminally differentiated B-lymphocytes (Hanna, Markoulaki 
et al. 2008). The reproducibility and potentiality of the iPSC technology has caused this field to 
advance very rapidly worldwide.  
 
Human iPSCs derived from patients with specific disorders are presented as a very valuable material 
to study human diseases in vitro and also in vivo. From a clinical point of view, two main applications 
can be pursued (Fig. 3):  
1) Disease modeling and drug development. Patient specific hiPSC could be a model of the patient 
pathology. As they have the ability to differentiate into any cell type of the human body, they could 
resemble the disease phenotype in the desired tissue and specific drugs could be tested. This 
strategy has been used to test drugs used for arrhythmias in hiPSC derived beating cardiomyocytes 
(Braam, Tertoolen et al. 2013), drugs for Niemann Pick type C disease in hiPSC derived neurons 
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(Swaroop, Thorne et al. 2012) or to study the responsiveness to DHA (Docosahexaenoic Acid ) in 
Alzheimer’s disease iPSC derived neurons (Kondo, Asai et al. 2013). Although yet not applied, many 
authors have also proposed the use of iPSC-derived hepatocytes for drug toxicity testing 
(Greenhough, Medine et al. 2010, Nakamura, Saeki et al. 2012)  
2) Cell source for regenerative medicine: As iPSCs can be generated from a concrete patient, they 
could serve as an unlimited source of autologous cells for replacement (Qin, Song et al. 2013, Yuan, 
Liao et al. 2013). In the case of a genetic disease, the mutation could be corrected on a safe manner 
before differentiating the cells towards the tissue of interest. This has not been applied in clinics yet, 
but many proof of principles have been reported in literature (Raya, Rodriguez-Piza et al. 2009, 
Howden, Gore et al. 2011, Liu, Suzuki et al. 2011, Sebastiano, Maeder et al. 2011, Soldner, Laganiere 
et al. 2011, Yusa, Rashid et al. 2011, Zou, Mali et al. 2011, Zou, Sweeney et al. 2011, An, Zhang et al. 
2012, Bedel, Taillepierre et al. 2012, Wang, Zheng et al. 2012)  
There is an additional application for hiPSCs under development, which is its use as an 
immunotherapy tool by in vitro generation of T lymphocytes with reactivity against a specific 
antigen. This application has been explored for HIV (Nishimura, Kaneko et al. 2013), for cancer 
(Vizcardo, Masuda et al. 2013) and for pathogen defense (Wakao, Yoshikiyo et al. 2013) with 
promising results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 3. Biomedical potential of hiPSCs. Cells obtained from a patient are reprogrammed to pluripotency. Due to their acquired 
capacity to differentiate into any cell type, these cells could serve for disease modeling and drug screening and also could be 
genetically corrected to serve as source for regenerative medicine, Modified from (Garcia-Gomez 2013) 
 
 29 
 
INTRODUCTION 
 
  
2.1 Choice of Reprogramming platform 
Since their initial description, many different procedures have been described to generate iPSCs. 
Viral vectors have been the preferred system because of their ability to express a gene of interest in 
a certain cell type due to their natural cell entry and replication mechanisms. That is why first 
reports of hiPSC generation used retroviruses to express the four defined TFs required for 
reprogramming (Takahashi, Tanabe et al. 2007, Yu, Vodyanik et al. 2007). Nevertheless, a future 
clinical application of hiPSC will ideally involve the use of non-integrative systems, in which the risk 
of insertional mutagenesis due to random integration of the reprogramming genes is avoided. Many 
different integrative, removable and non-integrative systems have been developed with its strengths 
and limitations (Table 1). First reported approaches for reprogramming were carried out by 
delivering each TF separately in different viral vectors whereas very soon, other groups reported the 
inclusion of all of them in a unique polycistronic lentiviral vector, which improved reprogramming 
efficiency (Carey, Markoulaki et al. 2009).  
Two of the four Yamanaka TFs, C-MYC and KLF-4, have been designated as oncogenes and their 
presence in the reprogramming cocktail was seen as a risk factor. It was shown that it was possible 
to remove them from the reprogramming cocktail but just for certain cell types, like hematopoietic 
progenitors (Liu, Zou et al. 2012, Meng, Neises et al. 2012) or neural stem cells (Kim, Zaehres et al. 
2009). Even reprogramming with OCT4 alone was achieved (Thier, Munst et al. 2010). Unfortunately, 
this kind of approaches usually decreased reprogramming efficiency.  
Another explored integrative possibility is the use of Cre-mediated excisable polycistronic lentiviral 
vectors (Somers, Jean et al. 2010, Papapetrou and Sadelain 2011) or transposon-based 
reprogramming systems (Woltjen, Hamalainen et al.), which could be removed after obtaining the 
hiPSC clones. In the first case just a LoxP signal will remain after excision by Cre recombinase and in 
the second the genome should end up, in principle, completely unmodified. 
However, the safest reprogramming procedure will eventually involve non-integrative systems. 
These systems are less genotoxic as the chance of integration is low (plasmids, adenovirus) or even 
null (Sendai viral vectors (SeV), mRNAs or proteins). Thomson’s group reported the first strictly non-
integrative system for hiPSCs generation in 2009 by using episomal plasmids for the expression of 
the four Yamanaka TF plus NANOG, LIN28 and SV40 large T antigen (SVLT) (Yu, Hu et al. 2009). In the 
same year, reprogramming by recombinant proteins (Kim, Kim et al. 2009), synthetic mRNAs 
(Warren, Manos et al. 2010), and non-integrating RNA SeV (Fusaki, Ban et al. 2009) was also 
reported. Reprogramming with recombinant proteins or mRNAs, although ideal, shows a reduced 
efficiency and the need for multiple rounds of transfection/protein delivery. SeV, which combine the 
safety of non-integrating systems with a high efficiency, are a very promising choice for cell 
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reprograming. Very recently another very promising non-integrative approach came out based on 
synthetic self-replicating RNAs expressing reprogramming factors (Yoshioka, Gros et al. 2013). Non 
integrative systems are not only safer but also generate iPSC showing a gene expression profile more 
similar to ESC than iPSC generated by integrative methods (Liu, Cheng et al. 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.1 Sendai Viral Vectors 
SeV are presented as a very promising tool for gene transfer in mammalian cells and therefore a very 
good tool for iPSC generation. These virus were isolated for the first time in Japan in 1950 (Kuroya 
and Ishida 1953) and have been associated with respiratory tract infections in many rodents and 
occasionally in pigs, being neither pathogenic nor tumorogenic for humans. As seen in figure 4, one 
of the major advantages of this vector is the fact that the whole replication process takes place as 
RNA and exclusively in the cytoplasm of the transduced cell without any risk of chromosomal 
integration. Additionally, as it is cell replication-independent, SeV do not need a specific cell cycle 
status. SeV also show a higher transgene expression rate than other common viral vectors (Yu, 
TF delivery method Efficiency/ Rounds Integrative Cell type 
Lenti/ 
retroviruses 
0.01-1/ single Yes 
Fibroblasts (Takahashi, Tanabe et al. 2007) 
Keratinocytes(Aasen and Izpisua Belmonte 2010) 
B-Lymphocytes(Hanna, Markoulaki et al. 2008) 
Human Adipose Stem cells (Sun, Panetta et al. 2009) 
BM-MSCs (Zou, Sweeney et al. 2011) 
CD34 Progenitors (Ye, Zhan et al. 2009) 
BM-MNC (Kunisato, Wakatsuki et al. 2010) 
Hepatocytes(Hansel, Gramignoli et al. 2013) 
Pancreatic Islet Beta Cells(Bar-Nur, Russ et al. 2011) 
Neural Stem Cells (Kim, Zaehres et al. 2009) 
Adenoviruses ≈ 0.0002/ multiple No Fibroblast (Zhou and Freed 2009) 
Sendai virus ≈ 1/single No 
Fibroblasts (Fusaki, Ban et al. 2009) 
T cells (Seki, Yuasa et al. 2011) 
CD34 progenitors (Ban, Nishishita et al. 2011) 
Excisable Lentivirus 0.01-1/single Removable 
Fibroblasts (Sommer, Stadtfeld et al. 2009, 
Papapetrou and Sadelain 2011, Sebastiano, Maeder 
et al. 2011, Soldner, Laganiere et al. 2011) 
CD34 Progenitors (Ramos-Mejia, Montes et al. 2012) 
Excisable Transposons ≈ 0.1/single Removable 
Fibroblasts (Kaji, Norrby et al. 2009) 
BM-MSCs (Zou, Mali et al. 2011) 
Minicircles ≈ 0.005/ multiple No Adipose derived Stromal cells (Jia, Wilson et al. 2010) 
Episomal Vectors 0,001/multiple No 
Fibroblasts (Yu, Hu et al. 2009) 
BM and CB MNCs (Hu, Yu et al. 2011) 
Proteins 0,001/multiple No Fibroblasts (Kim, Kim et al. 2009) 
miRNAs 0,1/single Yes Fibroblasts (Anokye-Danso, Trivedi et al. 2011) 
mRNAs 1-4/multiple No Fibroblasts (Warren, Manos et al. 2010) 
Self-replicating RNAs 0.01-1/single No Fibroblasts (Yoshioka, Gros et al. 2013) 
 
Table1. Technological platforms and cell sources for reprogramming, modified from (Garate, Davis et al. 2013) 
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Shioda et al. 1997). Several clinical trials have been carried out using SeV showing no adverse effects 
(Masaki, Yonemitsu et al. 2001, Masaki, Yonemitsu et al. 2002, Slobod, Shenep et al. 2004). All the 
characteristics that made the vectors based in this virus attractive for clinical purposes made them 
also an ideal tool for hiPSC generation. They can be used for many starting cell types with a high 
transduction efficiency leading to high reprogramming efficiency (≈1%). Their ability to replicate 
during the beginning of reprogramming avoids multiple transductions, but when iPSCs are 
established and divide very rapidly, the viral vectors tend to disappear, increasing the safety of the 
method (Fusaki, Ban et al. 2009, Ban, Nishishita et al. 2011, Ye, Muench et al. 2013).  
 
 
 
 
 
 
 
 
 
 
 
2.2 Choice of cell source for reprogramming 
Many different cell sources have been successfully used for induction of pluripotency using different 
reprogramming platforms (Table1). According to Hanna et al, as long as the reprogramming genes 
are expressed at an adequate level and the cell does not show any abnormality, any cell type is likely 
capable of giving rise to an iPSC line (Hanna, Saha et al. 2009). In fact, the in vivo induction of 
reprogramming genes induced the generation of iPSC from any tissue (Abad, Mosteiro et al. 2013). 
Therefore, the desired cell source is the most easily accessible and the one in which the 
reprogramming factors can be delivered more efficiently.  This is the reason why fibroblasts have 
been the preferred option by many groups (Takahashi, Tanabe et al. 2007, Park, Arora et al. 2008, 
Fusaki, Ban et al. 2009, Carvajal-Vergara, Sevilla et al. 2010, Liu, Sumer et al. 2010, Howden, Gore et 
al. 2011, Papapetrou, Lee et al. 2011, Sebastiano, Maeder et al. 2011, Tanaka, Takahashi et al. 2012), 
as they can be easily grown from a small harmless biopsy and efficiently be transduced and 
transfected. Another cell source presented as an alternative to fibroblasts is peripheral blood 
mononuclear cells (PB-MNC), which can be also easily obtained from routine blood tests. PB-MNC 
 
Figure 4: Sendai viral vector cycle. 
Once the cell is transduced by SeV, 
the viral RNA genetic material 
penetrates the cell and replicates. 
The RNA is transcribed and translated 
generating viral proteins together 
with the protein(s) of interest. The 
virus is genetically modified to avoid 
the generation of infectious particles. 
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present several additional advantages (Kunisato, Wakatsuki et al. 2010) among other sources. They 
are a heterogeneous cell population in which stimulation of the preferred cell type by cytokines is 
possible. Staerk, J. et al revealed that by stimulation by G-CSF, GM-CSF, IL-3, and IL-6 before and 
during the first days of reprogramming, the induction of pluripotency could be encouraged in 
progenitors and myeloid origin cells, avoiding reprogramming of genetically rearranged B or T 
lymphoid cells (Staerk, Dawlaty et al. 2010). Additionally, PB-MNC in enough numbers for 
reprogramming can be directly obtained without any need of culture expansion, which has been 
shown to induce genomic abnormalities. Also, they could be used to reprogram cells from any 
disease, even from patients in which skin biopsies are not recommended (i.e. aberrant scaring) 
(Sommer, Rozelle et al. 2012). However, bulk PB-MNCs cannot be nucleofected and its transduction 
with lentiviral vectors is not as efficient as it is in fibroblast. 
2.3 Erythroid differentiation of iPSCs 
hESCs are isolated from the Inner Cell Mass of the developing human embryos before gastrulation 
and therefore have the ability to differentiate into any cell type from the embryo (Thomson, 
Itskovitz-Eldor et al. 1998). hiPSCs acquire all the characteristics of hESCs in terms of pluripotency. In 
vitro differentiation of hESC and iPSC has been revealed as a very promising model that mimics 
gastrulation and in which all the events that take place during human embryonic development can 
be examined (Fig. 5). One of the developmental pathways that have been studied is the emergence 
of Hematopoietic Stem Cells (HSC) from mesodermal tissues. Hematopoietic cells arise in two waves 
during human embryogenesis: the primitive wave, generated in the Yolk Sac (YS) (extraembryonic 
mesoderm) just after gastrulation and the definitive one, which is the adult type hematopoiesis, 
which starts after 6-8 weeks in the aorta-gonad-mesonephros region (AGM) of the developing 
embryo. The erythropoiesis that takes place in the YS shows some differences with the one in adult 
hematopoietic tissues (Palis, Malik et al. 2010); the primitive erythroblast (EryP) generated are 
nucleated and produce mainly embryonic (ζ and ε) and fetal (γ) globin chains. Once heartbeat is 
established, they begin to circulate while maturing, and after several days in circulation they 
enucleate. Even after enucleation, embryonic erythrocytes show a larger size than erythrocytes 
generated from adult tissues (Baron 2013) (Fig. 6). Trying to reproduce embryonic development, 
several authors have shown the generation of erythroid progenitors by culturing hESC/iPSC in 
different platforms in which the presence of erythroid promoting cytokines (hSCF, hTPO, hEPO, hIL3, 
hIL6), iron saturated transferrin and insulin are common among them (Lu, Feng et al. 2008, 
Hatzistavrou, Micallef et al. 2009, Lapillonne, Kobari et al. 2010, Dias, Gumenyuk et al. 2011). Some 
of the cell markers used for the identification of erythroid differentiation are: Glycophrin A 
(CD235a), a glycoprotein present in erythrocyte membrane, and transferrin receptor (CD71), 
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Figure 5: Erythropoiesis during human development. Two waves of hematopoiesis have been reported during development: 
the primitive that arises from the Yolk Sac and generates primary primitive erythroblast, and the definitive one, which is the 
adult type and through the Long Term Hematopoietic Stem Cell, generates totally mature erythrocytes. Embryoid bodies 
generated from pluripotent stem cells resemble human gastrulation in vitro. 
 
implicated in iron transfer into the red blood cell. Erythroid cells derived from hESC/hiPSC are 
phenotypically similar to the ones that appear during the first waves of embryonic/fetal 
development, being mainly nucleated and expressing embryonic and fetal globins. Some in vitro 
protocols involving feeder supporting cells (Lu, Feng et al. 2008, Dias, Gumenyuk et al. 2011) or 
prolonged culture in the presence of human plasma (Lapillonne, Kobari et al. 2010) showed some 
adult β globin expression and some level of enucleation (10-60%). In an in vivo maturation approach 
carried out by Kobari L et al (Kobari, Yates et al. 2012), in which early differentiated erythroid cells 
were injected into the retro-orbital vein of immunodeficient mice, the modulation of the human 
globin chains was complete, being β and α chains each approx. 50% of the total globins.  
 
 
 
 
 
 
 
 
 
3. Gene correction of disease specific iPSCs 
The possibility of generating and correcting patient specific iPSC has opened up new avenues for 
regenerative medicine. Up until now, different strategies have been carried out for patient-specific 
hiPSC gene correction (reviewed in Garate, Davis et al. 2013). Although many of the reported 
approaches performed genetic correction directly in hiPSC, this is not always possible, as some 
disease causing mutations also interfere with the reprogramming process. For example, this is the 
case of Fanconi Anemia (FA), in which the generation of FA derived hiPSC was mainly possible after 
correction by an integrative lentiviral vector (Raya, Rodriguez-Piza et al. 2009). The use of integrative 
vectors for correction of the diseased cells, before or after cell reprogramming, has important risks 
already mentioned, mainly insertional mutagenesis. Other strategies for non-integrative gene 
correction are being studied, as in the case of integrative defective lentiviral vectors (Natale, 
Frangipane di Regalbono et al. 2007, Weidauer, Vatter et al. 2008), adenoviruses or adenoassociated 
viruses (Alberghini, Pasquinelli et al. 2007). But when the target cells are proliferative, no method to 
maintain the exogenous DNA has been developed yet. Having the opportunity of unlimited self-
renewal and clonal selection, we believe that the best genomic correction approach would be 
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homologous recombination (HR) mediated direct site integration, which could be fully explored in 
human pluripotent cultures (hiPSCs and hESCs). 
3.1 Homologous recombination mediated gene editing 
During gene editing, a desired DNA sequence is inserted into a specific place at the genome very 
accurately, at a single base resolution. HR is the cellular mechanism used to carry out this type of 
genetic modification and is part of the DNA repair machinery that under normal conditions is 
responsible for the maintenance of cell genome integrity. HR and Non Homologous End Joining 
(NHEJ) are the two main mechanisms activated to repair a DNA Double Strand Break (DSB) in the 
genome. HR is a very accurate reparation procedure as the undamaged DNA strand (sister 
chromatid) is used as a template to generate the new DNA sequence. In contrast, during NHEJ, DSB 
ends are directly ligated without the need for a homologous template, being highly error prone. HR 
is a very secure process to repair DSB. The fidelity of HR gives the specificity and accuracy that gene 
editing requires and therefore, researchers have developed molecular biology tools to introduce 
exogenous DNA into a specific spot of the genome by using the endogenous HR machinery. Part of 
the DNA of interest needs to be homologous or surrounded by homologous sequences to the locus 
where it will be inserted, the so-called Homology Arms (HA). Once a DSB is generated in the desired 
locus, the HR machinery uses the homology region of the exogenous DNA as a template, copying and 
inserting all genomic elements surrounded by the HAs. These techniques have been widely used for 
the generation of Knock-Out, and Knock-In transgenic animals (Robbins 1993) and their application 
was awarded by the Nobel price to Mario Capecchi, Oliver Smithies and Martin Evans in 2007, for 
being pioneers in disrupting or altering mouse genes (Smithies 2001). 
As targeted integration mediated by HR shows a low efficiency in mammalian cells (1 HR event per 
106 cells) (Cathomen and Joung 2008), positive and negative selection markers (i.e. drug resistance 
gene between HAs and suicide genes outside HAs) can be included in the targeting vector (also 
called Donor Matrix (DM)) in order to select those cells in which the desired insertion has happened 
correctly. The final structure and complexity of the DM will vary according to the targeting strategy 
and the place of the genome to be targeted. There are three different gene editing strategies that 
could be considered to correct or insert/express a transgene by HR (Fig. 6).  
1. Gene correction: One or more bases are exchanged from the original strand by integrating them 
within the homology sequence; this strategy is the one to be chosen when the goal is to 
introduce or repair point or small mutations.   
2. Safe harbor integration: Insertion of a whole expression cassette (promoter, transgene and 
regulatory signals) in a harmless place of the genome. Examples of this type of genomic locus 
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reported in literature are: AASV1, CCR5 or ROSA26 locus (Irion, Luche et al. 2007, Torres, Garcia 
et al. 2011, Yao, Nashun et al. 2011). 
3. Knock-In: a partial cDNA of the gene of interest is introduced in its endogenous locus. 
Commonly, a splicing acceptor is located before the cDNA to anchor the previous endogenous 
splicing donor. The endogenous elements of the locus will regulate the expression of the 
endogenous/exogenous resulting chimeric gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Independently of the chosen strategy, gene editing process can be separated in two different steps; 
generation of DSB and HR, being both crucial for gene editing efficiency. In order to activate HR 
machinery in the intended locus, a DSB should be generated, that as previously mentioned could be 
resolved by HR or by NHEJ. Unfortunately NHEJ is the preferred mechanism to solve this type of 
lesions increasing the risk of genomic deletions/insertions. Cell cycle status is also a critical 
parameter for gene editing as it requires transit through S-G2 phase of the cell cycle to take place 
(Delacote and Lopez 2008). These limitations make gene editing in human cells difficult to achieve, 
especially in hESC and hiPSC, which are difficult to clone from single cells (Amit, Carpenter et al. 
2000) and in which transduction efficiency with common techniques used for mouse ESCs is low (10-
50%) (Braam, Denning et al. 2008). In order to solve this bottleneck, different approaches have been 
reported to improve gene editing efficiency in hPSCs. The use of very long HAs (27.7 and 8.8 kb) in a 
Bacterial Artificial Chromosome (BAC) was carried out by Howden et al. (Howden, Gore et al. 2011) 
to correct gyrate atrophy hiPSCs showing an efficiency of 10%. Different reports have shown that by 
 
Figure 6: Homologous recombination matrix elements and different strategies for gene editing. A) Figure showing all the 
elements that a donor matrix could be composed of in order to integrate in a particular locus and to allow correctly targeted 
cells to be selected. HA: Homology Arm, PSG: Positive selection gene, TG: Therapeutic gene, NSG: Negative selection gene. 
B) Three different possibilities for gene editing can be considered. Left: a mutation (in red) is corrected leaving no other 
exogenous DNA. Middle: the DNA is introduced into a harmless place in the genome. Right: a piece of the cDNA is 
introduced in an intron, taking advantage of endogenous splicing machinery. Modified from (Garate, Davis et al. 2013) 
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using Helper-dependent adenoviral vectors (HDAdV), which have the ability to transduce hPSC very 
efficiently, the overall gene editing efficiency is increased (7-80%) (Liu, Suzuki et al. 2011, Aizawa, 
Hirabayashi et al. 2012). Another explored possibility is the induction of DSBs specifically in the locus 
to be targeted by using engineered DNA nucleases (Fig. 7), that have been shown to increase HR 
efficiency by up to 103 fold (Porteus and Carroll 2005). This strategy has been deeply studied and 
applied for correction of patient specific hiPSCs and has been reviewed in Garate, Davis et al. 2013 
and in Simara, Motl et al. 2013. 
3.2 DNA Nucleases 
The discovery of DSB generation in a specific site of the genome promoting HR in this specific locus, 
lead to the development of the first DNA nucleases with specific targeting, the meganucleases 
(Colleaux, D'Auriol et al. 1988). After that, very versatile engineered types of nucleases came out, 
first the Zinc Finger Nucleases (ZFNs) (Kim, Cha et al. 1996) and then the transcription activator-like 
effector nucleases (TALENs) (Cermak, Doyle et al. 2011) . Lately, a new approach has been explored, 
the CRISPR/Cas system (Mali, Yang et al. 2013). All of them are intended to generate DSB in a specific 
locus but each of them has its own particularities. A scheme of their structures and the strategy to 
use them for HR is depicted in figure 7.   
3.2.1 Meganucleases 
Rare cutting DNA nucleases or homing endonucleases (HE) were firstly explored in lower eukaryotes, 
being responsible for a process called intron homing, during which an intron is copied from one 
allele to another of the same gene after a DSB generation (Jasin 1996). One of the best characterized 
HE is I-SceI, which was isolated from the yeast Saccharomyces cerevisiae and recognizes an intron in 
the 21S Ribosomal RNA gene. The main advantage of this type of nucleases is that their recognition 
sites are much longer than the ones of bacterial restriction enzymes, and that they could be 
engineered to recognize other sequences. Their characteristics make these enzymes cut; in principle, 
only once in a particular site of the genome, which could be our site of interest. They recognize a 
sequence around 14-44 bp and assuming a random organization of the human genome, the 
frequency of occurrence of this sequence more than once is expected to be very rare (Colleaux, 
D'Auriol et al. 1988). They are composed of a DNA recognition domain, which is responsible for the 
HE specificity, and a cutting domain, which is the one that will catalyze the DSB generation. There 
are different families and each of them show different structures, some having two binding modules 
and working as homodimers, and some working as monomers (Stoddard 2005). The specificity of 
natural HE can be altered by mutagenesis of the DNA binding domain followed by functional 
screening (Chen and Zhao 2005, Arnould, Chames et al. 2006, Doyon, Pattanayak et al. 2006, Silva, 
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Belfort et al. 2006, Delacote, Perez et al. 2013),  and they are called customized Meganucleases 
(MG). Regarding their DNA binding domain design, a unique and specific MN recognition sequence 
can be found approximately every 300 bp (Paques and Duchateau 2007). One of the main 
advantages of this type of nucleases is their reduced cytotoxicity in mammalian cells (Rouet, Smih et 
al. 1994).  
3.2.2 ZFN 
Zinc Finger Nucleases (ZFNs) are artificial endonucleases firstly generated through a very fruitful 
collaboration between the groups of doctors S. Chandrasegaran and J. Berg. In order to generate a 
DNA nuclease with a specific targeting, they combined the DNA binding domain of Zinc Finger (ZF) 
proteins and the type IIS nuclease domain of the restriction enzyme Fok-I (Kim, Cha et al. 1996). As 
cleavage activity of FokI requires dimerization, ZFNs were designed to work as pairs of two 
monomers of ZFN in reverse orientation (Fig. 7). Each ZF modules is composed of a tandem repeat of 
Cys2-His2 that recognizes three nucleotides. Therefore an array of 3 or 4 ZF recognizes and binds a 
sequence of 9 or 12 nucleotides, leading to the targeting of a genomic sequence of 18-24 
nucleotides long (Porteus and Carroll 2005, Carroll 2011). Several in vitro studies in oocytes were 
performed in order to study and confirm the specific cutting, but the first genomic locus that was 
targeted in vivo by a ZFN was the yellow gene of Drosophila Melanogaster in the early 2000’s 
(Bibikova, Golic et al. 2002, Bibikova, Beumer et al. 2003). Later on, its use has been applied for the 
generation of transgenic plants, zebrafish, mouse, rat and xenopus and in several human somatic 
cell types, including HSCs, hESCs and hiPSCs. Lombardo et al. showed for the first time the insertion 
of GFP into the CCR5 safe harbor locus in hESC after inducing HR by ZFN expression; targeted hESC 
were able to differentiate into neurons keeping GFP expression (Lombardo, Genovese et al. 2007). 
Many reports have now shown ZNF mediated gene correction in disease specific hiPSCs, being until 
now the preferred type of DNA nuclease for this purpose. ZFN can be designed to target any gene 
but not any sequence, as not all the combinations of three nucleotides are feasible. 
3.2.3 TALE nucleases 
Transcription activator-like effector nucleases (TALENs) are also artificial endonucleases similar to 
ZFN but with a different DNA binding domain, sharing the nuclease domain. In this case the specific 
DNA binding is obtained using TAL effector (TALE) proteins, which were discovered in a plant 
pathogen from the species Xantomonas as plant genes regulators (Hopkins, White et al. 1992). The 
code for TALEs DNA recognition was elucidated by Adam Bogdanove (Bogdanove and Voytas 2011) 
and Jens Boch (Boch, Scholze et al. 2009) leading to a very versatile gene editing tool. TALENs (TAs) 
DNA recognition domain consist of tandem arrays of 33-35 aa (Fig. 7), being each of these units able 
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to bind one nucleotide. Thus, the DNA binding domain can be designed to recognize any desired 
genomic sequence. Best TAs cleavage conditions were found to be similar to ZFN, as dimers in 
reverse orientation (Li, Huang et al. 2011) and recently they have been described and licensed as 
single monomers (Beurdeley, Bietz et al. 2013). 
3.2.4 CRISPR/Cas system 
CRISPR/Cas system is a sequence specific RNA mediated DNA nuclease that is part of the bacterial 
and archeal immune system, aiming the destruction of invading viral and plasmid DNAs. The first 
reported adaptation of this prokaryotic system in eukaryotic cells was described this February (Mali, 
Yang et al. 2013) and, in half a year more than 20 studies have been reported in which this type of 
system was used in eukaryotic cells. It was efficiently used for the generation of transgenic models 
of many organisms including plants (Jiang, Zhou et al. 2013, Miao, Guo et al. 2013), mice (Wang, 
Yang et al. 2013, Yang, Wang et al. 2013) and zebrafish (Blackburn, Campbell et al. 2013, Hwang, Fu 
et al. 2013, Hwang, Fu et al. 2013, Jao, Wente et al. 2013, Xiao, Wang et al. 2013) and in many cell 
lines, including hPSCs (Hou, Zhang et al. 2013). The versatility of this system relies on the fact that 
the specificity is determined by a guide RNA that targets a DNA sequence of 20 nt (crRNA) and that is 
delivered separately from the protein that generates the DSBs, the Cas9. This also allows the 
targeting of multiple loci at the same time. The other needed element, the tracrRNA, is responsible 
for the delivery of the Cas9 to the targeted sequence and can be expressed as a fusion of the crRNA, 
also called single guide RNA (sgRNA). The technique development is so recent that there is limited 
data on efficiency and specificity, but there are two reports so far in which it is shown that its low 
specificity might be one of its main limitations (Cradick, Fine et al. 2013, Fu, Foden et al. 2013), being 
sequences with few mismatches highly cut.  
 
 
 
 
 
 
 
 
 
 
 
3.3 Limitations of the use of nuclease mediated gene editing, DSBs  Figure 7: DNA-Nuclease enhanced Homologous Recombination (HR). On the left, a schematic diagram of nuclease mediated HR. 
After Double Strand generation, the Homology donor is served as a repair template and the piece in pink is introduced in the 
intended locus. On the right, the structure and DNA binding of the 4 different used nucleases. CRISPR/Cas system image modified 
from http://www.addgene.org/crispr/jounglab/. ZFN and TALEN images modified from a commercial brochure of PNA Bio. 
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Although it is possible to perform nuclease mediated targeting in any site of the genome, including 
transcriptionally inactive loci (Hockemeyer, Soldner et al. 2009, Aizawa, Hirabayashi et al. 2012), the 
epigenetic status of the locus to be targeted influences targeting frequency, as it has been shown by 
using MGs (Daboussi, Zaslavskiy et al. 2012), ZFNs (Hockemeyer, Soldner et al. 2009) and TAs 
(Hockemeyer, Wang et al. 2011). The mechanism by which it is affected is poorly understood; it 
might be the recognition and accessibility of the nuclease to the target or the accessibility of the 
repair machinery elements to the locus. It has been shown that the presence of methylated CpGs 
dinucleotides (mCpG) in TAs recognition site can dramatically decrease its efficiency (Shijia Chen 
2013) and in the case of MN this also happens if the mCpG is in the central tetrabase of the 
recognition site (Valton, Daboussi et al. 2012). 
The main concern when using DNA nucleases is the off target cutting (Gabriel, Lombardo et al. 
2011), which is the recognition and DSB generation in other genome sequences different from the 
intended one. These unexpected DSB will be mainly solved by NHEJ, which is highly error prone and 
will lead to genomic modifications. Consequently, this type of cutting usually increases cell toxicity, 
decreases the desired DSB generation efficiency and can lead to undesired chromosomal alterations 
(Richardson and Jasin 2000). Theoretically, a DNA nuclease that recognizes a sequence of 18 bp will 
find its target once in every 7x1010pb, which means once in the human genome.  The problem is that 
the recognition might tolerate a variable number of mismatches and recognize and cut similar 
sequences to the original. This has been mainly studied in ZFN and by in vitro and in vivo assays, 
identifying off targeted sequences that were not recognized by bioinformatics approaches (Gabriel, 
Lombardo et al. 2011, Pattanayak, Ramirez et al. 2011). Conclusions from both studies matched with 
the ones generated by the biochemical assay SELEX, which is a very popular off target analysis tool 
based on affinity binding of immobilized ZF molecules to DNA molecules and subsequent analysis of 
the sequences captured by each monomer (Perez, Wang et al. 2008, Gabriel, Lombardo et al. 2011). 
The fact that ZFNs and TAs cut as heterodimers increases the possibility of off target cutting, as 
homodimers with a different target could be formed. There are several strategies under study to 
force their correct conformation in order to be able to cut and reduce the derived associations 
cutting in undesired sites, the so called forced heterodimers. 
3.4 Reported patient specific hiPSC gene correction  
The combination of patient specific hiPSCs and gene editing is a powerful source for regenerative 
medicine and therefore many proofs of principle have been described from different disea showing 
that they could be successfully corrected using nuclease mediated HR (Garate, Davis et al. 2013). So 
far, the majority of them used ZFN and gene correction strategy has been the most popular one. 
Table 2 shows all the reported strategies and its characteristics. 
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3.5 Limitation of the therapeutic use of hiPSCs: genomic instability 
As pointed out by Blasco et al (Blasco, Serrano et al. 2011), there are several facts related to genomic 
instability in cell reprogramming that should be taken into consideration: two of the four 
reprogramming genes are oncogenes (C-MYC and KLF4), reprogramming efficiency is increased by 
including SV40 large T antigen or by the suppression of some tumor suppressor genes (P53 or ARF) 
and, most importantly, the fact that mice generated from iPSCs developed tumors and showed 
developmental problems. As a consequence, many groups have studied the genomic integrity of 
pluripotent cultures making clear that genetic abnormalities may be introduced into the hiPSCs 
either through the reprogramming process, the tissue culture expansion, and/or the gene correction 
process (Gore, Li et al. 2011, Hussein, Batada et al. 2011, Laurent, Ulitsky et al. 2011, Martins-Taylor, 
Nisler et al. 2011). The risks of genetic correction are not only related to DSB generation but also to 
the fact that there are several steps of the procedure in which clonal cultures are selected and, due 
to the low replating efficiencies, cells with a proliferative advantage could be selected. There are 
many techniques that can be used for interrogating genomic integrity of hiPSCs. The most popular 
one is G-banded Karyotyping, by which it has been shown that there are common aneuploidies that 
occur during PSCs culture or reprogramming, like trisomy of chromosomes 12, 8, 20q and X, 
detected in both hESC and hiPSC and of Chr 17 in hESCs (Martins-Taylor and Xu 2012). However, 
chromosomal aberrations smaller than 5 MB in size cannot be detected by karyotyping and, 
therefore, many other methodologies have been developed for this purpose, like whole genome and 
whole exome sequencing, array-based Comparative Genomic Hybridization (aCGH) and high 
resolution SNP genotyping. Throughout the whole  year 2011, 4 studies came out in which by using 
one or more of these techniques several cell lines were analyzed showing the appearance of many 
genetic abnormalities (Gore, Li et al. 2011, Hussein, Batada et al. 2011, Laurent, Ulitsky et al. 2011, 
Disease Strategy Reference 
β-Thalassemia  Safe Harbor integration  (Macarthur, Fontes et al. 2012) 
Diamond Blackfan anemia Safe Harbor integration  (Garcon, Ge et al. 2013) 
Xl-inked Chronic Granulomatosis  Safe Harbor integration  (Zou, Sweeney et al. 2011) 
Sickle Cell Anemia  Gene correction  (Sebastiano, Maeder et al. 2011) and (Zou, Mali et al. 2011) 
Huntington’s disease Gene correction  (An, Zhang et al. 2012) 
β-Thalassemia Gene correction  (Wang, Zheng et al. 2012) 
Parkinson's disease Gene correction  (Soldner, Laganiere et al. 2011) and (Ban, Nishishita et al. 2011) 
a1-antitrypsin deficiency  Gene correction  (Yusa, Rashid et al. 2011) 
Tauopathy  Gene correction  (Fong, Wang et al. 2013) 
Diabetes Knock-In  (Hua, Shang et al. 2013) 
 
Table 2. Corrected iPSC reported in literature by ZFN mediated HR. Disease, correction strategy and reference are shown 
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Martins-Taylor, Nisler et al. 2011). By comparing early and late passage PSC two types of CNV could 
be distinguished, the ones generated during reprogramming and the ones generated during culture. 
It was also reported that some of the variations proceeded from the population over long-term 
culture pointing out that they were positively selected during reprogramming and negatively 
selected during long-term passage. Regarding replication stress and appearance of somatic coding 
mutations, Gore at al found an average of five coding mutations in each cell line being sometimes 
present in cancer related genes (Gore, Li et al. 2011).  
Regarding genome modifications during gene correction, several studies have looked at it carefully. 
In the study of gene correction of A1ATD-hiPSC, a complete genome integrity study was performed 
(Yusa, Rashid et al. 2011). The authors concluded that more genetic alterations were generated 
during the reprogramming process and the extensive culture of the hiPSC than during the HR 
correction. Thus, genome integrity should be carefully studied in gene-edited hiPSCs in the case they 
are intended to be used in clinical settings. 
 
As it was the case of erythroid diseases, such as Sickle cell anemia or β-Thalassemia, and taking into 
consideration the possible genomic modifications that could happen during hiPSC culture, we 
believe that Pyruvate Kinase Deficiency (PKD) patients could also benefit from this powerful 
technology and therefore, we have explored its use on the development of Knock-In gene corrected 
erythrocyte
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V. Aims 
PKD is a rare erythroid metabolic genetic disease, being the most common cause of Non-Spherocytic 
Hemolytic Anemia (CNSHA). Although in many cases the symptomatology is moderate, there are 
some severe cases in which the only definitive treatment is allogeneic bone marrow transplantation. 
In order to avoid transplant-associated complications, an autologous cell therapy in combination 
with gene correction is presented as a promising therapeutic approach. As cell source we consider 
that patient specific hiPSCs, having the ability to differentiate into any cell type and unlimited self-
renewal, are a very powerful cell type. Regarding the gene correction approach, we believe that 
nuclease mediated site-specific gene correction is also a very accurate method. With the purpose of 
studying the feasibility and safety of this kind of therapies, we wanted to develop strategies to 
reprogram and genetically correct PKD samples. Our overall goal was the design of an innovative 
therapy that could be used in a future for severe cases of PKD and to develop tools that could also 
be applied to other genetic hematological diseases. In order to reach our goal we had to achieve the 
following specific aims, also outlined in figure 8: 
 
1. Generation of transgene-free human induced Pluripotent Stem Cells from Pyruvate Kinase 
Deficient patients (PKDiPSCs) and evaluation of their potential for disease modeling. 
 
2. Knock-In gene correction of the PKLR gene by DNA-nuclease assisted homologous 
recombination in PKLR locus and study of the correction efficacy. 
 
3.  Evaluation of genomic integrity of corrected PKDiPSC lines. 
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Figure 8: Gene editing of induced pluripotent stem cells from Pyruvate Kinase Deficient patients. Specific aims of the present 
thesis manuscript are summarized in this diagram.  First, patient specific cells are reprogrammed to pluripotency (aim 1) and then 
genetically corrected by DNA nuclease mediated HR (aim 2). Uncorrected and corrected PKDiPS are going to be differentiated 
into erythroid cells in order to evaluate PKD phenotype before and after correction (aims 1 and 2). Genomic integrity of corrected 
PKDiPSC is also going to be evaluated (aim 3). 
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VI. Materials and Methods 
1. Patient and healthy donor samples 
Peripheral blood (PB) from Pyruvate Kinase Deficient (PKD) patients was obtained from Hospital 12 
de Octubre (Madrid, Spain) (patient PKD1), Fundación Jimenez Díaz (Madrid, Spain) (PKD2) and 
Centro Hospitalario de Coimbra (Coimbra, Portugal) (PKD3). In addition, PB from healthy donors was 
also collected in the Medical Care Service of CIEMAT (Madrid, Spain). All the patient samples were 
collected under written consent. 
PB mononuclear cells (PBMNC) were isolated by Ficoll-Paque (GE Healthcare, WI, USA: density 
1.077) following manufacturer recommendations and were kept frozen or used fresh in further 
experiments. 
1.1 Patient specific mutations detection 
Patient specific mutations were confirmed by DNA Sequencing. Genomic DNA was extracted from 
the different patient and healthy donor cells by QIAamp DNA Blood  kit (Qiagen, Hilden, Germany) 
and the sequences surrounding the mutations were amplified by high fidelity Pfx50 polymerase 
(Invitrogen, Life technologies, CA, USA) using  primers number 1, 2 and 3, 4 for PKD2, and primers 
number 5 and 6 for PKD3 (see primers table). PCR products were purified from agarose gel by 
QIAquick Gel Extraction Kit (Qiagen) and sequenced with the primers used for amplification 
(Stabvida, Portugal; Seqwrite, Houston Texas, USA). Sequences analysis was performed by Vector 
NTI software (Invitrogen) or by Lasergene 10 (DNAstar, WI, USA). 
2. Induced Pluripotent Stem Cells 
2.1 Generation  
Reprogramming was performed right after isolation (PKD2 and PB2) or from frozen samples (PKD1, 
PKD3 and PB1). PB-MNCs were pre-stimulated for four days in StemSpan (StemCell Technologies, 
British Columbia, Canada) plus 100 ng/mL hSCF, 100 ng/mL hFLT3L, 20 ng/mL hTPO, 10 ng/mL G-CSF, 
and 2 ng/mL hIL3 (Peprotech, NJ, USA). The cells were collected and transduced with either a mix of 
Sendai viral vectors (SeV) expressing OCT3/4, KLF4, SOX2, c-MYC and Azami Green or with STEMCCA 
excisable polycistronic lentiviral vector expressing mouse OCT3/4, KLF4, SOX2, c-MYC. Both vector 
systems were used at multiplicity of infection 3.  The Sendai Viral vectors were kindly provided by 
the company DNAvec (Ibaraki, Japan) in form of viral particles. The STEMCCA lentiviral vector was 
kindly provided by Gustavo Mostoslavsy and the viral particles were generated at CIEMAT as 
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described (Sommer, Stadtfeld et al. 2009). Transduced cells were maintained with the described 
cytokines for four more days and then supplemented with 10 ng/ml of bFGF. Five days after 
transduction cells were collected, counted and seeded on irradiated HFF-coated 100 mm culture 
plates with hES media (DMEM/F12, 20% knockout serum replacement [KO-SR], 1 mM L-glutamine, 
1% nonessential Amino Acids [All from Life technologies], 0.1 mM -Mercaptoethanol (Sigma-
Aldrich, MO, USA) and 10 ng/ml basic hFGF (Peprotech, NY, USA or Invitrogen)) at density 150-800 
cells/cm2. hES media was changed every other day. When hES-like colonies appeared, they were 
selected under the stereoscope (Olympus, Tokio, Japan) and a clonal culture from each colony was 
established. All the established iPSC lines were generated by SeV. 
2.2 Culture conditions 
hiPSC lines were maintained over a layer of irradiated fibroblast, which were either irradiated 
Human Foreskin Fibroblast (HFF-1, ATCC), irradiated Mouse Embryonic Fibroblasts (MEF, ATCC) or 
irradiated puromycin resistant MEFs (Puro-MEF, STEMCELL Technologies). Fibroblasts were cultured 
and expanded in DMEM medium, 1mM L-glutamine, 1% nonessential Amino Acids (All from Life 
technologies), 20% Hyclone FBS (Thermo Scientific, Thermo Fischer Scientific, MA, USA),  irradiated 
at 45 Gy and frozen in viability at 2.5 x 106 cells/vial. The day before iPSC splitting, feeders were 
seeded at 19,000 cells/cm2 in gelatin pre-coated plates. hiPSC lines were cultured in hES media, 
which was changed daily. When iPSCs reached 80-90% confluence and the colonies looked dense 
(usually once a week) they were passed in a 1:4-6 ratio using 1 mg/ml Collagenase IV (Life 
technologies) for 3 minutes and then scraping.  
For electroporation experiments, a single cell suspension was generated. Cultures ready to split (70-
80% confluent) were washed twice with PBS and treated with StemPro Accutase (Life Technologies) 
for 3 minutes. Cells already at single cell stage but still forming the colony were very gently washed 
with PBS and hES media was added. Cells were finally detached by pipetting up and down several 
times. When a higher cell survival was needed, like higher amplification ratio or after generating 
single cell suspensions, the cells were cultured for 1 day in hES media supplemented with 10 M of 
the Rock Inhibitor Y-27632 (Sigma-Aldrich). 
2.2.1 Freezing/Thawing 
On average, one 80% confluent well of a 6 well plate was used for generating 2 vials of frozen iPSCs. 
Cells were Collagenase IV treated, scraped and resuspended in hES media. An equal amount of 2X 
freezing media (20% DMSO, 20% hES media and 60% Hyclone FBS) was gently added while shaking 
the mixture. Cells were frozen overnight in a controlled freezing container at -80 °C. After 24 hours 
frozen vials were transferred to liquid nitrogen cryogenic tank. For thawing, the cryotube was quickly 
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transferred from the cryogenic tank to the water bath at 37°C. Before the cells were completely 
thawed they were taken out, drop wise mixed with hES media and spun down for 5 minutes at 200 
g. The cell pellet was resuspended in hES media with 10 M of Rock Inhibitor Y-27632 and 
transferred into a feeder coated 6 well plate.  
2.3 hiPSC characterization 
2.3.1 Alkaline Phosphatase  
hiPSC lines growing on feeders were fixed for 10 minutes with 2% PFA, washed twice with PBS and 
Alkaline Phosphatase staining was performed with VECTOR Blue Alkaline Phosphatase Substrate Kit, 
following manufacturer specifications (Vector Laboratories, CA, USA). The stained samples were 
analyzed and counted under an Olympus IX6 microscope (Olympus, Tokio, Japan) 
2.3.2 RT-PCR gene expression array 
Gene expression of 84 key genes involved in the maintenance of pluripotency and the self-renewal 
status of human embryonic stem cells (hESC) was analyzed by using hESC RT2 Profiler PCR Array as 
described by manufacturer (SaBiosciences, Qiagen). First, RNA was isolated from 1 confluent 6 wells 
plate of hiPSC by RNeasy Plus Mini Kit (Qiagen) and then cDNA was generated using 5 g of RNA/ 
reaction with RT2 First Strand Kit (SaBiosciences). cDNA was added to the quantitative PCR array 
plate and the rest of the protocol was followed as recommended by the manufacturer. The machine 
used was an ABI 7900 (Applied Biosystems, Life Technologies). cDNA extracted from the hESC line 
H9, obtained from Wicell (Wisconsin, USA) was used as control. 
2.3.3 Teratomas 
Teratomas were generated by subcutaneous injection of a whole confluent 6 well plate into 
immunocompromised NOD.Cg-PrkdcscidIL2rgtm/Wjl/SzJ (NOD scid gamma null (or NSG)) mice 
(Jackson Laboratories, Maine, USA). The culture was treated with collagenase IV, the colonies were 
cut in small pieces, spun down for 5 minutes at 200 g and resuspended in 140 ul of DMEM/F12. Just 
before injecting the mice the cell suspension was mixed with 60 ul of hES qualified Matrigel (BD 
Bioesciences, CA, USA). After 8-10 weeks the tumors were visible. The mice were sacrificed, the 
tumors were removed and the tissue pieces were fixed in 4 % PFA, embedded in paraffin and serially 
sectioned into 5 μm sections by the Histology facility of the CIEMAT. Every four slides, one was used 
to do hematoxylin and eosin staining as previously described (Certo, Gwiazda et al. 2012). The rest of 
the slides were used for immunostaining as described later.  
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2.3.4 Promoter demethylation 
The study of the presence of demethylated CpGs in NANOG and SOX2 promoters was kindly 
performed by the Myeloproliferative Syndromes laboratory of the Center for Applied Medical 
Research (CIMA, Pamplona). 
2.3.5 Karyotyping  
G-Banding and analysis of metaphasic chromosomes were performed by the Cancer Cytogenetic 
Core of the Texas Children Cancer and Hematology Center (Houston, Texas). Briefly, cells were 
incubated overnight with colcemide, then treated with KCl and a mix 3:1 of methanol/Glacial Acetic 
Acid and finally dropped into slides and Giemsa stained. The 23 sets of chromosomes were counted 
in 15-20 metaphasic cells in order to see if there was any chromosome aberration.  
2.3.6 Immunoglobulin Chain and T cell receptor rearrangement analysis 
Genomic DNA from hiPSC was purified and sent to the Histocompatibility and Molecular Biology 
Laboratory from Madrid Blood Transfusion Centre, where rearrangement analysis was kindly 
performed following BIOMED-2 strategy (van Dongen, Langerak et al. 2003).  
2.3.7 Comparative Genomic Hybridization (CGH) 
hiPSC were MEF depleted using mouse feeder removal MicroBeads, an LS Column, and a MidiMACS 
Separator following manufacturer recommendations (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Genomic DNA (gDNA) was extracted from purified hiPS using ArchivePure DNA Cell/Tissue Kit 
(Prime5, Hamburg, Germany), and quantity and quality of the obtained DNA were checked by 
spectrophotometry (Nanodrop) and agarose gel analysis. Copy Number Variation (CNV) analysis was 
conducted by Wicell cytogenetic laboratory (Madison, USA). Genomic DNA was labeled and 
hybridized using the SurePrint G3 ISCA CGH+SNP Microarray Kit, from Agilent, an array of CGH based 
on competitive differential hybridization of labeled genomic DNA to the 180,000 oligonucleotide 
whole genome tiling array containing ≈120,000 CGH probes and ≈60,000 SNP probes. It covered the 
whole genome with some spacing (25.3kb overall, 5kb in ISCA regions). Bioinformatics analysis was 
performed using Agilent CytoGenomics Edition 2.5.8.1 and infoQuant CGHfusion 6.1.1. Test samples 
were compared to Agilent’s genotyped reference DNA. It was considered as CNV when the 
aberration was covered with more than 3 probes.  
2.3.8 Exome sequencing  
Same samples as for CGH were used for exome sequencing, that was performed by Axeq 
Technologies (MD, USA). Briefly, gDNA was fragmented and a library of sequences corresponding to 
the human exome was generated by Agilent’s SureSelect v4 Exome enrichment kit. Then, the 
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samples were sequenced to at least 30 fold (30X) average on target depth coverage using Illumina 
HiSeq 2000 system with 100-bp paired-end sequencing method. Variant calling and gene annotation 
were performed as previously described (Ju, Kim et al. 2011). In addition, variants had to fulfill these 
criteria: 1) Read Depth: the number of uniquely mapped reads at the position had to be > 8; 2) The 
average base quality for the position had to be ≥30; 3) The allele ratio at the position had to be ≥20% 
for heterozygous variants. The resulting variants that were present also in PKD2 PB-MNC (original 
sample before reprogramming), even if they were very low represented, were filtered. No variant 
from corrected PKD2iPS in which the number of reads in PB-MNC was < 8 was considered as we 
could not discard their presence in the original population.  Variants present in the SNP database 
(SNPdb) were also removed. Resulting variants were validated by PCR amplification (primers 52-65) 
and Sanger sequencing as explained for patient specific mutations detection. 
2.4 Erythroid Differentiation 
hiPSC were differentiated according to 2 described protocols, the one of Robert Lanzas group (Lu, 
Feng et al. 2008) and the one described my Elefantys group (Hatzistavrou, Micallef et al. 2009) with 
some modifications. hiPSC were forced to form Embryoid Bodies (EBs) in both protocols, and from 
day 0 to day 1 they were cultured in hES media plus 10 uM of the Rock Inhibitor Y-27632.  In the one 
developed by Dr Lanzas group, the first day, the EBs were cultured with 50 ng/ml of BMP4 and VEGF 
and then SCF, FLT3L and TPO 40 ng/ml are added for 4 more days. In a second stage of 
differentiation, EBs were disaggregated and cultured in Blast Growing media (Lu, Feng et al. 2007) in 
order to form hemato-endothelial blast colonies. In the one described by Hatzistavrou et al; EBs 
were cultured in APEL differentiation media (Stem Cell technologies) supplemented with 20 ng/ml 
VEGF, 20 ng/ml BMP4 and 40 ng/ml SCF for the first 10 days, and then they were transferred to 
gelatin coated plates with APEL plus erythroid differentiation promoting cytokines 10 ng/ml VEGF, 
20 ng/ml IL3,  50  ng /ml SCF,  3  U /ml EPO, 20 ng/ml TPO, 20 ng/ml GM-CSF and 20 ng/ml IL6. All 
cytokines were from Peprotech. At day 21 of differentiation, erythroid markers CD235a and CD71 
and the pan leukocyte marker CD45 were analyzed by flow cytometry. In order to disaggregate the 
3D structures formed in the gelatin coated plates, we applied the following enzymatic treatment: 20 
minutes of collagenase IV 1mg/ml followed by 10 minutes of Trypsin/EDTA 0.25% (Gibco). 
3 Homologous Recombination enhanced by Nucleases 
3.1 Plasmids 
Cellectis therapeutics (Paris, France) designed two different PKLR01 Meganuclease (MG), version 1 
and version 2, and one PKLR01 TALEN (TA) to target the intron 2 of PKLR gene. The exonuclease 
TREX2 was also kindly provided by them. These nucleases were shared in the form of DNA plasmids. 
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The expression of the nucleases was driven by Elongation Factor 1 alpha (EF1α) promoter. 
Additionally, two plasmids coding for each subunit of the AAVS1 Zinc Finger Nucleases (ZFNs) were 
kindly provided by Sangamo Biosciences (CA, USA). 
3.2 mRNA synthesis 
Nucleases were used as mRNA in some experiments. In order to synthesize mRNAs of the two 
version of PKLR01 MG, two subunits of AAVS1 ZFN and TREX2, their cDNAs were cloned after a T7 
promoter. Briefly, cDNAs were amplified by PCR using the following primers that carry the T7 
promoter: primers nr 11 and 12 for cloning PKLR01 MG and TREX2, and primers nr 13 and 14 for 
AAVS1 ZNF subunits. PCR products were purified and cloned into pCR®-Blunt vector by Zero Blunt 
PCR Cloning Kit (Invitrogen). The sequence and orientation of the cloned products were confirmed 
by sequencing with M13 primers. PKLR01 TA plasmids were already provided with the T7 promoter. 
cDNAs were excised from the vectors by the following enzymes:  EcoRI or HindIII for MGs and TREX2, 
and HindIII and XhoI for ZNFs. Two hundred ng. of the digested and purified product were used to 
synthesize mRNA using the mMESSAGEmMACHINE® T7ULTRAKit (Ambion, Invitrogen) following 
vendors guidelines and purified by LiCl precipitation. The concentration and quality were analyzed 
by Agilent 2100 Bioanalyzer. TAs containing plasmids were linearized with HindIII and purified by 
phenol/chloroform extraction followed by 100% Ethanol and 3M Sodium Acetate precipitation. One 
µg of the linearized PKLR01 TA plasmid was used for mRNA synthesis as previously explained. 
3.3 Nuclease cleavage activity 
3.3.1 MG PKLR-specific DSBs generation analysis by deep sequencing 
HEK-293H cell line (Invitrogen) was cultured in DMEM medium with Glutamax (Gibco, Life 
Technologies, California, USA), 10% Hyclone FBS (Thermo Scientific) and 1% penicillin/streptomycin 
(Gibco). The cells were transfected with or without 3 g of nuclease plasmid with Lipofectamine 2000 
(Invitrogen) following vendor guidelines. MG expressing plasmids were co-transfected with a 
plasmid expressing TREX2 protein, which increases the sensitivity of the assay. After 72 hours, the 
gDNA was isolated and the surrounding PKLR01 target site was PCR amplified with different forward 
primers carrying different TAGs for sample identification after deep sequencing  (nr 7, 8, 9, TAGs in 
bold and underlined in Primer Table)  and reverse primer nr 10 using  Herculase® II Fusion DNA 
Polymerase (Stratagene, Agilent Technologies, CA, USA). The reverse primer has a common biotin 
TAG for all the samples. A different combination of primers was used for each sample. The PCR 
products with the appropriate TAGs were agarose gel purified and sent to Cellectis to perform the 
deep sequencing analysis. 
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3.3.2 Surveyor assay 
Different amounts of mRNA or DNA of MG, TA, ZFN and TREX2 were transfected by nucleofection 
according to the optimized protocol for AMAXA Nucleofection technology (Lonza, Basel, 
Switzerland), with several modifications. K-562 cell line was electroporated in human CD34+ 
nucleofector buffer using the U08 program. After nucleofection, cells were left in the cuvette for 20 
minutes at 37°C in order to be recovered from the electric pulse and then pipetted and transferred 
into the pre-equilibrated culture medium. For hiPSCs, 1-2 million cells were nucleofected in 
Nucleofection Solution 1 using A23 program. After nucleofection, cells were seeded into a fresh MEF 
feeder plate. Seventy-two hours after the nucleofection, gDNA was extracted from the cells and the 
nuclease target site was amplified by PCR with primers nr 15 and 16. These PCR products were 
directly used as samples for the Transgenomic SURVEYOR Mutation Detection Kit for Standard Gel 
Electrophoresis (Transegomic, NE, USA). First, the PCR products were forced to form heteroduplex 
by the following cycle in the thermocycler: 95°C for 10 min, 95°C to 85°C (2°C/ sec), 85°C to 25°C 
(0.1°C/ sec), 4°C forever. Then, 1 μl of Surveyor nuclease S and 1 μl of Surveyor enhancer S were 
added, and they were incubated for 1 hour at 42°C. The digested products were evaluated by 
separation on a 10% Novex TBE gel with Novex TBE Running Buffer and Novex TBE High density 
Sample Buffer (Invitrogen). The samples run for 1.5 hours at 100 V and were stained with 1:10000 
diluted SyberGold (Invitrogen). Cutting efficiency was evaluated by comparing the non-cleaved 
Homoduplex against the cut heteroduplex containing mutation sequences by Image J software. 
3.4 Generation of the targeting matrix 
Figure 9 shows a scheme of all the elements of the donor matrix that served as template for 
homologous recombination in the intron 2 of the PKLR locus. The homology arms (HAs) were 
designed 
to start 25 bp to the right side and 25 bp to the left side of the cutting site of PKLR01 MG. Both HA 
were designed to be 1 Kilobase (Kb) long. The HAs were chemically synthesized and then included in 
a pUC57 (pUC-HAs), leaving several restriction sites in the middle in order to clone the additional 
elements of the matrix. 1) Expression Cassette (EC), composed of the Splicing Acceptor (SA) from 
intron 1 of PPP1R12C gene, the codon optimized cDNA from RPK exons 3-11 (coRPKE3-11) with a 
FLAG tag and SV40 polyA at the end. 2) Selection Cassette (SC), composed of the mouse PGK 
promoter, which drives the expression of the Puromycin resistance and Thymidine Kinase fusion 
protein, and the BGH PolyA signal. The whole SC was floxed by LoxP sequences so that it could be 
removed by ectopic Cre expression.  
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The EC was constructed using Overlapping PCR (OpPCR) procedure, by the amplification of a longer 
product by using 2 PCR products as templates, which share some homology in their ends. These 2 
PCR products were the coRPK cDNA (PCR1) and the SV40polyA (PCR2), amplified by primers 17, 18 
and 19, 20 respectively. The Splicing Acceptor was included in the forward primer (primer nr 17) of 
the PCR1 product and the FLAG tag in the reverse (primer nr 18). All the amplifications were done 
with Pfx50 and the OpPCR protocol was as follows: PCR1 and PCR2 were agarose gel purified and 50 
ng of PCR1 and an equimolecular quantity of PCR2 were included in the OpPCR mixture without 
primers and the following cycle was applied. 94 °C for 5 min, 14 times: 94 °C for 20 seg., 60 °C for 30 
seg., 68 °C for 90 seg. Primers 17 and 20 were added and the previous cycle was repeated 20 more 
times. Then 68 °C for 5 mins. and 4 °C until stopped. After amplification, the EC was cloned into 
pCR®-Blunt vector by Zero Blunt PCR Cloning Kit and the quality of the sequence was verified by 
sequencing with M13 Forward and Reverse primers. Selection Cassette (SC) was kindly provided by 
Dr. Brian Davis laboratory (Houston, Texas, USA). Both Expression (EC) and Selection Cassette (SC) 
were included in pUC-HAs by the In-fusion HD Cloning Kit (Clontech Laboratories, CA, USA) following 
vendors guidelines. In more detail, pUC-HAs was linearized by a NheI restriction enzyme that was in 
the middle of the two HAs. The EC and the SC were introduced at NheI site in one step by using In-
Fusion Technology. According to the In-Fusion provider, each of the pieces to be cloned has to have 
homologous ends with the other fragments cloned around. The homologous sequences are included 
in the primers for PCR amplification of the products to include in the plasmid (primers 21-24). The 
linearized plasmid and the amplified EC and SC were agarose gel purified and the quality and 
quantity of each product were assessed in another agarose gel. For the In-Fusion reaction 50ng of 
the linearized plasmid and a molar ratio of 1:2:2 of the other 2 inserts were used in a final volume of 
10 μl. After In-Fusion reaction Stellar Competent cells (Clontech) were transformed and 30 colonies 
were screened by colony PCR as previously described (Machado, Manco et al. 2012) using primers 17 
and 20 and Herculase®  Fusion II polymerase. The expected PCR product was amplified in one of the 
30 colonies. This clone was grown and plasmid DNA was isolated. The presence of the correct 
 
Figure 9: PKLR Donor Matrix elements. Homology Arms are shown in orange, LA (Left Arm) and RA (Right Arm). EC: Expression 
Cassette: SA, Splicing Acceptor that will anchor splicing donor from endogenous exon 2. CoRPK E3-11, Codon Optimized 
version of RPK cDNA, exons 3 to 11. Before the Stop codon there is a Flag Tag that will allow us to follow the expression of the 
transgene. pA: SV40 PolyA signal. SC: Selection Cassette, floxed by LoxP signals: Mouse PGK promoter drives the expression of 
the Puromycin resistance and Thymidine Kinase fusion gene. pA: BGH PolyA signal. 
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targeting vector was assessed by the restriction enzyme HindIII. Sequencing the whole construct by 
primers nr 25-35 assessed the integrity of the PKLR targeting matrix. 
3.5 Homologous recombination in K-562 cell line 
Nucleofection was performed the same way as for Surveyor (or Cel1 assay) but in this case the 
PKLR01 MG was delivered as plasmid DNA and in combination with PKLR targeting matrix. Two days 
after transfection, puromycin at 2 μg/ml was added to the culture and it was maintained for 20 days.  
3.5.1 PCR assessment of Homologous Recombination  
PCR was carried out using two pairs of primers that  recognized the PKLR locus outside the homology 
arms and another that recognized inside the integrated targeting matrix (primers nr 36 and 37). This 
PCR was carried out by Herculase® II Fusion DNA Polymerase (Stratagene). 
3.5.2 Erythroid differentiation of K-562 
K-562 cells were differentiated by addition of 25 μM of Hemin BioXtra, from Porcine, ≥98.0% (Sigma-
Aldrich) as previously described (Baliga, Mankad et al. 1993). Differentiated and undifferentiated 
cells were analyzed by FACS. 
3.6 Homologous recombination in hiPSCs 
Nucleofection was performed the same way as for Surveyor assay. Different amounts of nucleases as 
plasmid DNA or mRNA were nucleofected by Amaxa. After nucleofection, the cells were seeded into 
a feeder of irradiated puromycin resistant MEFs and 48 hours after transfection, puromycin (0.5 
μg/ml) was added to hES media. When performed with MG, 10% of each condition was seeded into 
one well of a 6 well plate and 7 days post-selection, Phosphatase Alkaline Staining was performed in 
order to count resistant colonies and compare between the different conditions. The rest of the 
nucleofection reaction was seeded into a 100 cm tissue culture plate. The selection was carried out 
for 6-10 days and the resistant colonies were picked individually under the stereoscope and seeded 
into new Puromycin resistant MEFs to start a clonal population from each single colony. Puromycin 
was maintained in the culture until the whole homologous recombination analysis was finished.  
3.6.1 HR analysis  
3.6.1.1 Colony PCR  
One puromycin resistant colony per clone was picked into 100 ul of PBS. After spinning down for 5 
minutes at 300 g, it was resuspended in 20 l of lysis buffer: 5mM Tris pH 8.3, 0.45% NP40 and 
0.45% Tween20 and 100 μg/μl of Proteinase K and treated for 2 hours at 55°C and 10 minutes at 
95°C. 10 l of the lysis reaction were used per PCR. Two PCR types were performed looking for 
integration by HR: primers 36 and 37 (Primer pair 1, pp1) and 38 and 39 (primer pair 2, pp2). Both 
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reactions were carried out by Phusion Hot Start II High-Fidelity DNA Polymerase (Thermo Scientific), 
pp1 with CG rich Buffer and pp2 with high fidelity buffer. Another control PCR to check for DNA 
presence was carried out to look for an endogenous unmodified gene of the genome (CFTR gene) by 
primers 40 and 41 and GoTaq DNA polymerase (Promega, WI, USA) 
3.6.1.2 Southern Blot 
5-20 μg of genomic DNA were isolated from each clone and digested with ScaI and SpeI (New 
England Biolabs, MA, USA) in separate reactions for 8 hours at 37°C. The samples were concentrated 
by precipitation with ethanol and sodium acetate and resolved on a 0.8% agarose gel. Transfer to a 
NytranSuPerCharge nylon membrane was carried out overnight by turbo Blotter transfer system 
(Whatman, GE healthcare) following systems guidelines and then exposed to UV cross-linking (120 
mJ/cm2).  Pre-hybridization and hybridization were carried out by quick hybridization solution 
(Agilent technologies) in rolling cylinders inside the hybridization oven at 65°C. The probe was 
generated by excising the Targeting Donor by HindIII restriction enzyme and isolating a 1935 bp 
band from an agarose gel. It was labeled with radioactive P32dCTPs by Prime-It II Random Primer 
Labeling kit (Agilent) following vendor guidelines. Once labeled, the non-incorporated radioactivity 
was removed by cleaning the probe with IllustraNICK Columns (GE Healthcare). After 15 minutes of 
prehibridization, the probe was added to the quick hybridization solution and left overnight. After 12 
hours, the membrane was washed twice with 2X SSC, 0.1% SDS for 10 minutes at room temperature, 
then for 15 minutes with pre warmed 1X SSC, 0.1% SDS at 65°C and finally for 50 minutes with 0.1X 
SSC, 0.1% SDS at 65°C with two media changes. Then, the membrane was covered with plastic wrap 
and introduced in a Hyperscreen autoradiography cassette together with an Amersham Hyperfilm 
ECL (GE Healthcare) that was exposed overnight at -80°C covered. After a minimum of 10 hours, the 
film was developed in an automated processor. 
3.6.2 Western Blot 
The presence of untargeted RPK and flagged RPK was analyzed in hiPSC erythroid differentiation 
protein lysates. For RPK, a polyclonal antibody (Ab. nr 21) developed by Dr Meza (Táchira Medicine 
School, University of Los Andes, San Cristóbal, Venezuela) by rabbit immunization with the human 
recombinant enzyme (Diez, Gilsanz et al. 2005) was used. Flagged RPK was detected by Ab. nr 20 and 
β-Actin, used as loading control, with Ab. nr 22. Cell lysates were generated treating the cells with a 
buffer consisted of 50mM Tris pH 7.5, 150 mM NaCl, 1% NP40, 2mM EDTA supplemented with 
Protease Inhibitors (Roche Diagnostics, Switzerland). Total protein concentration was determined 
using Quick Star Bradford Protein Assay kit (Bio-Rad, CA, USA). Samples were mixed with NuPAGE 
LDS Sample Buffer (Invitrogen) and 2-mercaptoetanol and loaded into SDS polyacrylamide gel (4-
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12% Bis-Tris Nu-PAGE, XCell II Blot, Invitrogen) and run at 125 V for 1h. A pre-stained protein ladder 
was used (PageRuler, Thermo Scientific). Proteins were then transferred using a humid transfer 
system into nitrocellulose membranes (mb) (Hybond-ECL, Amersham Bioscience) at 150V for 1.5 
hours at 4°C. Protein containing mb was blocked with 5% milk in TBS for 1 hour at RT and incubated 
with primary Ab diluted in blocking buffer overnight at 4°C. The mb was washed three times with 
TBS-T (Tris-PBS, 0.05% Tween20) and incubated with secondary Ab conjugated to horseradish 
peroxidase (HRP) for 1 hour at RT. Detection was carried out using Amersham ECL Select Western 
Blotting detection Kit (GE Healthcare) and Kodak Medical X-Ray Films. 
4 General techniques 
4.1 Immunohistochemistry 
- For pluripotency analysis: hiPSCs were seeded on feeder pre-coated 2 well Lab Tek chamber slides 
(Nunc, Thermo Fischer, Thermo Fischer Scientific, MA, USA). When the colonies had the appropriate 
size (≈6 days), they were fixed with 4% PFA for 10 minutes at RT. Fixed colonies were washed twice 
and blocked and permeabilized with the following solution for 1 hour at room temperature: 1% BSA, 
10% FBS, 0.3M Glycine, 0.1% Tween20 in PBS. Two different double detections for presence of 
embryonic proteins were performed by immunostaining with: 1) rabbit anti-NANOG (Ab nr 6) + 
mouse anti-Tra160 (Ab nr 7) and 2) rabbit anti-OCT4 (Ab nr 8) + mouse anti-SSEA4 (Ab nr 9) (see 
antibodies table). The samples were incubated overnight in PBS, washed 3 times with PBS and 
incubated for 1 hour with anti Rabbit Ab conjugated to Alexa488 (Molecular Probes), anti Mouse Ab 
conjugated to Texas Red (Jackson Immunoresearch Laboratories, UK) and DAPI or Topro3 for DNA 
staining. After 3 washes with PBS, Vectashield mounting solution (Vector Laboratories) was added 
and the slides were covered and let dry overnight. Immunofluorescence images were acquired with 
Zeiss Axioplan2 epifluorescence microscope (Carl Zeiss) equipped with an AxioCam MRm camera 
(Carl Zeiss) and the pictures obtained were processed with AxioVision version 4.6.3 (Carl Zeiss) and 
Corel Photo-Paint 11 (Corel). 
- For teratoma analysis: First, slides were deparaffinizated at 54°C for 30 minutes followed by 20 
immersions in Histoclear followed and then rehydration in decreasing ethanol solutions of 100%, 
95%, 70%, 50% (v/v) and finally in water. Antigen retrieval was carried out in 10mM Sodium Citrate, 
0.05% Tween 20, pH 6.0 at 95°C for 20-30 minutes followed by cooling for another 20 minutes and 2 
washes with PBS. Slides were blocked for 30 minutes at RT with PBS/ 4% FBS/ 0.2% TritonX10. For 
immunostaining, slides were incubated overnight at 4°C with rabbit anti-neuron specific beta III 
tubulin (Ab. Nr 15). The rest of the protocol continued as previously explained for pluripotency 
analysis.  
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4.2 Flow cytometry 
- For population profile analysis: PB-MNC were stained for 30 minutes at 4°C in the dark using the 
following cocktail of conjugated antibodies: anti CD3-PECy5 (Ab nr 1), anti CD19-PE (Ab nr 2), anti 
CD14-PE (Ab nr 3), anti CD15-PECy5 (Ab nr 4) and anti CD34-PE-Cy7 (Ab nr 5) (See antibodies table 
for details). Then, they were washed and resuspended in DAPI containing PBA (1.0% BSA/0.1% 
sodium azide in PBS) buffer. Azami green expression was also analyzed in each positive population 
by flow cytometry in BD LSR Fortessa (Becton Dickinson, CA, USA). FSC files were analyzed with Flow 
Jo software v10 (TreeStar, OR, USA).   
- For pluripotency analysis of hiPSC: cultures were washed twice with PBS and then treated with 
Accutase for 5 minutes at 37°C. Then they were collected, washed with PBS, 2% FBS (FACS Buffer) 
and stained first with the following mix of Antibodies for 30 minutes at 4°C in a final volume of 100 
l: anti-CD29-Alexa 488 (Ab nr 10) and anti-SSEA4-APC (Ab nr 11). Then they were washed with FACS 
buffer, fixed with 2% PFA for 30 minutes at RT, washed again and permebilized with 
permeabilization buffer (0.1% Saponine and 0.1% BSA in PBS) for 30 minutes at RT in the dark. After 
washing, staining with anti-OCT4-PE (Ab nr 12) was done. Cells were finally analyzed by flow 
cytometry 
- For erythroid analysis: cells at days 15 and 20 of differentiation were collected and disaggregated, 
washed twice, resuspended in PBA buffer and stained with the following antibodies for 30 minutes 
in the dark at 4°C: anti CD235a-PE (Ab nr 17), anti CD71-FITC (Ab nr 18), and anti CD45-APC (Ab nr 
19).  
- FLAG expression was also assessed by flow cytometry. Cells were fixed, permebilized and washed 
by BD Cytofix/Cytoperm Fixation and Permeabilization Kit (BD Biosciences, NJ, USA) following vendor 
guidelines and stained with a monoclonal antibody against DYKDDDDK FLAG epitope conjugated to 
Alexa Fluor 647 (Cell signaling Technology, MA, USA) (Ab nr 20). One million cells were stained with 2 
μl of Ab in a final volume of 50 μl for 30 minutes at room temperature protected from the light.  
Cells were washed and analyzed as previously described.  
4.3 Gene expression analysis 
- For the study of Erythroid differentiation, RNA was extracted at day 21, and RPK and MPK 
expression were analyzed by quantitative reverse transcriptase PCR (qRT-PCR). RNA was isolated by 
TRIzol® (Life Technologies) extraction and isopropanol precipitation. For cDNA generation 
AmbionRETROscript First Strand Synthesis Kit or SuperScript VILO cDNA Synthesis Kit (Invitrogen, Life 
technologies) was used as recommended by the manufacturer. Thirty ng or more of equivalent 
cDNA were used in each reaction. The following primers were used for each transcript detection; 
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RPK: primers nr 46 and 47, MPK: nr 48 and 49 for and β-Tubulin: primers 50 and 51 (used as 
housekeeping gene). The specificity and efficiency of these primers was validated prior using them. 
qRT-PCR was carried out in an Applied Biosystems 7500 Real-Time PCR System (Life Technologies) 
using Fast SYBR Green Master Mix (Applied Biosystems, Life Technologies) as described by 
manufacturer.  
- Sendai viral transcripts presence was analyzed by reverse transcription PCR using a pair of primers 
that bind a sequence present in all the vectors used in our experiments. The detection of SeV cDNAs 
was performed by Pfx50 polymerase (Invitrogen, Life Technologies) using 2 l of cDNA and primers 
nr 42 and 43. To assess the quality of the cDNA sample, GAPDH presence (primers 44 and 45) was 
also analyzed. cDNA from  PB-MNCs transduced with azami green SeV was used as positive control.  
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VII Results 
1. Cell reprogramming 
In order to have an unlimited source of stem cells from PKD patients, our first goal was the 
generation of hiPSC from PKD patients that could be used for disease modeling and gene correction 
of the disease.  
1.1. Generation of hiPSCs from Peripheral Blood Monuclear Cells (PB-MNC) 
We investigated several procedures for the generation of hiPSC from PKD patients. In order to 
obtain a clinically oriented reprogramming platform, the efficiency of two available non-
integrative/excisable technologies were tested: Excisable reprogramming lentiviral platform 
(STEMCCA (Sommer, Stadtfeld et al. 2009)), which expresses the four Yamanaka´s Factors in a 
polycistronic construct and can be excised using Cre Recombinase, and reprogramming Sendai 
Viruses (SeV), non-integrative RNA vectors expressing the same factors in four independent vectors. 
In order to evaluate their efficiency, a comparison of both methodologies was carried out by 
reprogramming healthy donor PB-MNCs. The protocol used for reprogramming is represented in 
figure 10A. Non-lymphoid cells were pre-stimulated by a specific cytokines combination. Five days 
post-transduction, 15,000 cells/well were plated in each well of a 6 well plate pre-coated with 
human irradiated fibroblast feeders (HFF). After 4-6 days the first colonies appeared, that turned out 
to be unstable. During the second week, colonies with a clear morphology of pluripotent colonies 
came out: flat, dense and with well-defined colony edges. After 12 days, the cells were fixed and 
Alkaline Phosphatase (AP) staining was performed in order to estimate the quantity of 
reprogrammed colonies (Figure 10B). 
Efficiency was calculated as the number of colonies over the number of seeded cells, assuming that 
each colony was originated from a single reprogrammed cell, so ( . As the number of 
cells seeded is 15,000 the lowest efficiency that could be detected was 0.007% (= ). The 
efficiency of Sendai reprogramming vectors was 0.4-0.6%, whereas no pluripotent colony was 
formed after STEMCCA transduction. Thus, SeV reprogramming technology was selected for the 
generation of hiPSC from patient PB-MNC samples. 
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Figure 10: Peripheral Blood Mononuclear Cells (PB-MNC) reprogramming to pluripotency. A) Reprogramming methodology: 
Cells are prestimulated with the shown cocktail of cytokines and then transduced with either Stemcca excisable lentiviral 
polycistronic vector or Sendai reprogramming vectors. B) Reprogramming efficiencies comparison between the two 
reprogramming platforms is shown. Twelve days after seeded in HFF feeders, AP was performed to detect pluripotent 
colonies. 
 
 
1.1.1 Targeting non-lymphoid cells for reprogramming 
As PB-MNCs is a heterogeneous population composed of many different hematopoietic lineages and 
we would like to avoid any selection step to minimize the cells manipulation, reprogramming of 
lymphoid cells should be taken in consideration. If a T or B cell is reprogrammed, the genetic 
information corresponding to the T cell receptor (TCR) or to the immunoglobulin (Ig) chains is going 
to be rearranged and therefore, the resulting hiPSCs are not going to have the ability to generate a 
complete repertoire of T or B lymphocytes with different specificities, limiting its differentiation 
ability.  
 63 
RESULTS 
 
  
Trying to avoid lymphoid reprogramming, we added a combination of cytokines to prompt 
transduction, proliferation and survival of the non-lymphoid cell subsets present in human PB-MNC. 
To analyze SeV transduction efficiency under the stimulation conditions proposed, we looked at the 
proportion of transduced cells within the different hematopoietic subsets by a control SeV encoding 
for the Azami green fluorescent marker. The presence of marked cells in the different hematopoietic 
cell types was assessed five days after transduction (Fig. 11). We stained the cells with the following 
cocktail of antibodies and looked for Azami green expression in each positive population (T 
Lymphocytes: anti-CD3, B Lymphocytes: anti-CD19, Myeloid cells: anti-CD14 and anti-CD15 and 
Hematopoietic Progenitors: anti-CD34). A high proportion of the total transduced cells were 
lymphoid cells (50%) due to their high presence of in the original sample. However, in the myeloid 
and CD34 positive subset, the transduction percentage was much higher than in lymphoid cells: 54% 
of transduction in macrophages and granulocytes and 76% of hematopoietic progenitors whereas 
13% in lymphocytes, which indicates a preferential transduction of myeloid cells and hematopoietic 
progenitors under the selected culture conditions. These conditions were selected for the following 
experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.2 Pyruvate Kinase Deficient (PKD) patient and healthy donor reprogramming by SeV  
For the generation of patient specific hiPSCs, PB-MNCs were isolated from 3 PKD patients (PKD1, 
PKD2 and PKD3) and 2 healthy donors (PB1 and PB2) (Table 5 and Figure 12) and subjected to the 
selected stimulation and transduction protocol. Several clones (20-100) were successfully picked 
from 2 patients (PKD2 and PKD3) and 1 healthy donor (PB2). There was no apparent difference 
between the healthy and diseased hiPSCs, the kinetic of colonies appearance was as previously 
 
 
Figure 11: Analysis of transduction efficiency within different PB-MNC populations after stimulation with cytokines and 
transduction with an Azami green expressing SeV. Green plus white bars show percentage of each cell type within the pool. 
Green bars show transduced cells within the specific population and the values in percentages are presented on the top of 
each green bar. 
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Table 5: Reprogramming attempts in Pyruvate Kinase Deficiency patients and healthy donors 
 
 
 
described, starting to appear after one week but gaining pluripotent characteristics with time. 
Several clones from PKD1 (PKD1iPSC) could be selected and expanded for 2-3 passages but they 
disappeared due to technical problems. We were not able to reprogram PB1. In a second experiment 
using PKD1 and PB1, reprogramming was neither achieved. Bright field images of hiPSC cultures 
growing over a feeder layer are shown in figure 12 from the following lines: PKD2iPC c78, PKD3iPC c1 
and PB2iPSC c33.  
 
 
 
 
 
 
 
 
 
To verify the origin of the generated hiPSCs, disease specific genotypes were amplified by PCR and 
analyzed by Sanger sequencing (Fig. 12). Genetic alteration of PKD2 patient is a compound 
heterozygous mutant showing mutations in exon 4 (359C>T (Ser120Phe)) in one allele and in exon 9 
(1168G>A (Asp390Asn)) in the other allele of the PKLR gene, leading to a protein with no biological 
functionality (Rouger, Valentin et al. 1996, Zanella, Bianchi et al. 1997). PKD3 patient genotype is a 
IVS9(+1)G>C splice mutation in the invariant sequence GT of the splicing donor of intron/exon 9/10. 
These mutations usually generate unstable and rapidly degraded transcripts or truncated proteins 
(Manco, Ribeiro et al. 1999). The analyzed clones carried the mutations defined in the patients 
demonstrating their origin. On the other hand, the sequencing of the same location in the healthy 
donor (PB2iPSC) showed the wild type sequences, as expected.  
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Figure 12: Bright field images and PKD genotype of the hiPSC lines from PKD patients (PKD2 and PKD3) and healthy donor 
(PB2). Colonies growing over a MEF feeder showing typical ES morphology: flat, defined colony edges and dense. Mutant 
and wild type genotype of exons 4 and 9 can be seen in patient and healthy samples in the upper row. Lower row, mutant 
and wild type genotype of the splicing donor of intron9/exon10. 
 
1.1.2.1 hiPSC characterization 
A) Pluripotency analysis 
Pluripotency of hiPSC lines from PKD2, PKD3 and PB2 was analyzed by immunofluorescence, flow 
cytometry, RT-PCR array and teratoma formation. The expression of a broad set of differentiation 
and undifferentiation-associated genes was analyzed by quantitative RT-PCR (qRT-PCR) using an 
hESC RT2 Profiler PCR Array, which contains primers for the analysis of 84 key genes involved in the 
maintenance of pluripotency and the self-renewal status of embryonic stem cells, such as 
transcription factors involved in stemness, signaling molecules, cytokines, growth factors and 
differentiation markers. The level of expression of the analyzed genes in the sample (Y axis) was 
compared to the one of the reference cell line, the human Embryonic Stem Cell (hESC) line H9 (X 
axis) in the histograms of figure 13. The level of expression of the analyzed genes was equivalent to 
the one seen in the control in the majority of the genes, including the ones related to pluripotency 
and self-renewal (Fig. 13).  
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Four pluripotency-associated markers were also analyzed at the protein level by 
immunofluorescence. Figure 14 shows the correct colony morphology in which the cells were 
stained positive for OCT4 and NANOG or for TRA 1-60 and SSEA4. Surrounding fibroblasts were 
negatively stained for the assayed markers. OCT4 and SSEA4 were also analyzed by flow cytometry 
to test the status of the whole culture, showing that in the three cell lines more than 90% of the 
culture is maintained under an undifferentiation status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Pluripotency characterization of 
PB2iPSC (A), PKD2iPSC (B) and PKD3iPSC 
(C). Pluripotency associated markers 
analysis by immunofluorescence staining 
for NANOG or OCT4 in the nucleus (stained 
with DAPI or Topro3) and TRA1-60 or 
SSEA4 in the surface (left) and low 
cytometry of OCT4 and SSEA4 (right) 
 
 
 
Figure 13: qRT-PCR Pluripotency 
characterization of PB2iPSC (A), PKD2iPS C 
(B) and PKD3iPSC (C). Pluripotency 
associated gene expression array, where 
gene expression of stemness and 
differentiation genes is compared to H9 as 
reference hESC line. Black line represents 
no difference in gene expression whereas 
pink lines represent 3 fold change. 
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In order to test the in vivo pluripotency of the reprogrammed lines, 106-107 cells from each hiPSC 
clone were injected subcutaneously into immunocompromised NSG mice. The three cell lines 
generated fully differentiated teratomas within 8 to 12 weeks and all of them showed tissues 
corresponding to the three germ layers (mesoderm, endoderm and ectoderm) (Fig. 15). In more 
detail, by staining the teratomas with hematoxilin/eosin it was possible to see structures resembling 
Retinal Pigmented Epithelium (RPE) (stained very dark due to pigmentation), muscle (stained in 
pink), cartilage, secreting and glandular epithelium and neural rosettes. The teratoma generated by 
PKD2iPSC line showed no clear morphological evidence for ectodermal tissue, but positive areas for 
neural marker β-III Tubulin of ectodermal origin were identified by immunofluorescence analysis 
(Fig. 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total pluripotency induction is also associated to endogenous gene expression activation and 
therefore promoter CpGs demethylation of transcription factors belonging to the pluripotency core. 
By pyrosequencing technique we analyzed different CpG dinucleotides, 2 belonging to NANOG and 8 
to SOX2 promoters in PB-MNC, which is the sample before reprogramming, and in the following 
reprogrammed samples: PB2iPSC, PKD2iPSC, and PKD3iPSC. Based on the number of methylated 
Figure 15: In vivo pluripotency characterization of 
PB2iPSC (A), PKD2iPSC (B) and PKD3iPSC (C).  Multi-
germ layer differentiation capacity was assessed by 
hiPSC injection into immunodeficient mice and 
teratoma formation. Teratomas were pathologically 
analyzed by hematoxilin and eosin staining. Structures 
corresponding to the three germ layers are shown in 
the images, marked with arrows. White arrow: Retinal 
pigmented epithelium. Blue arrow: Muscle. Red arrow: 
Secreting epithelium. Orange arrow: neural rosettes. 
Green: Cartilage. Black arrow: Glandular epithelium. 
Immunofluorescence for the detection of ectoderm 
differentiation (β-III Tubulin, yellow arrow) was also 
performed. 
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events detected in each sample a number and a color were assigned (darker color and higher 
number means more methylated events) to each of the CpGs of the two analyzed promoters (Fig. 
16). The 2 assayed CpGs from NANOG promoter were demethylated in comparison to PB-MNC 
verifying the induction of activation of endogenous NANOG in the different analyzed hiPSCs. Same 
was observed in the 8 assayed CpGs from SOX2 promoter, which unexpectedly was not strongly 
methylated in PB-MNC.  
 
 
 
 
 
 
B) Karyotype analysis 
As previously explained, reprogramming process and pluripotent cultures maintenance is associated 
to genomic instability leading to chromosomal aberrations. In order to test the genetic stability of 
our hiPSC lines, karyotype analysis by G banding of metaphasic chromosomes was performed in 
PB2iPSC c33 p17, PKD2iPSC c78 passage 15 and PKD3iPSC c1 p10, showing no aneuploidies or large 
duplications/deletions (> 5 Megabases) in any of them (Fig. 17).  
 
 
 
 
 
 
Figure 16: Pluripotency characterization of PB2iPS, PKD2iPSC and PKD3iPSC. NANOG and SOX2 promoters demethylation 
was analyzed by pyrosequencing and compared to PB-MNC. Based on the number of methylated events a numeric number 
associated to a color scale was given to each sample. Darker color and higher number mean more level of methylation in 
the promoter CpG. The demethylation status of NANOG promoter is higher in the assayed samples than in PB-MNC. SOX2 
promoter is demethylated not only in hiPSC but also in PB-MNC. 
 
 
Figure 17: Chromosomal stability of PB2iPS, PKD2iPSC, and PKD3iPSC. Karyotype G-Banding of the 23 pairs of chromosomes 
showing that the three samples have the expected number of chromosomes and no detectable aneuploidy. 
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Figure 18: T cell receptor VJA gamma rearrangement analysis in PKD3iPSC clone 10 and clone 14 and in 2 controls: one 
monoclonal and a polyclonal control. The monoclonal sample shows one peak corresponding to one PCR product whereas 
the polyclonal shows multiple peaks. In the analyzed samples there are no TCR rearrangements as no amplification is 
observed. The peaks shown in the analyzed hiPSC samples are not real PCR products (see height peak scale). 
 
C) T cell receptor and Immunoglobulin genes somatic rearrangement analysis 
The analysis of somatic rearrangements of the immunoglobulin chains and T cell receptor (TCR) 
confirmed that the generated hiPSCs were reprogrammed from non-lymphoid cells. gDNA from five 
different hiPSC lines, PKD3 c14, PKD3 c10, PKD3 c35, PKD2 c78 and PB2 c33 was isolated and 
rearrangement analysis was performed following BIOMED-2 strategy.  For Immunoglobulin H (IgH), 
the 3 hyper variable regions and for T cell Receptor, gamma rearrangements VJA and VJB were 
analyzed. None of the assayed cell lines showed any rearrangements in any of the analyzed regions, 
discarding that they came from a mature T or B lymphocyte. Figure 18 shows a representative image 
of gamma VJA rearrangement analysis of two PKD3iPSC clones, clone 10 and clone 14 and 2 controls: 
a monoclonal population and a polyclonal population with more than one TCR rearrangement.  
Whereas the monoclonal control showed one peak and the polyclonal several, the hiPSC lines did 
not show any amplification, confirming that none of them had any somatic rearrangement. The 
peaks at the left of the image of hiPSC lines are not real products, as the intensity (height of the 
peak) is not comparable to the one seen in the controls. 
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D) Reprogramming vectors disappearance 
The main advantage of using SeV for reprogramming is that although they are auto-replicative and 
can be maintained in the cell for long periods of time, once hiPSCs are established and start to 
divide, SeV vectors tend to disappear because hiPSC divide faster than SeV replicate (Fusaki, Ban et 
al. 2009). In order to follow SeV disappearance during reprogramming, a vector expressing 
fluorescent Azami green was co-transduced with the reprogramming vectors and green florescence 
disappearance was followed once the hiPSC were established. The image in figure 19A shows a 
colony of one of the clones of PKD2iPS at passage 2, where the fibroblasts differentiated from the 
colony at the beginning of reprogramming retained Azami green expression, as they do not divide as 
much as the pluripotent cells inside the colony, which have lost the green fluorescence. In order to 
verify the complete disappearance of SeV transcripts, RT-PCR was performed to detect the presence 
of SeV mRNA in two hiPSC lines, PKD2iPS at passage 15 and PB2iPS at passage 30. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) RT-PCR was used as a positive control of each sample. As seen in 
figure R.19B, no SeV specific RT-PCR product was amplified in any of the analyzed lines whereas 
GAPDH was correctly amplified.   
 
 
 
 
 
 
 
 
 
   
1.2 Erythroid differentiation of PKDiPSC 
We then established an in vitro differentiation protocol for the generation of erythrocytes, the 
affected cells in this disease. 
1.2.1 RPK expression during in vitro erythroid differentiation  
Once we developed and characterized the patient-specific cell lines, we wanted to know if these 
cells showed phenotypic characteristics of PKD. There were many reported publications that show 
the generation of Glycophorin A (also called CD235a) positive cells, a differentiation marker 
expressed during erythrocyte differentiation and in mature erythrocytes (Lu, Feng et al. 2008, 
 
 
Figure 19: SeV disappearance. A) Image showing a colony from PKD2 at passage 2. While colony derived fibroblasts still 
harbor Azami green expressing viral vectors, rapidly dividing hiPSC within the colony have lost them.  B) RT-PCR analysis 
showing that in hiPSC at passage 15 or 30 no SeV transcript can be detected.  
 
 
 
71 
RESULTS 
 
  
Hatzistavrou, Micallef et al. 2009, Lapillonne, Kobari et al. 2010, Dias, Gumenyuk et al. 2011) from 
hESCs and hIPSCs. But the different protocols are very heterogeneous in other parameters such as 
purity of erythroid cells (%), enucleation, expression of fetal, embryonic or adult globins and what is 
crucial to us, the level of expression of RPK versus PKM proteins. We assayed the protocols 
described by Robert Lanza’s group (Lu, Feng et al. 2008) (Fig. 20A, method 1) and the one described 
by Elefanty’s group (Hatzistavrou, Micallef et al. 2009) (Fig. 20A, method 2), both of them based on 
Embryoid Body (EB) formation and explained in figure 20. RPK expression was higher in method 1 
than in method 2 and so was the relation RPK/MPK (1.35 for method 1 and 1.1 for method 2) (Fig. 
20B). However, method 1 showed a big disadvantage, the cell number amplification. Starting with 
same amount of cells, we ended up having 10-fold more cells with method 2 than with method 1.  As 
RPK was also expressed in method 2 and cell numbers were much higher, we selected method 2 for 
PKDiPSCs differentiation and therefore we performed a time course experiment of RPK expression, 
being the highest expression at day 20 of culture (Fig 20C).  
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1.2.2 Pyruvate Kinase deficiency phenotype in PKDiPSC derived erythrocytes  
When peripheral blood of PKD patients is analyzed for erythroid markers (CD235a and CD71), there 
is a clear phenotype associated with the disease, which is the accumulation of immature red blood 
cells, double positive for both markers, something not observed in healthy individuals, where almost 
 
 
Figure 20: Erythroid differentiation of hiPSC: A) Scheme of two erythroid differentiation procedures. Images of the PB2iPSC 
differentiation process at day 20 are shown.  Method 1: Erythroid colonies growing in methylcellulose culture. Method2: 
EBs are attached to the plate and red cells can be seen inside the three dimensional structure. B) Relative RPK and PKM 
expression comparison in both differentiation protocols at day 20. C) Relative RPK and PKM expression at different time 
points in method 2. 
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all the CD235a positive cells in peripheral blood are negative for CD71 (Fig. 21A). We asked if this 
phenotype could be reproduced in vitro after PKDiPSC differentiation. Therefore, we performed 
erythroid differentiation of 2 PKD-iPSC (PKD2 and PKD3iPSC) and the control hiPSC (PB2iPSC) and 
saw in an experiment that the phenotype was reproduced in vitro, being the proportion of CD71 
negative cells within the CD235a positive population much higher in PB2iPSC (69%) than in PKD2iPS 
(17%) and PKD3iPS (15%) (Fig 21B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Erythroid phenotype in PKD samples. A) Peripheral blood analysis of PKD2 and a healthy individual showed the 
presence of a double positive (CD235a
+
CD71
+
) immature population in PKD, which was much less represented in the 
healthy sample. B) PKDiPSC differentiation (PKD2 and PKD3) showed a similar phenotype than the observed in patient 
peripheral blood. Whereas 70% of erythroid cells are CD71 negative in PB2iPSC, in PKDiPSC there is an accumulation of 
immature CD235a
+
/CD71
+
 cells. 
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2 Nuclease mediated Knock In gene correction in PKLR locus 
2.1 Homologous recombination (HR) strategy design 
In order to restore the mutated PKLR gene in the PKD derived hiPSCs and take advantage of the 
endogenous gene regulation, a Knock-In gene correction strategy was designed (Fig. 22). Thanks to 
an established collaboration, the company Cellectis, which is specialized in the design and 
development of site-specific nucleases, developed DNA nucleases (MG and TA) that specifically 
generated DSB in intron 2 of the PKLR gene. The sequences targeted by each DNA nuclease are 
described in table 6. Once DSB have been generated, the HR cell machinery uses the Homology Arms 
(HAs) of the donor matrix (DM) as a template for restoration of the break and introduces the 
transgenic elements (Fig. 22A and B) cloned between the HAs of the DM. This DM included: 
1) Homology Arms, 2) the expression Cassette (EC): composed by the splicing acceptor (SA), the 
codon optimized cDNA from RPK exons 3-11, followed by a FLAG tag and the SV40 polyA at the end, 
and 3) the Selection Cassette (SC), composed by the mouse PGK promoter driving the expression of a 
puromycin resistance (PuroR) and Thymidine Kinase (TK) fusion protein flanked by LoxP sequences. 
Once the cassette is correctly integrated in intron 2 of the PKLR locus (Fig. 22C), the SA will tie to the 
endogenous splicing donor of the endogenous exon 2 and a chimeric mRNA is generated, including 
endogenous exons 1 and 2 and exogenous codon optimized exons 3-11 and the FLAG tag at the end. 
The presence of the FLAG tag will help us to easily follow the expression of the chimeric protein.  
Additionally, the presence of a polyA sequence at the end of the expression cassette should avoid 
the transcription of endogenous exons 3 to 11. Moreover, once targeted, the PuroR allows the 
selection of the cells in which the selection cassette is integrated. Once the correct targeting is 
confirmed, the selection cassette can be removed by ectopic Cre recombinase expression that will 
excise the sequences between the LoxP sites, leaving only one copy of the LoxP sequences.  
 
 
 
Table 6. PKLR specific DNA nucleases targeting sequences. 
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Figure 22: Knock In gene correction in PKLR locus. A) Scheme of the donor matrix used for the homologous recombination. A 
partial wild type cDNA (exons 3-11) of the RPK cDNA is going to be introduced in intron 2 of the PKLR locus by HR; the cDNA is 
flagged so that when the cassette is inserted a flagged transcript will be generated; floxed mPGK driven PuroR-Tk cDNA is also 
inserted for selection. B) Representation of the PKLR genomic locus indicating the place where the homologous recombination is 
going to take place, C) Diagram showing the PKLR genomic locus once the exogenous DNA has been integrated. At the bottom, 
scheme of the mRNA generated including endogenous exons 1 and 2 exogenous (blue), codon optimized exons 3-11 (light blue) 
and flag tag sequence (pink) at the end of the chimeric protein. Abbreviations: LA: Left Arm, RA: Right Arm, MG: Meganuclease, 
TA: TALE nuclease. Blue Boxes: Endogenous PKLR exons.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 PKLR Meganuclease Efficiency 
First, we started to work with the homing MG that specifically generated DSBs in intron 2 of PKLR 
gene, the PKLR01 MG. 
2.2.1 PKL01  MG versions comparison in 293T cell line by deep sequencing 
When a DSB is induced in the genome, the most common way of the cellular machinery to resolve 
the damage is by Non Homologous End Joining (NHEJ), which is highly error prone and usually 
generates insertions and/or deletions.  We took advantage of this cellular function to test the 
efficacy of different versions of the developed MG. We compared two available versions of this MG 
that targeted intron 2 by transfecting them in HEK-293H cells and analyzing the percentage of 
insertions or deletions (Indels), consequence of the DSB generation, by deep sequencing of a 300 bp 
around the cutting site of the MG (Fig 23). Both versions generated NHEJ resolved DSB (more than 
90% of the events were of 5 bp long but there were also longer events, like 40 pb long). Version 2 
(V2) was slightly more efficient, showing 6.7% of indels whereas version 1 generated 6.0% and 
therefore it was the chosen version for the next experiments.  
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2.2.2 PKLR Meganuclease dose optimization 
We optimized the dose of PKLR01 MG version 2 by nucleofecting different doses of MG in the form 
of mRNA into K-562 cell line, because the nucleofection of mRNA into more sensitive cells was less 
cytotoxic than the DNA nucleofection (Wiehe, Ponsaerts et al. 2007). DSB generation efficiency was 
measured by Surveyor assay (explained in figure 24A). In this case the indels and genomic 
modifications consequence of NHEJ are not detected by deep sequencing but by treatment by the 
Cel1 enzyme, which recognizes and cuts non-annealed sequences. In this concrete case the PCR 
product around the MG target site was 300 bp with the cutting site in the middle. As a consequence 
of Cel1 cutting, 2 products of around 150 bp were generated (Fig. 24B). As a control of the 
technique, we used the AAVS1 ZFN, which we already know that cuts efficiently in AAVS1 locus 
(Hockemeyer, Soldner et al. 2009). In order to increase the assay sensitivity, the MG was co-
transfected with mRNAs expressing TREX-2 protein, a non-processive 3′ exonuclease shown to 
degrade the 3′ DNA overhangs and therefore increasing NHEJ (Certo, Gwiazda et al. 2012). The 
following quantities of each mRNA were nucleofected: a) 3 μg of each AAVS1 ZNF subunit. b) 0.5 μg 
of  PKLR01 MG V2 + 3 μg of TREX c) 3 μg PKLR01 MG V2 + 3 μg of TREX d) 6 μg PKLR01 MG V2 + 3 μg 
of TREX. A plasmid expressing GFP under the control of EF1α promoter was used as transduction 
efficiency control, showing 65% of the cells expressing GFP. DNA electrophoresis in figure 24B shows 
surveyor assay results. AAVS1 ZFN cutting efficiency proofed that the system was working as 
expected (Fig. 24B, lane  2). After comparing the different PKLR MG doses, the highest DSB 
 
Figure 23: Comparison of two versions of PKLR01 MG for DSB generation in HEK-293H cell line by deep sequencing. After 
treatment with MG, the 300 bp surrounding PKLR MG recognition site were PCR amplified and analyzed by deep sequencing. 
Left graph shows the sizes of deletions generated as a consequence of the Double Strand Breaks (DSBs) by version 1 MG and 
the number of events of each size. The upper table shows the overall percentage of insertions and deletions generated by 
version 1 and 2 within the pool. 
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Figure 24: DSB generation efficiency of version 2 PKLR01 MG in 
K-562 cell line. A) Scheme showing surveyor assay, an indirect 
measurement of DSB generation by looking at mutations 
generated as a consequence of NHEJ repair mechanism. B) DNA 
electrophoresis showing surveyor assay results. First 2 lanes are 
control samples untreated and treated with AAVS1 ZFN 
respectively. Lanes 3-6: MG dose analysis. L3: untreated, Lanes 
4-6 sample treated with v2 PKLR01 MG as mRNA in deceased 
quantities. L4: 6 μ of MG, L5: 3 μ of MG, L6: 1.5 μ of MG. 
Percentages of DSB generation are shown in each line. Red 
arrows: Uncut PCR bands. White arrows: Cut bands. 
 
generation efficiency was obtained with 0.5 and 3 μg of MG (35% for both doses). Both doses were 
used in the next experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
2.3 HR analysis in PKLR locus using K-562 cell line 
In order to test the correct splicing in the targeted cells it is important to have an active locus, so 
that the transgenic FLAG tagged RPK protein can be expressed and detected. In this respect, K-562, 
an erythroleukemic cell line expressing RPK, was an appropriate cell line to test the developed HR 
tools. To induce HR in PKLR locus, K-562 was nucleofected with 0.5 and 3 μg of mRNA of PKLR01 v2 
MG in combination with 4 μg of the donor matrix (DM). Puromycin selection at 2 μg/ml was carried 
out for 20 days generating a pool of resistant K-562 cells to set up analysis techniques such as 
specific PCR to check for HR and flow cytometry of the FLAG tag for studying the expression of the 
chimeric protein using the exogenous splice acceptor introduced by HR. 
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2.3.1 PCR assessment of Homologous Recombination 
A pair of primers that recognized the PKLR locus outside the HA and inside the integrated targeting 
matrix was used (Fig. 25A). The expected 1176 bp band appeared just in the conditions in which MG 
was co-nucleofected with the DM, demonstrating the correct integration of the exogenous 
sequences in the desired place, the intron 2 of the PKLR gene (Fig. 25B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.2 Correct splicing assessment 
Once we confirmed the targeting in the PKLR locus, we evaluated if the splicing between the 
endogenous donor and the exogenous acceptor was taking place properly by analyzing the 
expression of the FLAG tag located at the end of the chimeric RPK protein in the targeted cell pools. 
By looking at the basal expression difference between the cell pools, the only condition in which we 
had FLAG tag  expressing cells was DM + 3 μg of PKLR01 v2 MG (5,75%, Fig. 26, upper histograms). K-
562, being an erythromyeloblastoid leukemia cell line, is a heterogeneous population, where a 
reduced subset of the cells express PKLR gene. In order to increase the expression of RPK, we 
induced its differentiation by Hemin treatment, which increased the percentage of cells expressing 
the FLAG tag, being even higher when the dose of 0.5 μg of MG was used, supporting the targeting 
at PKLR locus and the correct splicing after HR (Fig. 26, lower histograms). 
 
 
Figure 25: HR analysis in K-562. A) Diagram showing HR-specific PCR strategy. Pr1: Forward primer, Pr2: Reverse primer, HA: 
Homology Arm, SA: splicing acceptor. B) DNA electrophoresis showing HR-PCR amplification of an 1176 band. Lane 1: 
Uncorrected (UC) K-562, Lane 2: Donor Matrix (DM), Lane 3: DM + 0.5 μg of mRNA of v2 PKLR01 MG and Lane 4: DM + 3 μg of 
mRNA of v2 PKLR01 MG.  
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Figure 26: Flow cytometry analysis of FLAG expression in K-562 cell line after targeted integration and puromycin selection. 
Cells were analyzed after culture in the absence (upper row) or presence (lower row) of hemin in order to increase RPK 
expressing cells. 
 
 
 
 
 
 
 
 
 
 
2.4 HR in PKD2iPSC facilitated by PKLR MG  
So as to genetically correct the defect in the patient specific cell line PKD2iPSC, cells were 
nucleofected with 4 μg of the DM alone, or in combination with 0.5 μg of PKLR01 v2 MG mRNA. We 
choose 0.5 because cutting efficiency was equally high as 3 μg, the HR-PCR was positive and the 
percentage of FLAG expressing cells was higher after differentiation with hemin (Fig. 26).  As control, 
a targeting matrix for AAVS1 locus that constitutively expresses GFP was used in combination with 
mRNA of the AAVS1 ZFNs. In order to select those cells in which the matrix was integrated, 
puromycin selection was performed. The AAVS1 control gave us information about nucleofection 
efficiency, which was 29% (mean value, n=3) after 48 hours. A representative part of each reaction 
was seeded for alkaline phosphatase staining after one week of puromycin selection (Fig 27). In the 
condition in which the DM and MG was used, 21 colonies were scored whereas in the absence of the 
MG there were only 3 surviving colonies. Targeting efficiency could not be defined, as the number of 
colonies in the absence of selection was uncountable. 
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Figure 27: HR in PKD2iPSC mediated by MG.  Alkaline phosphatase staining after 7 days of puromycin selection. Puromycin 
was added to the upper wells and not to the lower ones.  A representative image of green florescence in one of the 
resistant colonies is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Twenty clones were manually picked and expanded for further analysis. As explained for K-562, a 
PCR in which the 1176 bp band would appear just in the case of HR was performed (Fig 28A). In the 
case of PKD2iPSC targeting, no unique bands appeared in any of the selected clones and the results 
were not reproducible between different PCR analyses and by using other alternative primer pairs. 
To further analyze if HR took place in the selected place, we selected 3 clones in which the PCRs 
were most reproducible and performed Southern Blot analysis (Fig 28 B, C). With this technique, 
single integrations can be distinguished from multiple integrations, as the radioactive probe 
hybridizes a sequence in the DM (Fig. 28B). By cutting the gDNA with the restriction enzymes SpeI 
and ScaI in separate reactions and assuming that the DM had been integrated in the right place, a 
band of 4410 bp (SpeI) and of 14273 (ScaI) should appear. Two of the clones (c9 and c12) showed 
multiple bands different than the expected ones, meaning that the donor matrix was integrated in 
more than one place of the genome. In the remaining clone, clone number 5, there might be 
integration in PKLR but also in other loci. (Fig. 28C). The explanation for the multiple targeting is that 
PKLR01 v2 MG was generating DSBs in other sequences of the genome in addition to intron 2 of 
PKLR gene, facilitating the HR in these non-desired places as well. When a blast search using the MG 
targeting site against human genome was performed, 26 additional targeted sequences were found. 
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Figure 28: MG assisted HR analysis in PKD2iPSC. A) DNA electrophoresis showing HR specific PCR in 18 puromycin resistant 
PKD2iPS clones and in puro resistant K-562 gDNAs UC: Uncorrected cells. B) Southern blot strategy: A radioactive labeled 
probe that binds the PuroR-TK was used and the following unique band sizes should be seen if the targeting had happened 
uniquely in PKLR locus: SpeI: 4410 bp, ScaI: 14273 bp. C) Southern blot film corresponding to digested gDNA of 3 puro 
resistant PKD2iPS clones. As seen in analyzed clones, multiple bands indicate integration in additional loci. Arrows mark 
expected size bands in clone 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5 HR by Transcription activator-like effector nucleases (TALENTM)  
In order to increase the specificity of the PKLR nuclease and reduce the frequency of off targets, our 
collaborators designed a TALENTM (TA) that specifically recognized a sequence that included the one 
that targeted the MG and that we could combine with the DM designed for the previous explained 
approaches. By using PKLR1 TA, same DSB generation efficiency analysis and HR was performed in 
PKDiPSCs. 
2.5.1 DSB generation efficiency 
First of all we tested the DSB generation efficiency in PKD2iPSC and PKD3iPSC by nucleofecting 2 
doses of DNA of PKLR1 specific TA (3 or 6 ug of each subunit), and performed the previously 
explained surveyor assay. We choose DNA for electroporation and the mentioned amounts because 
were the conditions suggested by our collaborators and reported in literature (Hockemeyer, Wang 
et al. 2011). As a consequence of the DSB correction by NHEJ, the two 150 bp bands would appear 
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(Fig 24).  It was possible to detect the bands (indicated with a white arrow) in both PKDiPSC lines but 
it was below the quantification range as we had to overexpose the gel with Ultraviolet light and the 
uncut band became saturated. Then, we could not quantify the different bands properly to get an 
efficiency value.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.2 HR mediated gene correction in PKDiPSC from two different patients  
As performed when the PKLR MG was used, TA induced HR was performed in PKD2iPSC and 
PKD3iPSC by nucleofecting the two TA subunits in combination with 4 ug of the PKLR DM. When DSB 
efficiency was measured, no big difference was detected between nucleofecting 3 or 6 ug of each 
subunit and therefore both doses were applied for HR. In PKD2iPSC targeting, after one week of 
puromycin selection less resistant colonies appeared than when the MG was used. Thirteen colonies 
from each reaction with different doses of TA were picked (26 in total). From them, 14 were 
expanded and colony PCR was performed. Ten out of fourteen gave the expected PCR product 
corresponding to PKLR Knock-In HR (Fig. 30A). In this particular case the PCR was performed by 
lysing a single colony and to be sure that negative clones were not due to gDNA absence, CFTR gene 
was amplified as control (Fig. 30A, lower bands). In all of them, excepting clone 17 the expected 
band was amplified, assuring the gDNA quality. As we had 10 positive clones from 13 clones in which 
the DNA quality was enough, we estimated an HR efficiency of 77% over the puromycin resistant 
clones. A similar protocol was performed in PKD3iPSC, resulting in similar targeting efficiency, 76% of 
puromycin resistant clones were correctly targeted, also assessed by HR-PCR. A description of the 
targeted clones generated during PKD2iPSC and PKD3iPSC Knock-In gene correction is showed in 
 
Figure 29: PKLR01 TALEN
TM
 (TA) DSB generation efficiency in PKD2iPSC and PKD3iPSC. PKD2iPSC: L1: treated with 3 ug of 
each TA subunit L2: untreated, L3: treated with 6 ug of each TA subunit. PKD3iPSC: L1: untreated L2: treated with 3 ug of 
each TA subunit, L3: treated with 6 ug of each TA subunit. Normal PCR product 300 pb (red arrow). After cutting, 2 bands of 
approx. 150 bp,(white arrow). The 230 and 71 bp bands that appeared during PKD2iPSC surveyor assay will be explained 
later in 2.5.2.3. 
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Figure 30. TALEN assisted HR in PKD2iPSC. A) 
Genomic PCR for the detection of correct integration 
in PKDiPSC B) HR analysis by Southern Blot. A probe 
against the selection cassette (see fig. 28) was 
generated and gDNA from targeted clones from TA 
assisted HR was digested with ScaI and SpeI for 
hybridization. UC: Uncorrected, M: DNA ladder. 
 
table 7. In order to analyze if there were additional copies of the DM integrated in other places of 
the genome, five of the corrected PKD2iPSC clones were expanded and Southern Blot analysis was 
performed as previously explained (Fig. 30B). After gDNA isolation, digestion, and probe 
hybridization in these 5 clones, all of them showed the single and expected band. The picture of the 
whole blot is shown in order to verify that no other bands could be detected.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.2.1 Non Homologous End Joining (NHEJ) in untargeted PKLR locus 
A PCR surrounding the PKLR1 TA cutting site was performed in order to analyze heterozygous or 
homozygous targeting and integrity of the untargeted PKLR locus. For this purpose the same primers 
as for the surveyor assay were used. First, for heterozygous vs. homozygous targeting, this PCR 
would not generate any product if both alleles were targeted, as it is a short PCR (301 pb) between 
the end of the left and the beginning of the right Homology Arm (HA). The PCR product was 
generated in all the targeted clones, so no homozygous targeting clones were present in PKD2iPSC 
HR (Fig. 31A). In PKD3iPSC, in contrast, three clones seemed to be homozygous (11.5%) (Table 7). 
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Figure 31. A) PCR surrounding the PKLR1 TA cutting site confirmed no homozygous targeting during PKD2iPSC HR. B) PCR 
product sequencing for analysis of NHEJ in PKLR untargeted allele. Overall, 40% of the clones showed genomic modifications 
(insertions and/or deletions). Sequences in red are insertions and red dashes represent deletions. Green and red flags 
represent same sequencing with forward and reverse primers respectively. 
 
 
Table 7: Targeted clones from PKD2 and PK3iPSC HR. 
The homozygosity of targeted PKD3iPSC clones needs to be verified by Southern blot. Second, we 
performed Sanger sequencing of the amplified product in order to check the genomic integrity of the 
untargeted PKLR locus. From the picture of the DNA electrophoresis, it was possible to notice that 
the sizes of the PCR products varied among the clones, suggesting the presence of indels as a 
consequence of NHEJ resolved DSBs. This was confirmed after sequencing, which revealed that in 
40% of the assayed clones from PKD2iPSC and 31% from PKD3iPSC, NHEJ related modifications were 
found in the untargeted alleles. In targeted PKD2iPSC, clone 12 showed a 14 nucleotides (nts) 
insertion and a 2 single base deletions, clone 22 had a 12 nts deletion, clone 23 showed 32 nts 
insertion and clone 10 had two insertions, one of a single nt and another of 20 nts, and 2 deletions: 
one of a single nt and other of 3 nts (Fig. 31B). 
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2.5.2.2 Off target analysis  
One of the main concerns when using DNA nucleases to increase HR efficiency in a particular site of 
the genome is the off target recognition of other sequences of the genome and consequent cutting. 
This has been described in genome regions in which the nuclease finds a similar sequence with some 
mismatches and generally generates NHEJ mediated genomic modifications. In order to check this 
possibility in the genome of several PKLR targeted clones from PKD2iPSC and PKD3iPSC, sequence 
integrity was verified by amplifying the region surrounding PKLR1 TA targeting site with 6 
mismatches or less and Sanger sequencing.  
The sequence that each subunit of PKLR1 TA recognizes in the human genome is described in the 
first row of table 8. As this particular TA is not an obligated heterodimer, a homodimer with a 
recognition sequence composed of a duplicate of one of the sites can be generated (left-spacer-left 
or right-spacer-right). A blast against the human genome using these sequences and its 
complementary reverse as queries was performed and no possible off targets with less than 5 
mismatches were found. Three sites with 6 mismatches and 2 with 5 were the final list of sequences 
that were found (table 8) and interrogated in the following targeted clones: corrected PKD2iPSC 
clone 11 and 3 and corrected PKD3iPSC clones 80 and 31. Figure 32 shows a representative 
alignment of one of the possible off target sequences, off target 1, which genomic region was 
amplified by PCR and the sequence integrity was analyzed by Sanger sequencing. None of the 
analyzed clones showed unexpected genomic modifications in this site and neither in off targets 2, 4 
and 5. The sequence surrounding off target 3 could not be amplified by PCR due to the complexity of 
the sequence.  Nevertheless, as the first base in 5` is an A and not a T as it is recommended for a 
TALE recognition site, it should not be recognized (Boch, Scholze et al. 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8: TA PKLR01 target and probable off target sequences found in human genome. 
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Figure 33. A) Chromatogram of sequencing of Single Nucleotide Polymorphism in PKD2. One allele shows a G whereas the 
other is an A. B) Possible HA harboring SNP effect in HR process. 
 
 
 
 
 
 
 
 
 
 
2.5.2.3 Allele specific targeting  
Two unexpected bands from approximately 230 and 71 bp were identified in the surveyor assay of 
original PKD2iPSC (Fig 29). We speculated that these additional bands might have appeared due to 
the presence of a Single Nucleotide Polymorphism (SNP) in one of the alleles of PKD2 sample. The 
consequence might have been that after the annealing/reannealing process, the PCR form one of 
the alleles would hybridize with the PCR from the other, giving rise to a 1 base mismatch susceptible 
to be cut by Cel1 enzyme. By Sanger sequencing we analyzed the surveyor assay PCR product 
obtained from PKD2iPSC gDNA and found that 50% of the PCR products showed a G (expected) 
whereas 50% showed an A (unexpected) in the position 190 of the PCR product (Fig R. 33A). 
This SNP is 43 base pairs away from the expected PKLR1 TA cutting site and therefore is part of the 
right HA of the DM (Fig. 33B).  The sequence of our DM contained a G (Fig 33B) and we studied 
whether the difference in a single nucleotide in an allele nearby the DSB can promote allele 
specificity. As all the targeted clones from corrected PKD2iPSC (coPKD2iPSC) were heterozygous, we 
amplified the untargeted allele around the SNP by PCR and sequenced it to know which allele had 
undergone HR. Ten out of ten untargeted amplified products carried an A in the mentioned position, 
 
Figure 32: Representative alignment of sequencing results of 4 PKLR targeted clones from the PKLR TA off target 1 
surrounding sequence. None of the targeted clones showed NHEJ derived genomic modifications. Red square indicates the 
genomic sequence corresponding to off target 1. 
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Figure 35:  Pluripotency maintenance after HR. A) Pluripotency associated gene expression profile of corrected PKD2iPSC clone 
11 correlates with the one observed in the hESC line, H9. B) NANOG and SOX2 promoters CpGs dinucleotide demethylation. 
 
demonstrating that all the clones were targeted in the allele that had the G as it is shown in figure 34 
and confirming that the presence of a SNP can lead to allele specific HR. On the contrary, this SNP 
was no present in PKD3 and therefore no allele specific targeting in any coPKD3iPSC clones was 
observed. 
 
 
 
 
 
 
 
2.5.2.4 Pluripotency maintenance after HR  
In order to verify the maintenance of pluripotency in coPKD2iPSC, gene expression of 84 key genes 
was measured by hESC RT2 Profiler PCR Array, as previously explained. As seen in figure 35A, the 
gene expression profile after gene correction correlated to the one shown by the reference hESC line 
H9. In addition, demethylation of SOX2 and NANOG promoters in clone 11 of coPKD2iPSC was also 
verified (figure 35B). Additionally, clone 31 of coPKD3iPSC was able to generate a teratome in NSG 
mice (data not shown). Altogether, these results demonstrate that gene correction process did not 
affect pluripotency status.  
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Sequencing around SNP in untargeted alleles of corrected PKD2iPSC, showed that all the clones had an A. So all the 
clones were targeted in the allele that had the G, showing allele specific targeting 
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2.5.2.6 Flagged RPK expression in differentiated coPKD2iPSC 
The presence of the flagged RPK as a result of a correct targeting was analyzed in coPKD2iPSC by 
western blot. Wild type PB2iPSC, PKD2iPS and coPKD2iPSC clone 11 were differentiated into the 
erythroid lineage (Fig 37A) in order to activate PKLR promoter and at day 20 protein lysates were 
generated.  Two immunoblots were performed; one with anti-RPK polyclonal antibody (Fig 37B, 
upper blot) and the other one with Anti-FLAG TAG monoclonal Antibody (Fig 37B, lower blot). β-
tubulin was used as loading control. The percentage of erythropoietic cells (CD235a positive) was 
variable among the different assayed cell lines (Fig 37A) and therefore we loaded protein quantities 
equivalent to the erythroid differentiation efficiency to have similar RPK levels in the three cell lines. 
As seen in the upper image of figure 37B, RPK is expressed in the three cell lines and in the two 
reported protein isoforms: the L isoform (upper band) and the proteolyzed Lc isoform (lower band) 
(see introduction 1.1 for details). The anti-FLAG antibody bound the two RPK isoforms in the 
coPKD2iPSC lysate, giving exactly the same protein sizes pattern than when using the anti-RPK 
antibody (blue arrows in Fig 37B), confirming correct targeting by Knock-In and the expected splicing 
and protein processing of chimeric RPK. 
 
 
 
  
 
 
 
 
 
 
 
2.5.2.5 Erythroid differentiation in corrected PKD2iPSC  
In order to verify the phenotype consequence of gene correction, coPKD2iPSC clone 11 was 
differentiated into the erythroid lineage and at day 21 CD235a and CD71 markers were analyzed to 
confirm the erythrocyte maturation status (Fig. 36). As seen in hiPSC from a healthy donor (PB2iPSC) 
 
Figure 37: Healthy donor, PKD2 and corrected PKD2 iPSC erythroid differentiation and flagged RPK analysis by western blot. A) 
Percentage of CD235a
+
 cells present in the in vitro cultures determined by flow cytometry. B) Western blot analysis of protein 
extracts from the in vitro differentiated cells. See text for details about protein quantities loading. Blue arrows mark the bands 
corresponding to flagged RPK detection in coPKD2iPSC. 
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Figure 36. Erythroid maturation profile of coPKD2iPSC. A) Flow cytometry of erythroid markers CD235a and CD71 showing a high 
percentage (82%, (3.78 / (3.78 + 0.85)) of the total erythroid cells (CD235a
+
) being negative for CD71 as a consequence of 
maturation. B) CD71 loss at day 21 of differentiation is represented as CD71 negative cells/ total CD235a positive cells. Images 
show red pellets at day 21 from all the cell lines. 
 
in figure 21,  in which 69% of erythroid cells positive for CD235a had lost CD71 at day 21, 
differentiation of coPKD2iPSC ended up generating a 82% of cells positive for CD235a and negative 
for CD71 (Fig. 36A and B). The presence of these mature erythroid cells confirms that impaired 
erythropoiesis of PKDiPSC is restored after KI correction mediated by PKLR1 TA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.6 Genome Stability analysis  
As a consequence of reprogramming, prolonged culture, correction process and clonal selection of 
pluripotent cells, many genomic aberrations could be generated. PKD2iPSC line was already proven 
to be karyotipically normal (Fig. 17) but, as reported by many authors, numerous genomic 
abnormalities could have been generated that are not detectable by G banding of metaphasic 
chromosomes, which has a resolution of 3-10 Mb. Therefore, we analyzed Copy Number Variations 
(CNV) by array based Comparative Genomic Hybridization (aCGH) and somatic mutations by exome 
sequencing of the following samples: Peripheral blood mononuclear cells of PKD2 patient 
(PKD2MNC), the hiPSC line generated from this sample (PKD2iPSC) and one of the corrected clones 
generated from PKD2iPSC (coPKD2iPSC). 
Copy Number Variation (CNV) analysis  
For CNV analysis an array of probes that covered the whole human genome with some spacing was 
used. CNV were detected as DNA segments that have gained (CN ≥3) or loss (CN ≤ 1) a copy number 
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Table 9: Copy Number Variations (CNVs) in coPKD2iPSC, clone 11. 
 
state in comparison with the reference genomic DNA. Losses of Heterocygosity (LOH) events are also 
detected due to collection of probes for Single Nucleotide Polymorphisms (SNPs) genotyping.                                                
Thirty two CNVs were found in coPKD2iPSC clone 11 (Table 9). The majority of them were already 
present in the uncorrected PKD2iPSC (91%) and many of them also in the original population of 
mononuclear cells (PKD2MNC) (75%). An interesting and surprising observation was the one seen in 
CNV nr. 7, which is a LOH of 6.3 Megabases (Mba) found in PKD2MNC that was not detected in 
PKD2iPSC and detected back in coPKD2iPSC. Only CNV nr. 1 and 29 were generated during gene 
correction or during its consequent clonal selection and culture. The first one is a deletion of 60.6 kb 
that includes the following described genes: OR2T10, OR2T11, OR2T35, which are a family of 
olfactory receptor genes.  The second is an amplification of 6 kb that includes the FGD1 gene. None 
of them have been associated to survival advantage related to pluripotent cultures. They could also 
be a consequence of TA off target cutting and therefore we analyzed the sequences surrounding the 
CNV for homology with the PKLR TALEN targeting sites. No sequences with less than 8 mismatches 
were found in the vicinity of these CNVs. CNV marked in light red were detected in PKD2iPSC and not 
in PKD2MNC, probable being a consequence of reprogramming induction and prolonged culture. 
None of the genes present in these amplified/deleted regions have ever been associated neither to a 
proliferative or survival advantage nor to be involved in hematopoietic differentiation. 
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Somatic mutation analysis 
The whole exome of the three samples (PKD2MNC, PKD2iPSC and coPKD2iPSC) was interrogated by 
Illumina HiSeq 2000 system. After bioinformatics analysis by comparing the sequencing data with 
the human genome reference, variant calling was performed and a list of 67729 variants was 
generated. After removing the ones that were already present in PKD2MNC, the list was reduced to 
5797 variants. After selecting those included only in exonic regions the list decreased to 420 variants 
and after removing the ones that were included in the SNP database to 202. Then the ones in which 
the number of reads was lower than 8 and the variants that were present in less than 20% of the 
reads were removed, generating a list of 76 variants.  By looking at the sequencing raw data of these 
76 genomic regions in the IGH (Integrative Genomic Viewer, Broad institute) genome viewer, some 
of them were removed for having less than 8 reads in the original PKD2MNC and therefore being 
impossible to discard if they were already present in the original population before reprogramming. 
The final list of variants (Table 10) included 10 variants and 4 of them were also detected in 
PKD2iPSC. From them, just 3 of them were present in around 40% of the reads. In order to verify the 
presence of these mutations by Sanger sequencing, these regions were PCR amplified and 
sequenced. The mutations in RUSC2, TACR2 and in APOA5 were confirmed (Fig 38). The rest of the 
mutations were also analyzed by sequencing, being none of them verified.  
 
 
 
 
Table 10: Genetic variants in coPKD2iPSC clone 11 
 
 
Figure 38 Single nucleotide variants (SNV) verified by Sanger sequencing in coPKD2iPSC clone 11. RUSC: G>T, APOA5: 
G>A and TACR2, A>G (complementary reverse sequence is displayed in chromatogram, T>C). 
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VIII Discussion 
During the present thesis we have generated hiPSCs from PKD patients, with high efficacy and on a 
safe manner, which recapitulated the PKD phenotype once differentiated into the erythroid lineage. 
Moreover, we have accomplished their gene correction through a Knock-In approach in PKLR locus 
that restored the PKD phenotype and analyzed the genome alterations using state of the art 
techniques for genome sequence analysis. 
1 Cell Reprogramming 
The idea of generating an unlimited source of cells with the ability to differentiate into any cell from 
an adult somatic tissue is presented as a very promising approach for regenerative medicine 
(Robinton and Daley 2012, Cherry and Daley 2013, Svendsen 2013). The establishment of the 
conditions for the generation of hiPSC, by means of reprogramming, has opened a big window in this 
new field. Consequently, this discovery was awarded with the 2012 Nobel Prize for Physiology or 
Medicine to two researchers that were crucial for the development of this technology; Shynya 
Yamanaka (Takahashi and Yamanaka 2006) and John Gurdon (Gurdon 2006). The two main 
applications of reprogrammed cells are the already under development use for disease modeling 
and drug discovery (Egawa, Kitaoka et al. 2012) and as autologous cell source for regenerative 
medicine, which will probably be demonstrated in a near future.  
1.1 Generation of hiPSCs from PKD patients for gene correction 
First steps in gene therapy field are based in additional gene therapy (GT), which is the incorporation 
of a therapeutic copy of the affected gene, which will commonly integrate in a genomic locus 
different from the affected one. In this regard, previous work from our group proposed an 
innovative therapy based on additional GT for PKD by using corrected mouse HSC, which reverted 
many PKD symptoms in PKD mice (Meza, Alonso-Ferrero et al. 2009). Nevertheless, additional GT 
has important drawbacks. In addition to the already mentioned random integration that could 
potentially end up in insertional mutagenesis events, for diseases in which the correction does not 
impair a selective advantage such as PKD, a high chimerism might be established that could assure 
GT success. In this respect, genes that confer advantage can be included in the GT vector, as it was 
shown in the latest reported GT attempt for PKD (Trobridge, Beard et al. 2012). However, by using 
patient specific hiPSC for gene correction instead of patient HSCs, as it is a clonal population in which 
corrected clones can be selected and expanded, these drawbacks could be solved. Being a clonal and 
unlimited source of cells, safety analysis could be performed such as integration sites interrogation, 
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or therapeutic transgene and surrounding genes expression analysis. This was performed by 
Tubsuwan et al, by conducting a deep biosafety analysis of hiPSC generated from a patient with β-
thalassemia, that was cured 5 years ago by lentiviral gene transfer in HSC  while showing a myeloid-
biased cell clone (Tubsuwan, Abed et al. 2013). The idea of using corrected hiPSC derived HSC for 
transplantation would also solve one of the main bottlenecks for HSC GT success, which is the 
available number of cells for transplantation, which in some cases is limited.  
We are proposing the use of gene corrected patient specific hiPSC as therapeutic option and thus we 
believe that there are many aspects of the reprogramming process that are crucial to be taken into 
account, such as the safety and efficiency of the reprogramming process, the cell source for 
reprogramming and the differentiation into the desired tissue. 
1.1.1 Reprogramming on a safe manner 
hiPSC suitable for clinical pursues should not include integrated forms of reprogramming genes 
mainly because of safety issues, but also because they are more similar to hESCs in terms of gene 
expression (Cheng, Hansen et al. 2012), genome stability (Liu, Cheng et al. 2012) and differentiation 
ability (Ramos-Mejia, Montes et al. 2012, Sommer, Christodoulou et al. 2012). Up until now, there 
have been many described non-integrative reprogramming methods. Among them, two were 
preferred in terms of combining efficiency and biosafety: 1) Excisable reprogramming polycistronic 
lentivirus (STEMCCA), that showed a high efficiency when reprogramming different cell types, 
including CD34 progenitors (Ramos-Mejia, Montes et al. 2012) and can be removed by Cre 
recombinase excision; and 2) Sendai viral vectors (SeV), that are non-integrative RNA vectors and 
highly efficient in transduction (Fusaki, Ban et al. 2009). There was a report on reprogramming PB-
MNC by lentiviral vectors showing an efficiency of 0.001-0.0002 % (Staerk, Dawlaty et al. 2010), but 
at that point no one ever described PB-MNC reprogramming by SeV. When we assayed STEMCCA 
lentiviral system in PB-MNCs, due to technical problems, our detection range was below the 
described efficiency. So, we could not reprogram any clone. Nevertheless, by plating same amount 
of cells, reprogramming of PB-MNC by SeV reached up to 0.4-0.6% of reprogramming efficiency, 
being much more efficient than with lentiviral vectors. Nevertheless, although the STEMCCA can be 
excised, one of the LoxP site will remain, and this implies a genome modification that could be 
avoided by using SeV. Also, in the scenario in which more than one copy of STEMCCA would have 
been integrated, they could recombine in the presence of Cre recombinase. 
There is a very recently described methodology that could be equivalent to reprogramming by SeV, 
which are the so called self-replicating RNAs (SR-RNAs), based on the replicative form of 
Venezuelan Equine Virus (VEE-RF) (Yoshioka, Gros et al. 2013). As it is in the case of SeV 
reprogramming, there is no chance of viral integration and the transcription factors expression is so 
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high that makes the process very efficient (equivalent to retroviruses). Authors claim that in 
comparison with SeV, there is an important biosafety advantage related to reprogramming 
sequences disappearance. As the SR-RNAs are maintained in the presence of puromycin, once the 
drug is removed, they disappear due to cellular degradation. Based on our results on SeV transcripts 
amplification by PCR, the vectors dilution consequence of rapid cell division works in this system and 
there are no residual reprogramming genes at passage 15 of culture. We also believe that SeVs show 
and advantage in comparison to SR-RNAs which is the high viral transduction efficiency that we have 
also proven, especially in hematopoietic progenitors (CD34+) within PB-MNCs, in which 76% of the 
cells within this lineage were transduced. When using SR-RNAs, the delivery method is transfection 
and there are many cell types in which this method is not as efficient as it is in fibroblasts. 
1.1.2 Use of PB-MNC as cell source for reprogramming  
We chose to use PB-MNC for three main reasons: 1) They can be obtained by a minimally invasive 
procedure, 2) Can be directly obtained in enough numbers without the need for expansion, which 
could cause genomic instability and increases the time for hiPSC generation, and 3) Although 
unproven, they could have hematopoietic differentiation ability advantage.  
The most important disadvantage of the PB-MNC would be its low transduction efficiency and this 
might be the reason why the reprogramming efficiency when using lentiviral vectors decreases from 
1% described for fibroblast to 0.001-0.0002% (Staerk, Dawlaty et al. 2010). Nevertheless, by using 
SeV vectors in combination with the cytokine stimulation conditions described, we obtained high 
transduction efficiency, increasing reprogramming efficiency to 0.4-0.6%. More interestingly, the 
combination of our system with the recently described Knock-Down of MBD3 (Rais, Zviran et al. 
2013), should be tested to improve the efficiency of PB-MNC reprogramming by SeV.  Rais et al 
showed that the Knock-Down of this gene, a core member of the Mbd3/NuRD (nucleosome 
remodeling and deacetylation) repressor complex, lead to a deterministic and synchronized 
reprogramming in the human and the mouse system. 
Another point that should be taken into account when using PB-MNCs is that, as it is a 
hematopoietic heterogeneous population, there is a high percentage of cells belonging to the 
lymphoid lineage that have undergone somatic rearrangement. This could be used as a genomic 
signature for hiPSC tracking or for specific immunotherapy (Themeli, Kloss et al. 2013) but there are 
situations in which the ability to generate a complete repertoire of T or B cells would be desirable. In 
this regard, as also shown by Staerk et al (Staerk, Dawlaty et al. 2010), we have proved that by 
stimulating proliferation and promoting the transduction of a specific subset within PB-MNCs with 
specific cytokines, none of the resulting hiPSC lines showed neither T cell receptor (TCR) nor 
immunoglobulin (Ig) chain genomic rearrangements. By analyzing SeV transduction in the different 
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cell lineages within PB-MNCs after cytokines stimulation, we showed that half of the transduced cells 
were T or B cells, but this was not enough to prompt reprogramming, as when somatic genomic 
rearrangements were analyzed none of the lines showed neither TCR nor IgH rearrangements. This 
data suggest that these cytokines prompting survival and proliferation might be affecting 
reprogramming efficiency, as it has been already shown in the case of the IL-6 (Brady, Li et al. 2013). 
The effect of cytokines stimulation on reprogramming should be deeply studied as it could provide 
insight into pluripotency induction. Others have proposed the purification of CD34+ from normal 
(Merling, Sweeney et al. 2013) or mobilized PB-MNC (Ye, Muench et al. 2013) in combination with 
SeV vectors for reprogramming . We believe that by using our proposed cocktail of cytokines, we are 
targeting the reprogramming of non-lymphoid cells without any need for previous cell purification.  
1.1.3 PKD and healthy samples reprogramming 
Our initial goal was to generate iPSCs from five independent human samples, three from PKD 
patients and two from healthy donors. We processed PKD1 and PB1 and kept them frozen for later 
reprogramming. Once thawed and transduced, we could not isolate any clone from PB1 and we 
isolated some from PKD1 but they did not survive due to technical problems unrelated to the 
sample. We tried a second reprogramming experiment with both samples but no clones could be 
isolated. In order to analyze if it could be related to the freshness of the sample, PB2 and PKD2 were 
reprogrammed right after isolation and many lines were established from both samples. In order to 
explore the hypothesis that reprogramming is more efficient in fresh samples, we tried to reprogram 
PKD3 from frozen sample and successfully isolated many lines. Another important fact that could 
have influenced PB1 reprogramming was the high percentage of lymphoid cells within this PB-MNC 
sample (98%). Little is known about cellular barriers for reprogramming (Qin, Blaschke et al. 2012), 
but it has been reported that there are some samples in which the establishment of pluripotency is 
more difficult than others. So far, difficulties associated to DNA damage (Marion, Strati et al. 2009), 
high doses of tumor suppressor genes (Li, Collado et al. 2009) or to defects in homologous 
recombination (Gonzalez, Georgieva et al. 2013)  and non-homologous end joining (Molina-Estevez, 
Lozano et al. 2013, Tilgner, Neganova et al. 2013) have been reported. We believe that there might 
be sample specific characteristics that could have made more difficult PKD1 or PB1 reprogramming 
but that the sample was frozen could also have influenced the outcome. In order to verify this 
hypothesis, new blood samples should be extracted and a new reprogramming with fresh PKD1/PB1 
PB-MNC should be attempted.  
None of the obtained patient hiPSCs had any defect in proliferation and all the lines grew as 
expected showing the typical hESC morphology. One clone from each sample was randomly selected 
for expansion and characterization. The first thing we made was to analyze if the patient iPSC had 
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the specific patient mutations and, once verified, we performed a deep characterization in which the 
pluripotency of the 3 lines was assessed. We analyzed the presence of many pluripotency related 
molecules at gene expression level and at protein level, including the ones belonging to the 
pluripotency core (Heng, Orlov et al. 2010). Promoter demethylation of two of them, NANOG and 
SOX2 was also assessed, confirming the total and stable induction of pluripotency in the three cell 
lines. Surprisingly, SOX2 promoter was also demethylated in PB-MNCs, which might have facilitated 
its reprogramming. By looking at the undifferentiation status of the whole culture by flow cytometry, 
we could verify that there was no tendency to differentiation and that there was a high confluency 
(MEF percentage was always lower than 10%). Having a pure and confluent culture is a crucial point 
for hiPSC maintenance and for performing reproducible differentiation experiments.  The final proof 
that pluripotent cell lines have the ability to generate any cell type from the body is to generate a 
chimera as it is made in mouse iPSCs (Carstea, Pirity et al. 2009). For obvious reasons, this is not 
possible in the human system and therefore an in vivo differentiation system based on teratoma 
formation was performed. The presence of tissues belonging to the three germ layers (mesoderm, 
endoderm and ectoderm) confirmed the capacity of the generated cell lines to produce any tissue 
and consequently its pluripotency. Some authors have argued about the need to establish a 
standardized minimal set of assays for hiPSC characterization (Loring and Rao 2006, Luong, Auerbach 
et al. 2011) but the tendency is that each cell bank determines the assays needed in order to keep 
the cell line. Even a unique bioinformatics assay based on gene expression that would substitute the 
other assays has been proposed (Muller, Schuldt et al. 2011). We have performed an extensive 
characterization, with which we are confident on the pluripotency of the PKD patient and healthy 
hiPSCs. 
 
1.1.4 PKD phenotype recapitulation during PKDiPSC erythroid differentiation 
Once we generated the PKDiPSCs, we induce its differentiation into the erythroid lineage and 
evaluated the disease-associated phenotype. Therefore, we assayed two of the many described 
erythroid differentiation protocols using the healthy donor PB2iPSC in order to verify that the level 
of maturation was enough for RPK to be expressed. One of the main limitations of all the described 
approaches is the absence of efficient and full maturation and enucleation of erythrocytes (Sommer, 
Stadtfeld et al. 2009). In method number 1 the level of RPK expression was higher but it showed a 
big disadvantage in our hands which was the cell expansion. In this regard the method nr. 2, 
although RPK level was lower, promoted cell expansion, allowing the availability of enough material 
for further biochemical analysis. When RPK and PKM expression levels were analyzed in method 2 at 
different time points, both genes were expressed, being PKM even higher than RPK at day 20. One 
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possible explanation for this is that there are many highly proliferative cell types different than 
erythrocytes generated during differentiation that might express high levels of PKM and that might 
increase in numbers during the differentiation process. In order to avoid this interference, 
erythrocyte-like cells could be purified either by fluorescent or magnetic cell sorting. Overall, it was 
important for us to have enough material to analyze the different parameters related to disease 
correction and thus method nr. 2 was the chosen one for PKDiPSC differentiation.  
Previous work from our group analyzed the different erythroid developmental stages in PKD mice by 
looking at the mouse erythroid markers Ter119 (equivalent to human CD235a) and CD71 (Meza, 
Quintana-Bustamante et al. 2007, Meza, Alonso-Ferrero et al. 2009). They described 4 populations: 
early proerythroblasts (Ter119medCD71high); II, basophilic erythroblasts (Ter119highCD71high); III, late 
basophilic and polychromatophilic erythroblasts (Ter119highCD71med); and IV, orthochromatophilic 
erythroblasts and mature erythroid cells (Ter119highCD71low) (see intro. 1.1) When bone marrow and 
spleen of PKD mice were analyzed (Meza, Alonso-Ferrero et al. 2009), a predominance of immature 
erythroid precursor cells was observed (proerythroblasts, basophilic erythroblasts, and 
polychromatophilic erythroblasts) and late erythroid populations were significantly lower than in 
wild type mice. This anemic phenotype has been also described in thalassemic mice (Somers, Jean et 
al. 2010). Whereas in bone marrow of wild type mice there is a small percentage of immature 
erythroid cells (populations II and III), in peripheral blood of healthy humans the majority of 
erythroid cells belong to population IV. When we analyzed these cell subsets in peripheral blood of 
one of the PKD patients (PKD2), cells belonging to population II and III were much more prominent 
than in healthy donors. Importantly, when the differentiation was carried out in PKDiPSC, we 
observed a high accumulation of cells belonging to groups II and III after 20 days of PKD2iPSC and 
PKD3iPSC differentiation. The percentage of cells within these two subsets was ten-fold higher than 
the ones present in PB2iPSC differentiation, confirming the feasibility of hiPSC obtained from PKD 
patients for modeling the disease. 
2 PKDiPSC Knock-In gene correction  
There are three main strategies for gene editing mediated gene correction: 1) targeted gene 
correction, 2) Knock-In gene correction and 3) safe harbor integration. The selection of the best 
strategy depends on the disease and type of mutation to be corrected. Targeted correction is the 
cleanest choice and the one that has been more frequently reported in patient hiPSCs (Garate, Davis 
et al. 2013). However, this approach is only appropriate for one specific patient or group of patients 
carrying the same mutation, which limits its use. Alternatively, safe-harbor integration is applicable 
to treat all the genetic diseases already addressed by gene addition therapies, as it is the same 
strategy directed into a specific genomic site. However, since the therapeutic gene loses its 
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endogenous regulation, a specific promoter may be required to obtain a tight physiological 
regulation; additionally, the definition of a safe-harbor locus might not be accurate. The Knock-In 
strategy is an intermediate possibility in which a large number of patients of a specific disease might 
be treated. Additionally, the endogenous elements of the locus will regulate the expression of the 
therapeutic gene. However, there are two concerns regarding the Knock-In strategy: the first one, 
shared with the safe harbor approach, is that the use of a specific cDNA transgene may exclude the 
co-expression of various splicing variants; and the second one is the unfeasibility to correct 
promoter mutations. In our case, we were dealing with a disease in which many different mutations 
have been described (more than 190), being the majority of them in exons three to eleven. 
Particularly, in the case of PKD, from the reported mutations described so far, just two were in 
promoter regions and one in exon two. In addition, a tight physiological gene regulation is very 
important, as RPK expression is restricted to very specific cell types in which expression is needed. 
That is why we decided that Knock-In was the best strategy to genetically correct PKD.  
We included a codon optimized version of RPK cDNA as it has been shown to increase gene 
expression level (Wiehe, Ponsaerts et al. 2007), followed by a FLAG tag that allowed us to follow the 
expression of the correctly spliced therapeutic cDNA.  
An element of the donor matrix that is subject of controversy is the Selection Cassette (SC). Although 
its use is common, when Soldner et al generated isogenic lines for Parkinson disease modeling 
(Soldner, Laganiere et al. 2011), in one of the approaches they did not include a SC for two reasons. 
i) they wanted to modify the locus minimally and ii) they wanted to avoid the cloning steps 
associated to a selection process as it will increase the selective pressure into the culture. But we 
believed that even by using DNA nucleases, the HR efficiency remains too low, as it is shown in figure 
27. The ratio of cells that grew in the presence of puromycin was very low compared to the number 
of colonies in the absence of it, meaning that the number of cells that incorporated the matrix was 
low.  That is why we believed that the inclusion of a SC in the targeting matrix is very important for 
later selection of correctly targeted clones. The number of clones that should be picked and 
expanded in the absence of selection in order to have a correctly targeted clone is very high (1 out of 
240 in the case of Soldner et al.), and that is why be decided to include this element. Nevertheless, 
our SC is floxed by LoxP sequences in order to be removed by transient expression of Cre 
recombinase. Even though, one of the LoxP sequences will remain after the excision, but from our 
point of view and taking into consideration the fact that it is included in an intron, the genetic 
modification will most probably going to be harmless.  
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2.1 Meganuclease mediated homologous recombination 
The first assayed nuclease was the PKLR01 MG. As engineered MGs are developed from naturally 
occurring rare-cutting endonucleases, we thought that the possibility that they could show a 
reduced toxicity and a higher specificity should be explored. Additionally, as they cleave as 
monomers, they could avoid the problems associated with the delivery, coordinated expression and 
dimerization of two molecules as it is the case of other engineered DNA nucleases (Grizot, Epinat et 
al. 2010). We started analyzing the cleavage efficiency of two of the versions that Cellectis kindly 
provided us in HEK-293H cell line. Both showed an acceptable mutagenesis being version 2 slightly 
more efficient, so we decided to use it to correct PKDiPSC by Knock-In approach, since MG-induced 
targeted mutagenesis and HR efficiencies are strongly correlated (Daboussi, Zaslavskiy et al. 2012).  
For the next experiments, we decided to move to the eryhtroleukemic K-562 cells, as it is a cell line 
in which PKLR locus is active and RPK is expressed, so we could analyze the splicing after HR. We 
assayed different doses of PKLR01 MG in the form of mRNA, as it has been shown that nucleofection 
of mRNA is more efficient, less toxic and yields a higher protein expression in human primary cells 
(Wiehe, Ponsaerts et al. 2007). The cutting efficiency decreased when using high doses of MG (6 µg, 
26%), whereas it was constant (35%) with 0.5 and 3 µg. As 6 µg is not such a high quantity of mRNA 
to be toxic, it might be due to a high toxicity of the MG. Once we confirmed mutagenesis in PKLR 
locus, we performed HR by combining the MG with the DM and selecting for 20 days with 
puromycin. In the condition in which just the matrix was nucleofected, a pool of puroR K562 cells was 
also generated, most probably due to random integration of the matrix. HR-specific PCR confirmed 
targeting in PKLR locus, and our next question was if the therapeutic transgene was being generated 
properly. Thus, we analyzed the presence of the FLAG tag by flow cytometry. K-562 is a 
heterogeneous cell line in which just a subset of cells has an active PKLR promoter and the level of 
expression might not be high. That is why, the detection of the FLAG tag was observed only in a 
small subset of the cells, and at very low levels. We stimulated the erythroid differentiation by 
hemin (Baliga, Mankad et al. 1993), which increased the number of cells expressing PKLR gene and 
therefore the expression FLAG tag, and confirming gene targeting in at least a subset of cells from 
the selected pool. This preliminary set-up of the HR conditions was very useful for its later 
application in patient iPSCs.  
Next, we performed HR experiments in PKD2iPSC and isolated and expanded puromycin resistant 
clones. As the HR-specific PCR was not as clean and resolving as expected, Southern Blot (SB) 
analysis was performed, which gave us information about integration sites. SB revealed that the DM 
was not integrated where expected, at least not uniquely, suggesting that the MG could have 
targeted other places of the genome. This was confirmed by reanalyzing the target sequence of 
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PKLR01 MG in the human genome, revealing that it was not uniquely found in intron 2 of PKLR gene, 
but also in other 26 sites of the genome. This would also explain the low percentage of cells 
expressing the flagged RPK in K-562, as many of them would be targeted in other loci different than 
PKLR. The SB expected pattern was only found in one of the three analyzed clones and it was not 
unique. This unexpected setback points out the importance of a preliminary in silico engineering of 
nucleases in order to reduce off targets. 
The predominance of integration in other loci different than PKLR is surprising even if the MG was 
cutting at other places, as the homology arms from the DM should prompt the integration in PKLR 
locus. Maybe the generation of DSBs was prompted in other loci more than in PKLR. This could be 
related to the presence of methylated CpGs in the targeting sequence of the MG, as it has been 
previously reported to affect MGs (Daboussi, Zaslavskiy et al. 2012), and TAs (Shijia Chen 2013) 
efficiency. It was established that in order to have an effect on DSB generation efficiency by MGs, 
the methylated CpGs had to be in the central tetrabase of the recognition site (Valton, Daboussi et 
al. 2012), but this effect of methylation should be deeply analyzed as it could vary depending on the 
used nuclease and the targeted locus. We analyzed the methylation status of the CpG present in the 
left extreme of the targeting sequence in hiPSCs and it was indeed methylated, but we cannot 
conclude the effect of methylation because we had no sample in which it was demethylated. 
The reason for HR-specific PCR working better in K-562 than in PKDiPSC might be the fact that in the 
first one, as we were working with a pool of different targeted cells, among them, there might be 
some targeted cells in PKLR locus that could have generated the PCR product.   
The unspecificity of PKLR01 MG should not be generalized to other MGs, as it has been shown that it 
was due to a design mistake. In addition, there are many studies in which successful MG mediated 
targeting in human cells have been reported (Grizot, Smith et al. 2009, Cabaniols, Ouvry et al. 2010, 
Popplewell, Koo et al. 2013). One disadvantage of MGs is that they cannot be designed against any 
desired genome sequence, and there was no other MG available that could be combined with our 
generated targeting matrix. That is why we, in collaboration with Cellectis, decided to use another 
type of DNA nuclease, the PKLR1 TALENTM (TA).  
2.2 TALENTM mediated homologous recombination 
The simplicity of TAs design allows a fast engineering, being even possible to be designed by the user 
without the need to purchase them. This is the reason why, in just two years, TALENs have been 
used in many of the applications in which ZFN had already being used: hPSCs gene editing and rat, 
mouse, zebrafish, and worm transgenic models generation. In an attempt to compare TAs and ZFNs 
in hESCs and hiPSCs (Hockemeyer, Wang et al. 2011), several loci have been targeted and HR 
efficiencies with both types of nucleases have been compared. It was concluded that both ZFNs and 
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TAs show similar efficiencies and accuracy. Nevertheless, an in vitro gene disruption comparison 
between ZFN and TAs showed that TAs were more efficient and less cytotoxic (Mussolino, Morbitzer 
et al. 2011).  
The TA designed for targeting intron 2 of PKLR included the targeting sequence of PKLR01 MG, being 
25 bp longer. By bioinformatics analysis it was not possible to find the targeted sequence in other 
places of the genome in addition to the PKLR locus. We assayed its cutting efficiency by the surveyor 
assay directly in PKDiPSC. We performed an attempt by nucleofecting both TA subunits as mRNA 
(data not shown) but we detected no cutting whereas as plasmid DNA we did. The reason for this 
might be that an optimization of the in vitro mRNA synthesis assay should have been performed as 
the length of each TA subunit was 3 Kb whereas the MG was 1 kb.  Even when using plasmid DNA, 
cutting efficiency was lower than the one observed in K-562, actually being below the quantification 
range. One factor that could be related to this decrease is the DNA nucleofection efficiency. When a 
GFP expressing plasmid was nucleofected in PKD2iPSCs and GFP was analyzed, 29% of the SSEA4+ 
population was positive for GFP, whereas in K-562 it was 65%. Being the TA expressing plasmids 
larger, and taking into account that the two plasmids expressing both subunits should enter the cell, 
it is understandable that the cutting efficiency decreases. Regarding the effect of methylation on 
DSB generation efficiency, it should also be taken into account than PKLR1 TA recognition site has 
two CpGs that resulted to be methylated in hiPSCs.  
Using the PKLR1 TA, we performed HR experiments in PKD2iPSC and PKD3iPSC, resulting in a 
targeting efficiency of 77% and 76% within the total of puromycin resistant clones, respectively. 
Unique targeting was confirmed in 5 of the PKD2iPSC targeted clones, verifying the specificity of 
PKLR1 TA. Although a proper evaluation of PKLR1 TA efficiency would include data in the absence of 
puromycin, we believe that the presented data clearly demonstrates the accuracy and applicability 
of the PKLR1 TA. 
PKD is a recessive disease and thus, correcting just one allele would be enough to restore the 
phenotype. Nevertheless, we believe that the capacity of the designed HR approach to generate 
homozygous corrected clones is important, as there are many other scenarios in which both alleles 
should be targeted. When we analyzed if the targeting happened in homozygosis or heterozygosis, 
in PKD2iPSC there was not any homozygous clone, whereas in PKD3iPSC there were 3 potential 
clones (11%). Still, the integration in both alleles in these three clones needs to be confirmed by 
southern blot.   
The presence of NHEJ mediated genome modifications in the untargeted allele has been analyzed in 
many gene correction studies without finding any evidence of it (Sebastiano, Maeder et al. 2011, 
Soldner, Laganiere et al. 2011, Zou, Mali et al. 2011). This is especially important in targeted gene 
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correction approaches as the matrix is inserted in the gene and a genomic modification of the 
untargeted locus might be deleterious. In our case we were targeting an intron and therefore, a 
genome modification would probably have no effect, but we believed it was interesting to analyze 
its integrity for HR strategy design purposes. This analysis revealed genome modifications in the 
untargeted allele of several clones (40% in PKD2iPSC and 31% in PKD3iPSC) pointing out another 
characteristic that should be considered when using DNA nucleases. The high percentage of 
homozygous targeted clones in PKD3iPSC together with the high NHEJ in the untargeted alleles in 
both PKDiPSCs imply a high DSB generation by the PKLR1 TA. It also suggests that the outcome of the 
PKLR1 TA surveyor assay in PKDiPSC is more related to difficulties for proper nucleofection of both 
TA subunits rather than to a reduced DSB generation efficiency.  
Another very important possible consequence of using DNA nucleases is the possibility of cutting 
other sequences of the genome that are similar to the intended one, the so called off targets. PKLR1 
TA targeting sequence was very unique being impossible to find by bioinformatics approaches other 
sequences in the genome with less than 5 mismatches. All the found sequences with 5 and 6 
mismatches were interrogated by Sanger sequencing in several clones from coPKD2iPSC and 
coPKD3iPSC, being all of them intact. In other studies, this type of analysis was performed by next 
generation sequencing, so that very low represented events could be detected. In our case, as the 
corrected clones come from a unique cell due to the clonal nature of hiPSC lines, if in this cell a 
NHEJ-modification would have been produced in any off target, it should be present in all the clonal 
population. Some authors have suggested that bioinformatics approaches based on sequence 
homology are not accurate enough for off targets prediction and have proposed alternative in vitro, 
in vivo and biochemical assays (Gabriel, Lombardo et al. 2011, Pattanayak, Ramirez et al. 2011).  We 
have not considered them here, but this additional biosafety analysis should be performed in the 
case the cells would be used for clinical settings. 
2.2.1 Allele specific targeting 
The reason for having no homozygous targeted clones in PKD2iPSC might have been in the sequence 
of the Homology Arm (HA) of the Door Matrix (DM). When the surveyor assay was performed in 
PKD2iPSC, two unexpected and high intensity bands appeared. They were consequence of an SNP 
close to the TA targeting site in one of the alleles of PKD2iPSC that was confirmed by Sanger 
sequencing. We thought that the presence of a mismatch between the HA and the genomic DNA to 
be targeted, could influence HR efficiency. Two studies reported the effect of variable sequences 
within different strains in mouse ESC on gene targeting (te Riele, Maandag et al. 1992, Zhou, Rowley 
et al. 2001) but, as far as we know, there are no studies analyzing the effect of SNPs in the HAs of the 
donor matrix. We concluded that the targeted allele in all the clones was the one that had 100% 
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homology with the HA. In order to proof the effect of this SNP on HR, we should generate a DM to 
target specifically the allele where the SNP is. As in PKD3iPSC there is no SNP close to TA target site, 
HR took place in both alleles, as we have observed. The use of this potential new DM should 
theoretically strongly reduce HR in PKD3iPSCs. There are many questions about this process such us 
how the SNP would influence if it would have been in the other arm, or how far can it be from the 
beginning of the HA in order to have an impact on HR efficiency. Another fact that could also have 
influenced HR in this locus is the repetitive nature of the right HA sequence.  
For PKD gene correction, this is not crucial as by correcting any of both alleles it would be enough to 
cure this disease. This would not be the case of a dominant disease such as sickle cell anemia, in 
which the correction should be done preferentially in the allele that harbors the disease causing 
mutation. Another reported disease correction approach that would have taken advantage of an 
SNP in a specific chromosome, would be the one in which down syndrome hiPSC were corrected by a 
Xist mediated inactivation of one of the extra chromosomes (Jiang, Jing et al. 2013). They selected 
the clone in which just one chromosome was inactivated, but they could have targeted the 
expression of Xist lncRNA into one of the three chromosomes in the case it would have been and 
SNP in the vicinity of the ZFN targeting sequence. From our point of view, a deep study of HAs SNPs 
influence in HR process would be very useful for future gene targeting strategies design. 
2.2.2 Transgene expression and phenotype restoration in corrected PKDiPSC 
HR process had no deleterious effect on pluripotency maintenance in corrected PKD2iPSC 
(coPKD2iPSC) as it was shown by pluripotency gene expression array and SOX2 and NANOG 
promoter demethylation. When coPKD2iPSC was differentiated into the erythroid lineage, the 
expression of the flagged RPK was assessed by western blot and the two bands corresponding to 
both RPK isoforms could be detected using an anti-FLAG antibody, assessing the correct targeting in 
PKD2iPSC. Once we had the proof that the wild type transcript was expressed once the cells were 
differentiated, what was crucial to be analyzed was the effect of gene correction in PKD phenotype. 
The maturation profile of coPKD2iPSC, expressed as CD71 loss within the CD235a positive cells, was 
similar to the one described for PB2iPSC, being a high percentage of erythroid cells negative for 
CD71.   
2.3 Genome stability analysis 
Since the derivation of hESC in 1998 and the generation of hiPSCs in 2007, many studies have 
reported the appearance of genomic variations in pluripotent cultures such as aneuploidies, 
subchromosomal copy number variations (CNV) and single nucleotide variations (SNV) (Liang and 
Zhang 2013). These might be generated due to the selective pressure established during the 
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reprogramming process or prolonged culture. In addition, we should take special attention to the 
ones that could have been generated by the process of HR, especially by the use of DNA nucleases 
and the clonal selection procedures.  
A comprehensive karyotyping study of many hESC and hiPSC lines conducted by the WiCell Research 
Institute concluded that 13% of the analyzed lines showed aberrant karyotypes (Taapken, Nisler et 
al. 2011). Gaining an extra copy of a chromosome might increase the dose of a gene beneficial for 
self-renewal, clonogenicity or proliferation rate and therefore be selected and fixed in the culture. 
An example of this hypothesis is the commonly found trisomy of chromosome 12 (Draper, Smith et 
al. 2004), in which NANOG and GDF3 genes are located. In our case, none of the analyzed cell lines 
showed any aneuploidy. Nevertheless, all of them were below passage 17 and although culturing for 
longer periods would increase the chances of genomic aberrations, it does not have to, as high 
passage hiPSC have been reported in which no aneuploidies were detected (Taapken, Nisler et al. 
2011). Corrected clone 11 from PKD2iPSC was analyzed 16 passages later for chromosome gains or 
losses but in this case by CGH, which has a higher resolution (25.3kb overall, 5kb in ISCA 
(International Standards of cytogenetic arrays) regions, which are regions shown to be involved in 
cancer). Six CNVs and one Loss of Heterozygosity (LOH) events were detected that were not present 
in the original tissue, PKD2PB-MNC. There were two deletions and four amplifications and their 
mean size was 943 Kb. None of them were the ones commonly described e.g. around NANOG gene 
in chromosome 12 or around DNMT3B in chromosome 20. From these six, two CNV were detected 
after correction, CNV 1 and 29. There were no genes associated to a survival or proliferation 
advantage either in the amplified or deleted regions. Although the probability for generating such 
big modifications by the TA is very low, we also looked for sequence homology surrounding the CNV 
without finding any evidence of it.  
One of the main limitations of this and other similar genomic techniques is that the outcome of the 
analysis will be the one harboring the majority of cells and low frequency variations in the sample 
before reprogramming might be beyond the detection limit. A study in which deep sequencing 
techniques were used for genome analysis concluded that the majority of observed CNV in hiPSC 
were already present in the original source but at low frequency, consequence of the somatic 
mosaicism present in many human tissues (Abyzov, Mariani et al. 2012). It might be a possibility that 
the four CNV that appeared in the PKD2iPSC were not truly de novo. The two that appeared after 
correction were actually de novo as they were not detected in the PKD2iPSC sample.  
In this regard, the whole exome sequencing is a more quantitative technique; generally the number 
of reads from a concrete region is higher than 10 and consequently, a low represented Single 
Nucleotide Variant (SNV) could be detected but in a lower number of reads. The higher the read 
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depth, the better low represented SNVs can be detected. We used a 30X platform in which the 
average number of reads was 30 but there are other sequencing platforms in which it could be much 
higher, for example the Ion Torrent semiconductor sequencer, which could give a 50X read depth 
(Rothberg, Hinz et al. 2011). In our whole exome sequencing study, ten SNVs were detected that 
were not present in PKD2PB-MNC, being four of them also present in the uncorrected PKD2iPSCs. 
From them, just 3 could be verified by Sanger sequencing. The rest, being all of them present in 
around 20% of the reads, could not be verified. This might be because their dose is below the 
detection range by Sanger sequencing or because they were wrongly detected in the exome 
sequencing. Nevertheless, as they have not been fixed in the culture, their presence might not be as 
important as a mutation present in all the cells.  
The observed SNVs in our samples could corroborate the hypothesis that hiPSC related mutagenesis 
might be stochastic, as the in majority of studies in which they have been analyzed, there were not 
shared (Liang and Zhang 2013).  
As it was in the regions affected by CNVs, none of the verified SNVs affected genes already described 
to be involved in essential biological processes and neither in hematopoiesis. Nevertheless, special 
attention should be taken to the genes present in these regions as their function for the intended 
application might be crucial. In our case, they are not genes that have been described to be involved 
in essential processes or related to the hematopoietic system, but there are many genes that have 
not been described yet or gene functions that might not be accurate and therefore this is a fact that 
should be deeply analyzed before hiPSC can be used in the clinics.   
Another fact that should be studied is the acquisition of genome modifications during the 
differentiation process. In a study by Laurent el al., the most rapidly arising genomic aberrations 
were the ones generated during a directed differentiation experiment (Laurent, Ulitsky et al. 2011), 
pointing out that it is a highly selective process that should be deeply studied before the 
differentiated cells could be used for clinical pursues. On the other hand, and taking into 
consideration the reported difficulties to generate transplantable HSCs, the treatment of erythroid 
diseases could be performed by using autologous mature enucleated erythrocytes. In this regard, 
the absence of a nucleus would reduce the risks associated to the acquired genomic modifications. 
3 Future perspectives 
Our results corroborate the feasibility of hiPSC and HR technology for disease modeling and as a 
platform for the development of safe innovative therapies that could be used for many genetic 
diseases in the future. The synergy between reprogramming and gene editing is prompting the 
progress of this new field and our work adds valuable information to the different described 
strategies that are needed before this type of therapeutic approaches reach the clinics. As there are 
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many technical limitations that need to be solved, mainly genomic modifications and differentiation 
limitations, we believe that a big effort needs to be done to understand all the steps involved in the 
development of gene corrected differentiated cells so that such a powerful tool for regenerative 
medicine could be fully explored. 
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IX Conclusions 
The aim of this thesis is the feasibility analysis of the combination of hiPSC and gene editing 
technologies as a therapeutic tool for PKD treatment, and from the results obtained during its 
development several conclusions can be outlined: 
 
1. Induced Pluripotent Stem Cells (iPSCs) from Pyruvate Kinase Deficient (PKD) patients 
(PKDiPSC) and healthy donors (PBiPSC) have been generated on a safe manner, by 
transduction of peripheral blood mononuclear cells (PB-MNC) using Sendai viral vectors 
(SeV) expressing reprograming factors, showing a higher efficiency than the ones reported 
with similar methodologies. 
 
2. Erythroid differentiation of PKDiPSCs resembles the immature phenotype observed in 
peripheral blood of PKD patients, assessing the use of hiPSC for in vitro modeling of 
hematopoietic diseases. 
 
3. By the use of PKLR1 TALENTM, PKDiPSC derived from two different patients have been 
targeted by homologous recombination uniquely in PKLR locus, showing no off target 
genomic modifications, and leading to the expression of the therapeutic recombinant RPK 
and the restoration of the erythroid phenotype. 
 
4. The presence of a single nucleotide polymorphism in PKD2iPSC lead to an allele specific 
targeting, inserting the therapeutic matrix exclusively in the allele that perfectly matched 
the donor matrix. 
 
5. Few genomic variants have been acquired in corrected PKD2iPSC, being none of them the 
commonly described ones in hiPSC and not affecting genes reported to be involved in 
survival or hematopoiesis.  
 
6. The correction of hiPSCs by HR is revealed as a powerful tool for gene replacement therapy 
for PKD. 
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IX Conclusiones 
El objetivo de la presente tesis es el estudio de combinación de iPSC de pacientes con su corrección 
genética mediante recombinación homóloga, como una alternativa terapéutica para el tratamiento 
de la Deficiencia en Piruvato Quinasa (DPQ). De los resultados obtenidos durante su desarrollo 
destacan las siguientes  conclusiones: 
 
1. Se han obtenido células madre pluripotentes inducidas (iPSC) a partir de muestras de 
pacientes con DPQ (DPQiPSC) y de donantes sanos de forma segura, mediante la 
transducción de células mononucleares de sangre periférica con vectores virales Sendai 
(SeV) que expresan factores de reprogramación, mostrando una eficiencia de 
reprogramación  superior a metodologías similares. 
 
2. La diferenciación eritroide de DPQiPSC mostró un fenotipo inmaduro, similar al observado 
en los pacientes con DPQ, confirmando el uso de hiPSCs para modelado in vitro de 
enfermedades del sistema hematopoyético. 
 
3. Mediante el uso de PKLR1 TALENTM, se corrigieron iPSC de dos pacientes de DPQ mediante 
recombinación homóloga en el locus PKLR, sin detectarse ninguna modificación genética 
indeseable debida a la nucleasa. Se confirmó la expresión de la proteína terapéutica RPK 
recombinante, lo cual restauró el fenotipo eritroide. 
 
4. La presencia de un polimorfismo de un solo nucleótido en una de las muestras dio lugar a 
una integración específica de alelo, introduciéndose la matriz terapéutica exclusivamente en 
el alelo que era perfectamente homólogo. 
 
5. Se han adquirido algunas modificaciones genómicas durante el proceso de reprogramación, 
cultivo y corrección. Ninguna variante adquirida ha sido previamente descrita en hiPSC ni se 
encuentra en genes involucrados en supervivencia o en hematopoyesis. 
 
6. La corrección genética de hiPSCs mediante recombinación homóloga se presenta como una 
poderosa herramienta de terapia génica de reemplazo para el tratamiento de DPQ.
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New Frontier in Regenerative Medicine:
Site-Specific Gene Correction in Patient-Specific
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Abstract
Advances in cell and gene therapy are opening up new avenues for regenerative medicine. Because of their
acquired pluripotency, human induced pluripotent stem cells (hiPSCs) are a promising source of autologous
cells for regenerative medicine. They show unlimited self-renewal while retaining the ability, in principle, to
differentiate into any cell type of the human body. Since Yamanaka and colleagues first reported the generation
of hiPSCs in 2007, significant efforts have been made to understand the reprogramming process and to generate
hiPSCs with potential for clinical use. On the other hand, the development of gene-editing platforms to increase
homologous recombination efficiency, namely DNA nucleases (zinc finger nucleases, TAL effector nucleases,
and meganucleases), is making the application of locus-specific gene therapy in human cells an achievable goal.
The generation of patient-specific hiPSC, together with gene correction by homologous recombination, will
potentially allow for their clinical application in the near future. In fact, reports have shown targeted gene
correction through DNA-Nucleases in patient-specific hiPSCs. Various technologies have been described to
reprogram patient cells and to correct these patient hiPSCs. However, no approach has been clearly more
efficient and safer than the others. In addition, there are still significant challenges for the clinical application of
these technologies, such as inefficient differentiation protocols, genetic instability resulting from the repro-
gramming process and hiPSC culture itself, the efficacy and specificity of the engineered DNA nucleases, and the
overall homologous recombination efficiency. To summarize advances in the generation of gene corrected
patient-specific hiPSCs, this review focuses on the available technological platforms, including their strengths
and limitations regarding future therapeutic use of gene-corrected hiPSCs.
Introduction: Regenerative Medicine—Cell Plus
Gene Therapy
Regenerative medicine aims to replace and/or to re-generate damaged cells, organs, or tissues in order to
restore normal function. Cell therapy is an important regen-
erative medicine approach, in which either differentiated cells
or stem cells capable of differentiation are transplanted into an
individual with the objective of yielding specific cell types
present in the damaged tissue and consequently restoring its
function. The most successful example of cell therapy is bone
marrow (BM) transplantation, in which the transplanted he-
matopoietic stem cells (HSCs) are able to regenerate the pa-
tient’s blood. BM transplantation started in the 1950s and now
is a widely established procedure for many hematopoietic
diseases (Thomas et al., 1977). Cell therapies for other tis-
sues then followed in the footsteps of the hematopoietic ex-
perience. Nowadays, there are numerous ongoing clinical
trials using various types of stem cells and some of them are
U.S. Food and Drug Administration (FDA)-approved cell-
based products (www.fda.gov/BiologicsBloodVaccines/
CellularGeneTherapyProducts/ApprovedProducts/default
.htm).
Cell replacement can be done with autologous or alloge-
neic stem cells. When performing allogeneic cell therapy, the
risk of immune rejection usually requires the use of immuno-
suppressive drugs, which can induce toxicity and increase the
risk of infections and cancer, which could be life-threatening.
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This, together with the low availability of suitable donors,
makes autologous cell therapy frequently the preferred option
for regenerative medicine. However, in the case of monogenic
diseases, in which all the cells from the body initially carry the
disease-causing mutation in their genomic DNA, a gene cor-
rection approach should be considered to generate disease-free
autologous cells. Thus, a combination of cell and gene therapy
is used. Since the first gene therapy clinical trial in 1990 (An-
derson et al., 1990), much effort has been made to develop safer
and more efficient approaches.
The first gammaretroviral vectors used in clinical trials
were associated with enhancer-mediated cis- and trans-
activation, which induced insertional mutagenesis and ended
up in leukemia associated with the gene therapy procedure
(Hacein-Bey-Abina et al., 2003, 2008; Fischer et al., 2010). In
the ongoing clinical trials, lentiviral and retroviral vectors
have deletions in their long terminal repeats (LTRs) to min-
imize trans-activation of the genes surrounding the integra-
tion. However, insertional mutagenesis still remains an issue.
Other strategies, such as the use of nonintegrating viral
vectors, are being studied, as in the case of integration-
defective lentiviral vectors (Yanez-Munoz et al., 2006; Matrai
et al., 2011), but procedures to maintain nonintegrated DNA
in proliferating cells have not yet been developed. The in-
troduction of genetic material in specific, known, and char-
acterized loci of the genome via homologous recombination
(HR) would be an ideal option. HR will allow, in principle,
specific correction of the mutation without any additional
modification in the genome, or introduction of the genetic
material in a known and safe genome locus. HR is based on
the natural DNA repair process, in which a double-strand
break (DSB) is corrected with a homologous DNA sequence.
The therapeutic application of HR involves exchanging the
mutation for the correct sequence, or even introducing the
correct version of the gene in the targeted locus.
An important consideration is the source of cells for au-
tologous cell therapy. For some purposes, as is the case for
hematological diseases, a hematopoietic multipotent stem/
progenitor cell present in the adult body can be used. Other
examples of these kinds of progenitors in humans include
neural stem cells (Galli et al., 2003), mesenchymal stem cells
(Deans and Moseley, 2000), and intestinal stem cells (Yui
et al., 2012). In the majority of these adult stem cells, an im-
portant limitation is that correction of mutations by HR has
rarely been described to occur in a manner that retains the
multipotentiality of the stem cells. In addition, these kinds of
progenitors have been described for only a few tissues in the
body. Thus, an autologous stem cell source with wide ex-
pansion and differentiation potential is required for future
clinical use of HR in the context of regenerative medicine.
This issue has been solved with the generation of human
induced pluripotent stem cells (hiPSCs) (Takahashi et al.,
2007). Human iPSCs offer a powerful novel technology in
gene and cell therapies. Their essentially unlimited growth
capability allows successfully targeted cell selection, with the
possibility that 100% of potentially transplanted cells would
be corrected. The fact that they represent a clonal cell pop-
ulation is also advantageous as we can completely interro-
gate the whole exome or the whole genome for any
abnormality that could be accumulated during the entire
manipulation procedure, as has been addressed in several
reports (Table 1 and Fig. 1). We deal with some of these
pioneer works involving hiPSCs and HR technologies in this
review.
Generation of Patient-Specific Pluripotent Stem Cells
Choice of reprogramming platform
Since Yamanaka and colleagues first reported the gener-
ation of mouse iPSCs in 2006 (Takahashi and Yamanaka,
2006), and later the groups of Yamanaka (Takahashi et al.,
2007) and Thomson (Yu et al., 2007) in human cells in 2007,
many laboratories around the world have been able to re-
program a large variety of somatic cells into pluripotent stem
cells, from neural stem cells ( J.B. Kim et al., 2009) to termi-
nally differentiated B lymphocytes (Hanna et al., 2008). The
reproducibility and potentiality (unlimited self-renewal and
ability to differentiate into any cell type) of these cells has
caused the iPSC field to advance rapidly. hiPSC technology
brings together all the potential of human embryonic stem
cells (hESCs) in terms of self-renewal and pluripotency
without the problems associated with hESC generation (i.e.,
ethical issues associated with embryo disruption and im-
munoincompatibility with the recipient of the cells). There-
fore, hiPSC technology arises as one of the most promising
fields for future cell therapies for many human diseases.
For the generation of hiPSCs, the first reports used gam-
maretroviruses to express the four defined factors required
for reprogramming, OCT4, SOX2, KLF4, and c-MYC (Taka-
hashi et al., 2007), or OCT4, LIN28, NANOG, and SOX2 (Yu
et al., 2007), separately in different viral vectors. Because of
the nature of the vectors, expression of the factors was si-
lenced after the endogenous pluripotent genes were acti-
vated at an adequate level. Safer and more efficient
reprogramming approaches have since been developed and
many patient-specific hiPSCs have been generated both to
model human diseases and correct the diseased hiPSCs
through gene therapy approaches. Depending on the cell
type being reprogrammed, the number of factors used could
be reduced and, more importantly, oncogenes or tumor-
related proteins used for reprogramming, such as c-MYC or
KLF4, could be removed from the original reprogramming
cocktail. This, for example, was the case for reprogramming
hematopoietic progenitors (Liu et al., 2012; Meng et al., 2012)
or neural stem cells ( J.B. Kim et al., 2009), in which these two
factors could be removed. Even reprogramming with OCT4
alone was achieved (Thier et al., 2010). However the repro-
gramming efficiency decreases after removing any repro-
gramming factor. Although avoiding tumor-related genes
increases the safety of the reprogramming process, the safest
reprogramming protocol will ultimately involve removable
reprogramming transgenes or, even better, nonintegrative
systems that will avoid potential adverse effects associated
with the integration of the vector sequences in the cell ge-
nome (Sommer et al., 2010). Several groups have developed
Cre-mediated excisable polycistronic lentiviral vectors
(Somers et al., 2010; Papapetrou and Sadelain, 2011) or
transposon-based reprogramming systems (Woltjen et al.,
2011), which could be removed after obtaining the hiPSC
clones. The first truly nonintegrative reprogramming ap-
proach described in human cells was reported by the
Thomson group using episomal plasmids for expression of
the four Yamanaka transcription factors plus NANOG,
LIN28, and SV40 large T antigen (SVLT) (Yu et al., 2009). In
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the same year, reprogramming by recombinant proteins (D.
Kim et al., 2009), synthetic mRNAs (Warren et al., 2010), and
nonintegrating RNA Sendai viral vectors (Fusaki et al., 2009)
was also reported (Table 1). The majority of disease-specific
hiPSCs reported until now have been generated with inte-
grative systems, but an increasing number of disease-specific
hiPSCs have been generated using these novel and poten-
tially safer approaches (Table 1).
Choice of cell source for reprogramming
As reported by Hanna and colleagues, an adequate level
of expression of the reprogramming factors in any cell type
would likely allows the creation of an iPSC line (Hanna et al.,
2009). The preferred cell source for reprogramming will most
likely be the most easily accessible and the one in which the
reprogramming factors can be successfully delivered. That is
why fibroblasts have been widely used by many groups
(Takahashi et al., 2007; Park et al., 2008; Fusaki et al., 2009;
Carvajal-Vergara et al., 2010; Liu et al., 2010; Howden et al.,
2011; Papapetrou et al., 2011; Sebastiano et al., 2011; Tanaka
et al., 2012). Fibroblasts can be easily grown from a small
human biopsy and can be efficiently transduced with viral
vectors. Another cell source that can be easily obtained and
presents several advantages are peripheral blood mono-
nuclear cells (PB-MNCs) (Kunisato et al., 2010). These cells
can be obtained from routine blood tests or in patient follow-
up, can be frozen and stored, and are easily cultured; in
addition, stimulation of the preferred cell type within the
PB-MNCs by cytokines is possible. Jaenisch’s group (Staerk
et al., 2010) showed that by stimulation of PB-MNCs with
granulocyte colony-stimulating factor (G-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF), interleukin
(IL)-3, and IL-6 before and during the first days of repro-
gramming, the induction of pluripotency could be prompted
in progenitors and cells of myeloid origin, avoiding repro-
gramming of B or T cells.
However, there are important questions that remain un-
solved. For example, is the cell source origin going to influ-
ence the characteristics of its corresponding hiPSCs? Several
groups have compared hESCs and hiPSCs at the gene ex-
pression level and for their genome methylation status. Some
authors have found significant differences between hiPSCs
and hESCs, including an epigenetic memory of the original
cell source in the hiPSCs (Chin et al., 2009; Deng et al., 2009;
Doi et al., 2009; Marchetto et al., 2009; Ghosh et al., 2010).
Other groups attributed these differences to the intrinsic
differences between various hiPSC clones of the same re-
programming experiment or to the various technological
platforms that have been used for reprogramming (Guenther
et al., 2010; Newman and Cooper, 2010; Bock et al., 2011).
This issue has been deeply analyzed, and it has been pointed
out that the small number of clones analyzed, in the studies
in which a large difference is observed, could have nega-
tively influenced the conclusions (Yamanaka, 2012). In the
event that epigenetic memory is proven to be true, would the
original cell source have an influence on the differentiation
capacity of a specific hiPSC line? According to K. Kim and
colleagues, hiPSCs derived from cord blood cells showed a
hematopoietic differentiation advantage when compared
with hiPSCs derived from keratinocytes (K. Kim et al., 2011).
On the other hand, other authors did not find epigenetic
FIG. 1. Gene correction ap-
proach for a hematopoietic
disease, using induced plu-
ripotent stem cells. Color
images available online at
www.liebertpub.com/hum
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memory in hiPSC lines derived from hepatocytes (Ohi et al.,
2011). This issue, clearly important for therapeutic applica-
tions, will require further study in order to determine to
what extent the ultimate transplantable cell type should in-
fluence the source of patient-specific cells for reprogram-
ming. As this issue remains unclear, we believe that the cell
source should be, first, the most accessible and least invasive,
and then, depending on the future use of the hiPSCs, an
epigenetically related cell source should be considered if
available. This is the case of hiPSCs for cell therapy of blood
diseases, in which either fibroblasts or PB-MNCs could be
used, based on their accessibility, but PB-MNCs may per-
haps prove to be a better option provided they exhibit a
differentiation advantage into the hematopoietic lineage.
Correction of Patient-Derived Pluripotent Stem Cells
At present, various strategies have been tested and proven
for the correction of patient-specific hiPSCs. Although this
review is focused on genetic correction directly in hiPSCs,
this is not always achievable, because some genetic diseases
imply a reprogramming barrier, as has been the case for
Fanconi anemia (FA). In this case, genetic correction was
carried out before the generation of FA-hiPSCs (Raya et al.,
2009). All the approaches described in this review could also
be done before generating patient-specific hiPSCs if the cells
of origin allow the culture needed for the genetic correction
and selection of corrected cells.
Random integration
The first reports of correction of patient-derived hiPSCs
used lentiviral vectors to correct the disease through trans-
gene addition (Raya et al., 2009). However, these vectors,
because of their nearly random integration pattern in the
genome, are susceptible to transcriptional silencing, de-
pending on whether the integration site resides in a silent or
active transcriptional region of chromatin. Furthermore, as
mentioned previously, integrated vectors may show enhancer-
mediated cis- and trans-activation and might consequently
induce insertional mutagenesis. The identification of inte-
grations in safe harbor genomic sites (e.g., far away from
genes or coding information) could represent an alternative,
safer mode of therapy. The self-renewal and almost indefi-
nite growth properties of hiPSCs enable analysis of the in-
tegration sites of these vectors at a clonal level and the
selection of those that could be potentially safer (Papapetrou
et al., 2011; Bedel et al., 2012). However, the definition of a
safe harbor site in the genome is challenging, and it will
probably change as we get to know the genome in more
depth. Future therapeutic applications of hiPSCs for cell
therapy would benefit from a site-specific gene correction
approach. The cooperation between hiPSC technology and
homologous recombination (HR) has been extensively ex-
plored. HR is presented as an exciting and novel alternative
to avoid insertional mutagenesis associated with integrative
vector-mediated correction.
Site-specific gene editing
Gene editing is a process in which a DNA sequence is
replaced or introduced into a specific locus at single-base
pair resolution. This precise site-specific introduction re-
quires an accurate recognition mechanism of the target site
on the genome. Under normal conditions, maintenance of the
integrity of the genome requires repair of the continuous
cellular DNA damage with high fidelity. HR is a truly ac-
curate DNA repair mechanism that is basically a ‘‘copy and
paste’’ mechanism and is also used to resolve double-strand
breaks (DSBs) in the DNA. This process uses an undamaged
homologous segment of DNA as a template (conventionally,
the sister chromatid) to copy the information across the DSB.
Because it copies a normal copy of the undamaged DNA, HR
is the most secure process by which to repair DSBs. The
fidelity of HR gives the specificity and accuracy that gene
editing requires.
The natural HR process has been exploited by researchers
to achieve the desirable site-specific gene editing within a
targeted locus by introducing exogenous genomic sequences,
homologous to the target locus, flanking the desired DNA
material to be inserted. These techniques have been widely
used for the generation of knock-out and knock-in transgenic
animals (Robbins, 1993). Routinely, homology arms are ho-
mologous DNA sequences that cover the target where HR
will take place. Between these two arms, a therapeutic or
correct sequence of the gene should be found. In addition,
drug resistance genes can be introduced between both ho-
mology arms for positive selection or suicide genes outside
of the homology arms for negative selection. The final
structure and complexity of this construction, also called the
repair matrix, will vary according to the needs of the re-
searcher (Fig. 2). With the development of disease-specific
hiPSCs, this methodology has already been used to correct
mutations (Howden et al., 2011; Liu et al., 2011; Ohi et al.,
2011).
Gene editing via HR in human cells is inefficient and de-
pendent on the generation of a DSB at the specific target site
FIG. 2. Scheme of the repair
matrix, pointing out the vari-
ous required elements, and of
the various disease correction
strategies for homologous re-
combination (HR). Color ima-
ges available online at www
.liebertpub.com/hum
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(Carroll, 2011). In the absence of a repair matrix, non-
homologous end joining (NHEJ) is the dominant pathway to
solve these DNA lesions in human cells, and its resolution is
highly error-prone (Grabarz et al., 2012). In addition, HR
varies in different cell types and requires transit through the
S–G2 phase of the cell cycle to take place (Delacote and Lo-
pez, 2008). These limitations have typically made gene
editing in human cells difficult to achieve. Various ap-
proaches have been used to improve gene editing by HR,
such as the increase in the length of the DNA sequences
homologous to the target site (homology arms) (Song et al.,
2010), the use of adeno-associated vectors to more efficiently
introduce the repair matrix in the cells (Khan et al., 2010), and
the improvement of selection methods for the identification
of correctly edited cells, or the stimulation of HR by inducing
DSBs using specific DNA nucleases. The use of engineered
DNA nucleases that recognize specific sites of the genome is
an active area of investigation and is the most commonly
reported method for correction of patient-specific hiPSCs.
Engineered DNA nucleases are enzymes that have been
developed to induce DSBs specifically at a unique and de-
fined sequence in the cell genome. The rationale for inducing
the double-stranded DNA break in the immediate vicinity of
the mutant sequences is that these DSBs have been shown to
increase the efficiency of homology-directed repair (HDR) by
103- to 104-fold (Porteus and Carroll, 2005). Engineered DNA
nucleases are formed by a nuclease domain and a DNA-
binding domain, the sequence specificity of which can be
artificially modified. The most widely used DNA nucleases
are zinc finger nucleases (ZFNs), homing meganucleases
(MNs), and transcription activator-like (TAL) effector nu-
cleases (TALENs). They potentially identify a unique se-
quence within the genome and generate DSBs to induce the
recruitment of the cell repair machinery to repair the DSBs,
ideally by HR. The DNA-binding domain of ZFNs is derived
from DNA-binding zinc finger proteins and is composed of a
tandem repeat of Cys2His2 zinc fingers, each of which rec-
ognizes three nucleotides. The DNA-binding domain is
linked to the nuclease domain of the restriction enzyme FokI.
ZFNs work as pairs of two monomers of ZFN in reverse
orientation. This ZFN dimer can be designed to bind to a
genomic sequence 18–36 nucleotides in length (Porteus and
Carroll, 2005; Carroll, 2011). TALENs have a similar struc-
ture to ZFNs, but the DNA-binding domain comes from TAL
effector proteins. The DNA-binding domain in TALENs is a
tandem array of amino acid repeats. Each of these units is
able to bind to one of the four possible nucleotides. Thus, the
DNA-binding domain can be designed to recognize any
desired genomic sequence. TALENs also cleave as dimers (Li
et al., 2011). In contrast to these synthetic DNA nucleases,
natural MNs are a subset of homing endonucleases. MNs are
monomeric proteins that have four DNA-binding domains
that recognize a DNA sequence from 14 to 40 nucleotides in
length. Directed mutagenesis can be applied to modify the
DNA sequence specificity. A unique and specific MN rec-
ognition sequence can be found approximately every 300 bp
(Paques and Duchateau, 2007).
ZFNs were first developed in 1996 by Y.G. Kim and col-
leagues and applied for disrupting gene expression by in-
troducing mutations in the selected gene (Kim et al., 1996).
More recently, they have been widely used for gene editing
in hESCs and hiPSCs. For example, Lombardo and col-
leagues showed the insertion of the gene encoding green
fluorescent protein (GFP) into the CCR5 safe harbor locus in
hESCs after inducing HR by ZFN expression; targeted hESCs
were able to differentiate into neurons keeping GFP expres-
sion (Lombardo et al., 2007). TALENs have been also tested
in hESCs and hiPSCs (Hockemeyer et al., 2011). One of the
most important potential disadvantages of engineered nu-
cleases is the possibility of their cutting other, related se-
quences of the genome, the so-called off-target sites. After
targeting several loci and comparing HR efficiencies and the
presence of off-targets with both types of nucleases, these
authors concluded that both ZFNs and TALENs show sim-
ilar efficiencies and accuracy (Hockemeyer et al., 2011).
Nevertheless, an in vitro gene disruption comparison be-
tween ZFNs and TALENs showed that TALENs were more
efficient and less cytotoxic in this assay (Mussolino et al.,
2011). Other authors have reported that targeted efficiency
by various nucleases seems to be affected by the epigenetic
status of the locus to be targeted (Daboussi et al., 2012). The
presence of methylated CpGs (mCpGs) in the TALEN rec-
ognition site can dramatically decrease its efficiency (Valton
et al., 2012b) and in the case of MNs this also happens if the
mCpG is in the central tetrabase of the recognition site
(Valton et al., 2012a)
The proof of principle for the clinical application of nu-
clease-mediated gene editing was tested in hiPSCs from
patients affected by various genetic diseases some time later.
To correct or insert/express a transgene by HR, three dif-
ferent strategies can be considered (Fig. 2 and Table 2). In the
following sections we discuss the various attempts applied
for nuclease-based correction.
Targeted safe harbor integration. For safe harbor inte-
gration, a complete expression cassette (the therapeutic
transgene, promoter, and possibly additional regulatory
signals [e.g., enhancer]) is inserted into a specific genome
locus that is not susceptible to transgene silencing via epi-
genetic mechanisms. Ideally, the targeted integration will
either not affect expression of the neighboring genes or at
least allow modified cells to function normally if the target-
ing results in disruption of the safe harbor locus. This seems
to be the case for AAVS1, CCR5, and ROSA26 loci (Irion et al.,
2007; Torres et al., 2011; Yao et al., 2011). Special attention
should be taken to avoid targeting loci previously considered
nonfunctional but now known to fulfill important regulatory
functions as per ENCODE (the Encyclopedia of DNA Ele-
ments). One potential advantage of the safe harbor strategy
is that there should be significantly less cell-to-cell variation
in transgene expression than that resulting from random
integration. Although the addition of a promoter to express
the therapeutic gene is needed, the main advantage of the
safe harbor strategy is the wide variety of diseases that could
be treated with a similar repair matrix, only exchanging the
therapeutic gene for each disease. Examples are as follows:
X-Linked Chronic Granulomatous Disease: Seminal work
published by Malech’s group in March 2011 showed, for the
first time, ZFN-mediated phenotype correction in neutro-
phils generated from X-linked chronic granulomatous dis-
ease (X-CGD) hiPSCs by inserting a wild-type copy of the
CYBB gene (encoding the gp91phox protein) driven by the
CAG (cytomegalovirus early enhancer/chicken b-actin) chi-
meric promoter in the previously described AAVS1 safe
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harbor locus (Zou et al., 2011b). Puromycin selection was also
included in the inserted DNA to select recombined clones. In
addition, in some of the AAVS1 alleles that were not tar-
geted, there were mutations associated with NHEJ correc-
tion, evidence for cleavage by ZFNs at this site. Having a
high number of targeted clones makes it possible to select
and grow just those that show no off-target integrations or
new mutations. Importantly, after differentiation of the cor-
rected X-CGD hiPSCs, the resulting neutrophils showed
equal levels of therapeutic reactive oxygen species (ROS) to
neutrophils derived from wild-type hiPSCs.
b-Thalassemia: To achieve a more physiological expres-
sion level of the transgene, Chang and Bouhassira (2012)
used the specific b-globin promoter for directing expression of
the transgene when targeted into the AAVS1 locus. After
puromycin selection, all the clones analyzed were targeted at
the AAVS1 locus and 50% represented homozygous targeting
(i.e., targeting into both AAVS1 loci) as assessed by PCR and
Southern blot. Erythroid differentiation of corrected clones
showed restoration of hemoglobin quantity and quality
without disturbing any AAVS1 locus-neighboring genes.
Targeted correction. Targeted correction typically uses
site-specific nucleases designed to recognize a site in the
immediate vicinity of the mutation targeted for correction
together with a repair matrix precisely matching that of the
targeted endogenous sequences, with the exception of the
base or bases intended for alteration. The mutant target bases
are substituted for by the wild-type bases present in the in-
troduced repair matrix, thus correcting or repairing the gene.
In repairing the defective sequence within the endogenous
gene locus, the corrected genetic material is maintained
within its normal chromatin environment. This ensures the
appropriate genetic regulation and expression in the cell. In
situations in which the mutant gene product exercises a
dominant negative influence over the normal gene product,
gene correction may be the only suitable strategy. Gene
correction is especially useful for diseases in which the ma-
jority of patients have the same well-defined, limited alter-
ations in the DNA sequence, such as sickle cell anemia or
cystic fibrosis. When different mutations for the same gene
have been reported, gene correction would turn into a
patient-specific therapy and therefore the repair matrix, and
also perhaps the site-specific nucleases, should be tailor-
made for each patient or set of patients. Examples of this
approach are as follows:
Parkinson’s Disease: hiPSCs from a patient with the A53T
mutation in the a-synuclein gene were corrected by ZFN-
assisted HR in the mutated locus. In this case, the targeting
sequence in the donor vector was approximately 1 kb of the
wild-type sequence of the a-synuclein gene with the targeted
mutant base in the middle, close to the ZFN cleavage site. As
there was no selection cassette in the donor, a selection-free
approach was mandatory and the number of clones that had
to be analyzed to obtain a correctly targeted clone was higher
than with selection-based approaches. This procedure could
also be seen as an advantage, as there was just one clonal
step instead of two or three, therefore reducing the manip-
ulation steps and the probability of additional genetic alter-
ations.
Sickle Cell Anemia: Two studies have been published for
the genetic correction of hiPSCs from patients with sickle cell
anemia (Sebastiano et al., 2011; Zou et al., 2011a). The first
report showed specific ZFN-mediated gene correction of the
bs (A >T) mutation in the HBB locus (Zou et al., 2011a). The
authors used a donor vector with a loxP-flanked (‘‘floxed’’)
hygromycin resistance selection cassette that, after nucleo-
fection of the ZFNs and the repair matrix, allowed the de-
tection of hygromycin-resistant clones. PCR analysis and
Southern blotting verified the presence of hiPSC clones cor-
rectly targeted within the HBB locus and in no additional
loci. After erythrocyte differentiation of the corrected hiPSCs,
the authors suspected that the presence of the selection cas-
sette affected expression of the corrected transcript. To avoid
possible interference, the selection cassette was excised in 4
of 24 clones by Cre recombinase. Surprisingly, in those clones
in which the selection cassette was excised, expression of the
corrected gene was still only 25–40% of the expression of the
uncorrected allele. The authors speculate that the reduced
expression level could be due to two main reasons: either the
presence of the remaining loxP sequences after excision of the
selection cassette, or the presence of a nucleotide variant
(A >G) affecting a GATA-containing 3¢ enhancer that may
have been generated during HR. This study points out that a
selectable cassette could have clear benefits in reducing the
number of clones to be analyzed, but it could potentially
adversely affect the intended correction by repressing the
expression of the transgene unless excised. This work also
highlights the importance of investigating the possible ac-
quisition of genetic modifications during reprogramming
and/or HR because such mutations could influence the be-
havior of the corrected hiPSCs. The other gene correction
approach for the sickle cell mutation bs was published by
Sebastiano and colleagues, following a similar selection-
based approach (Sebastiano et al., 2011). They achieved effi-
cient targeting and showed no additional modifications in
the nontargeted allele due to NHEJ and no off-target modi-
fications.
b-Thalassemia: The correction of mutations in the b-globin
gene was also addressed by Wang and colleagues, who
performed genetic correction by ZFN-assisted HR (Wang
et al., 2012) and also applied a drug selection procedure to
increase targeting efficiency. They were able to differentiate
the corrected hiPSCs, as well as uncorrected hiPSCs, to he-
matopoietic progenitors. Moreover, human b-globin was
detected in the peripheral blood of immunodeficient mice
transplanted with the corrected hiPSC-derived hematopoi-
etic progenitors, confirming the genetic correction of b-
thalassemia.
a1-Antitrypsin Deficiency: ZFN-mediated gene correction
was also performed at the a1-antitrypsin (A1AT) locus to
correct A1AT deficiency (A1ATD) in hiPSCs derived from a
patient with the Glu342Lys point mutation. This approach
used a puromycin resistance cassette flanked by piggyBac
inverted repeats. Subsequently, the selection cassette was
removed from the homozygously targeted clones by piggy-
Bac transposase, obtaining corrected hiPSC clones without
any residual sequence footprint. Corrected, excised hiPSC
clones were subsequently differentiated into hepatocyte-like
cells, confirming the successful correction of A1ATD (Yusa
et al., 2011).
Targeted knock-in. In the targeted knock-in strategy, a
full or partial cDNA of the therapeutic transgene gene is
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directly introduced into the endogenous mutant gene locus,
generally near the start of the gene in order to precede all or
the majority of the mutant exons. Typically, splicing signals
are incorporated into the transgene sequences such that ex-
pression of the introduced cDNA is regulated by the en-
dogenous regulatory elements of the locus where it is
inserted. In principle, this strategy maintains the genetic
regulation of the gene and it is applicable to diseases in
which a large number of distinct gene mutations occur (in
contrast to a single mutant genotype responsible for a sig-
nificant majority of patients). The knock-in strategy is a
highly versatile HR strategy capable, in principle, of treating
a large number of patients using a single set of gene-
modifying tools (i.e., site-specific nucleases and repair ma-
trices), while preserving the endogenous regulation of the
therapeutic gene. Although this strategy has been used to
express marker genes led by endogenous promoters (Hock-
emeyer et al., 2009, 2011; Wang et al., 2011), there is not yet
any reported example of this strategy for the correction of
patient-specific disease hiPSCs.
We have successfully generated, using Sendai vectorized
reprogramming factors, hiPSCs from patients with pyruvate
kinase deficiency (PKD), who suffer from nonspherocytic
hemolytic anemia. We are pursuing a correction strategy that
is capable, in principle, of treating all PKD patients with
mutations from exon 3 to the end of the PKLR gene by de-
veloping an appropriate repair matrix. Moreover, expression
of the corrected R-type pyruvate kinase (RPK) transcript will
be regulated under the control of the endogenous PKLR
promoter after the knock-in of the partial RPK cDNA into
intron 2. If successful, only the corrected RPK protein should
be expressed in red blood cells.
Selection of one of these previously described strategies
(see the sections Targeted Safe Harbor Integration, Targeted
Correction, and Targeted Knock-In, above) requires consid-
eration of both the disease and the number of patients in
whom this strategy could be used. For each of these strate-
gies, the type of therapeutic matrix to be used will be dif-
ferent (see Fig. 2).
Risks of Genome Alteration
One of the most important issues in using the aforemen-
tioned novel methodologies (i.e., epigenetic reprogramming
and site-specific gene correction) will concern ensuring the
integrity of the chromosomal DNA. Even though these
methodologies have been employed only in the limited
number of studies cited previously, it is already clear that
genetic abnormalities may be introduced into the hiPSCs
either through the reprogramming process, the tissue culture
expansion, and/or the gene correction process itself (Blasco
et al., 2011; Gore et al., 2011; Pera, 2011).
In the study of gene correction of A1ATD hiPSCs, a
complete genome integrity study was performed. Com-
parative genomic hybridization confirmed that reprogram-
ming and prolonged culture generated amplifications or
deletions ranging from 20kb to 1.3Mb. But, importantly,
there was one corrected line of three lines examined that
retained a normal genome. These authors also detected ge-
netic alterations in 2 of 6 lines after HR correction and in 4 of
16 lines after the excision process. They concluded that more
genetic alterations were generated during the reprogram-
ming process and the extensive culture of the hiPSCs than
during the HR correction (Yusa et al., 2011).
In the study of a-synuclein gene correction (Soldner et al.,
2011), the authors examined the hiPSC lines for copy number
variation (CNV), because CNVs were previously reported to
commonly result from reprogramming as well as from pro-
longed pluripotent stem cell culture. The authors saw on
average 77 CNVs per cell line with an average size of 158 kb.
These genetic alterations were most likely generated during
reprogramming and culture as there were no substantial
differences after gene editing and excision. They also per-
formed whole genome expression array analysis before and
after correction and did not detect any expression pattern
differences related to gene targeting, indicating that repro-
gramming itself had a greater impact on genome integrity
than the gene-targeting procedures.
In addition to the risks of genomic alteration, it should
also be taken into account that a considerable number of
hiPSC differentiation protocols include the forced expression
of tissue-specific transcription factors (Hanna et al., 2007;
Karumbayaram et al., 2009; Belay et al., 2010; Takayama et al.,
2012). These procedures constitute an additional step of ge-
nome manipulation. Similar procedures of transient expres-
sion or genome excision by means of the Cre–loxP system, as
done for the expression of hiPSC reprogramming factors,
should be used to avoid additional side effects.
Although not related to genome alterations, another po-
tential risk of hiPSC use is their potential immunogenic
properties. Some authors have argued the possibility that
despite being autologous, hiPSCs could trigger an immune
reaction after transplantation. The latest reports regarding
this issue have shown that differentiated hiPSCs are not
immunogenic at these stages (Araki et al., 2013).
Concluding Remarks
The number of disease-specific hiPSC lines is increasing
rapidly. Until now, only a few of them have been genetically
corrected by gene-editing approaches. The unlimited prolif-
erating capacity of hiPSCs, while maintaining pluripotent
properties, allows for the application of HR techniques and
the subsequent selection of properly corrected clones. Selec-
tion of the best gene-editing strategy depends on the disease
to be corrected (Fig. 2 and Table 2). Targeted correction is the
cleanest option. The patient mutation is corrected while
leaving no exogenous elements, with the sequence of the
corrected locus being indistinguishable from that of a wild-
type locus. However, this approach is suitable only for a
specific patient or group of patients carrying the same mu-
tation, which limits its use. On the other hand, safe harbor
integration is applicable to treat all the genetic diseases al-
ready addressed by genetic therapies with retro/lentiviral
vectors. However, because the therapeutic gene loses its
endogenous regulation, a specific promoter may be required
to regulate its expression; in addition, the definition of a safe
harbor locus might not be accurate or complete until we have
a more in-depth knowledge of regulatory elements within
the human genome. The knock-in strategy is an intermediate
possibility in which a large number of patients with a de-
fined disease might benefit from this strategy, reducing its
development costs. Moreover, the endogenous elements of
the locus will regulate expression of the therapeutic gene.
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However, one concern regarding the knock-in strategy,
shared with the safe harbor approach, is that the use of a
specific cDNA transgene may exclude the coexpression of
various splicing variants.. The election among them will
depend of knowledge of the targeted locus.
Gene-editing procedures need improvements in terms of
efficiency and safety before being applied in humans. The
synergy between reprogramming and gene editing is
prompting progress in this field of research, in which a wide
spectrum of genetic diseases could be treated. Moreover,
patient-specific hiPSCs are an ideal platform to improve gene-
editing techniques in order to achieve the high efficiency and
specificity that gene therapy needs for its future clinical use.
There are still bottlenecks for their clinical application. Gene-
corrected hiPSCs currently lack robust differentiation pro-
cedures to generate a variety of transplantable cells. For
example, in the hematology field, the generation of hemato-
poietic stem cells capable of long-term reconstitution of the
whole hematopoietic system has been reported (Amabile et al.,
2013). Unfortunately, the need for teratoma formation to ob-
tain functional HSCs in this report avoids its potential clinical
application. Another possibility is the transplantation of more
mature progenitor cells or terminally differentiated cells ca-
pable of long-term survival after infusion such as T cells,
erythrocytes, or platelets. Similar strategies could be followed
for other tissues. In addition, the development of homologous
recombination technology in hiPSCs has broken new ground
for its application to other stem cells already used in clinics,
such as HSCs (Lombardo et al., 2007). We fully expect that
future gene therapy protocols using the aforementioned
methodologies will emerge.
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